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Abstract   9
Abstract 
 
 
 
Cyclic bis(3’-5’)diguanylic acid (c-di-GMP) has been the focus of many research 
endeavors for biologists in the last decade. Indeed, this cyclic dinucleotide has been 
identified as a novel secondary messenger recently.[8-11, 49] This new discovery caused 
increasing interest in the regulation system which involves c-di-GMP. This insight, recently 
led to widespread findings about c-di-GMP in other bacteria. The cyclic bis(3’-5’)-nucleotide 
has been shown to regulate the transition from motility to sessility in bacteria including 
Caulobacter crescentus[15], Escherichia coli and the pathogenic bacteria Pseudomonas 
aeroginosa and Salmonella typhimurium[7]. 
This cyclic dinucleotide also showed an influence on community behavior like biofilm 
formation in pathogenic bacteria including Pseudomonas fluorescens[16], Yersinia pestis[17] 
and Vibrio cholerae[18]. It is also involved in the inhibition of Staphylococcus aureus cell–cell 
interactions and biofilm formation, as well as in the reduction of the virulence of the biofilm-
forming strains of the same bacterium in a mouse model of mastitis infection.[19] 
These findings suggest that cyclic diguanylic acid might be useful in preventing biofilm 
formation on clinically relevant surfaces such as medical devices and potentially, in the 
control and treatment of human and animal infection.[17] The biological activity might be even 
wider since reports have pointed out that this compound may have anticancer activity.[18] 
 
Thus, c-di-GMP represents an excellent platform for drug design in medicinal chemistry 
and especially in the field of antibiotics where compounds with new modes of action are 
required. However, the mechanisms of c-di-GMP dependent signalling remain unknown, 
mainly because little data is available on c-di-GMP.[8,10] In order to study the biochemistry of 
this cyclic dinucleotide more in detail we have started this project dedicated to the synthesis 
of c-di-GMP and its analogues. 
We intended to develop a synthetic pathway which could afford an efficient, reliable, 
flexible and scalable route to synthesize c-di-GMP. At the beginning of this work, the only 
reported synthetic route for c-di-GMP was the van Boom et al.[22-23] method starting from 
guanosine and using the phosphotriester methodology. This method was the starting point of 
our own synthetic investigations, even so the published synthesis needed tedious purification 
steps and its length rendered it only moderately suitable for eventual scale-up purposes.  
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In the course of this work, two more synthetic pathways were reported by Hayakawa et 
al.[29] and Jones et al.[30] claiming better yields, easier realization and shorter reaction 
sequences. We then decided to apply some of their improvements, by modifying the 
guanosine building block to make it less polar but still use the phosphotriester methodology 
towards an easier assembly of c-di-GMP. However, no previously described method afforded 
large quantities of c-di-GMP. 
After having explored the different existing synthetic routes, it quickly became obvious 
that we would have to design a new method to obtain this compound in sizeable amounts to 
satisfy the demands for the biological investigations. We have decided to adopt a brand new 
approach in which we start from ribose building blocks and synthesize a sugar-phosphate 
backbone, and to introduce the base at a late stage (Scheme A). Through this route we 
anticipate to completely solve the difficulties, generally caused by the 2’-OH protection, by 
using the 1’,2’-acetal protecting group.  
 
 
 
 
Scheme A: New synthetic approach for the synthesis of c-di-GMP. 
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Abstract   11
In order to show the flexibility of our new synthetic route, the synthesis of base-
modified analogues of c-di-GMP was undertaken. The intend was to show that the synthesis 
is not specific for purine bases but can be applied to pyrimidine bases as well as non natural 
nucleobases, such as xanthine or theophylline for example. Finally, we applied the same 
strategy to the synthesis of internucleotide linkage modified analogues. 
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1. INTRODUCTION 
1.1 Cyclic Nucleotides: a Background 
The idea that purines could act as extracellular signaling molecules was first proposed 
over 80 years ago.[1] Extracellular nucleotides have since been implicated in a wide range of 
biological processes, including smooth muscle contraction, inflammation, platelet 
aggregation and pain, among many others. Cell-surface receptors for these purines and 
pyrimidines, termed purine receptors, have been identified and classified in two groups, P1 
and P2 receptors, recognizing adenosine 5’-triphosphate (ATP), adenosine 5’-diphosphate 
(ADP), uridine 5’-triphospahte (UTP) and uridine 5’-diphosphate (UDP).[2] 
Intracellular signaling relies on the perception of such a signal at the plasma membrane 
by a receptor, then activating the formation of a secondary signal within the cell, which 
ultimately modifies the activity of an effector molecule. The lack of knowledge about the 
receptors and effectors in those signaling processes has often been the difficulty. Recently, a 
variety of novel molecular genetic approaches have been adopted, to address not only the 
target systems where a specific signaling molecule is active in plant cells, but also the 
processes in which such molecules may be involved. Hence, an increasing array of signaling 
molecules, their biosynthetic enzymes and effectors are emerging. In recent work, a variety 
of processes have been shown to be triggered by secondary signaling molecules.[3]  
Nucleotides such as cyclic adenosine monophosphate (cAMP) or cyclic guanosine 
monophosphate (cGMP) (see Figure 1) have been recognized as important molecules in 
biological signal transduction pathways in animals and higher plants. They have also been 
shown to perform parallel regulatory functions in bacteria and lower organisms.[4]  
 
 
 
Figure 1: Cyclic ribonucleotide second messengers. 
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cAMP, a prototype second messenger when first discovered, has been established as 
a signaling molecule in both eukaryotes and prokaryotes. From its discovery, by Nobel Prize 
winner Earl Sutherland,[5] and the subsequent demonstration of its role in mediating the 
action of mammalian hormones in the liver, the idea of secondary-messengers was 
developed. According to this concept, mammalian hormones and neurotransmitters, acting 
as primary messengers, remain outside the cell. While binding to their specific receptors, a 
change of conformation occurs; this change transmits their signal to the interior of the cell 
resulting in the synthesis and release of the secondary messenger cAMP inside the cell.[6] A 
second cyclic nucleotide, 3’,5’-cyclic guanosine monophosphate (cGMP), has been shown to 
have a more restricted role, in mammals at least. It has been isolated from living tissues and 
found to be carrying out second messenger roles.[6] 
cAMP and cGMP are general cell signaling molecules of eukaryotes, such as humans, 
plants and fungi. In those organisms, these two molecules have been shown to be involved 
in a broad spectrum of cellular processes such as in the regulation of metabolic processes, 
cell differentiation, immunity, the transduction of olfactory and visual signals, 
photomorphogenesis, as well as in the regulation of complex behavioral processes of higher 
organisms such as learning and depression.[7] 
While bacterial pathogens can interfere with the cGMP signaling of their eukaryotic 
host cells, prokaryotes in general do not seem to use cGMP for signaling. This suggests the 
existence of an alternative molecule. And indeed, recent discoveries seem to suggest that 
bacteria make extensive use of another cyclic guanosine compound: cyclic diguanylic acid 
(c-di-GMP).[8-11]  
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1.2 Biological Occurrence and Mode of Action of Cyclic Diguanylic 
Acid 
Bacteria modify their cell surface in response to environmental cues. These changes 
can facilitate either dispersion to a new environment or adhesion to a surface, including 
aggregation with members of their own or other species. The particular outcome is often 
determined by changes in exopolysaccharides (EPS) and proteinaceous appendages. 
Gluconacetobacter xylinum, for example, produces an extracellular matrix of cellulose. In the 
last few decades, studies of this feature led to the identification of plant cellulose synthase 
genes, which then allowed the discovery of bis(3’-5’)-cyclic diguanylic acid (c-di-GMP) (see 
Figure 2) as a regulatory nucleotide in the β-1,4-glucan (cellulose) biogenesis. The proteins 
regulating the intracellular levels of c-di-GMP for these bacteria contain two genome 
sequences, the so-called GGDEF and EAL domains. They are widespread domains in 
bacteria, but remained mostly uncharacterized signaling systems. The members of this 
protein family, that have been characterized, showed one common theme: regulation of 
bacterial cell surface adhesiveness. Since proteins containing those domains are found in 
diverse bacteria, it is highly likely that signaling by c-di-GMP is a conserved physiological 
basis for their activities.[12] 
 
 
 
Figure 2: Cyclic diguanylic acid (c-di-GMP). 
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in the sense that it binds directly to the enzyme in a reversible manner at a regulatory site, 
distinct from that of the catalytic or substrate-binding sites.[13] The enzymes controlling the 
turnover of c-di-GMP are called diguanylate cyclase (DGC), which catalyzes its formation, 
and phosphodiesterase A (PDEA), which catalyzes its degradation.[14]  
This insight, recently led to widespread findings about c-di-GMP in other bacteria. The 
cyclic bis(3’-5’)-nucleotide has been shown to regulate the transition from motility to sessility 
in bacteria including Caulobacter crescentus[15], Escherichia coli and the pathogenic bacteria 
Pseudomonas aeroginosa and Salmonella typhimurium[7], and community behavior like 
biofilm formation in pathogenic bacteria including Pseudomonas fluorescens[16], Yersinia 
pestis[17] and Vibrio cholerae[18]. It is also involved in the inhibition of Staphylococcus aureus 
cell–cell interactions and biofilm formation, as well as in the reduction of the virulence of the 
biofilm-forming strains of the same bacterium in a mouse model of mastitis infection.[19]  
The recent suggestion that c-di-GMP might be a novel secondary messenger[8-11] has 
caused increasing interest in the regulation system which involves this cyclic dinucleotide. 
These findings also suggest that cyclic diguanylic acid might be useful in preventing biofilm 
formation on clinically relevant surfaces such as medical devices and potentially, in the 
control and treatment of human and animal infection.[20] The biological activity might be even 
wider since reports have pointed out that this compound may have anticancer activity.[21] 
Even though all these results have shown the implication of c-di-GMP in various 
biological processes, a clear understanding on the molecular level has yet to be achieved. In 
order to further investigate these questions, high quantities of c-di-GMP are needed.  
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1.3 Structure and Properties of Cyclic Diguanylic Acid 
Because of the rising importance of c-di-GMP in microbiological investigations, this 
cyclic dinucleotide has been brought into the spotlight. This intriguing molecule has sparked 
interest as a result of its particular properties that might be due to the biological activity it 
displays. Therefore, the structure of c-di-GMP has been investigated. Bis(3’-5’)-cyclic 
diguanylic acid is a cyclic dinucleotide where the two ribose units of guanosine 
monophosphates are connected via two intermolecular 3’-5’ phosphodiester bonds. This 
linkage builds a 12-membered circular sugar-phosphate backbone that provides a rigid 
framework which holds the guanines in parallel planes, 6.8 Å apart. (Figure 5) 
 
 
 
Figure 5: Structure of c-di-GMP. A: chemical structure of a c-di-GMP molecule. B: 
crystallographic representation of a molecule of c-di-GMP. (Nitrogens are in blue, oxygen 
atoms are in red and phosphorus atoms are in orange. The diagram was produced in the 
programme DINO.)[22] 
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According to published work[22-23], when crystallized in the presence of hydrated 
magnesium ions, two c-di-GMP units form an intercalated unit stabilized by stacks of four 
guanine bases, such that the imidazole ring of one guanine is positioned over the pyrimidine 
ring of the next. (see Figure 6) Each outer guanine of the four-member stack is nearly 
coplanar with the adjacent base in the stack. However, the two central bases are not 
coplanar but partially unstacked.  
In addition, this dimer is also stabilized by a set of parallel hydrogen bonds between the 
nitrogen of the guanine and the oxygen of the phosphate of the other monomer. The 
hydrogen bonds also include the hydrated Mg2+ complex, since two of the four water 
molecules interact with both oxygen atoms of the phosphate groups not involved in 
interactions with the base and the other two water molecules form hydrogen bonds with the 
oxygen atoms of the two central bases. Thus hydrated magnesium ions play an integral role 
in the interaction between the two c-di-GMP monomers. 
When considering the two independent c-di-GMP molecules, they have been shown to 
have very similar conformations when superposed. The 12-membered ring formed by a 
cyclic phosphodiester backbone, exhibits no deviations from standard torsion angles in this 
type of rings, which suggest that the ring closes easily. Also, a nearly perfect twofold 
symmetry is maintained by the backbone atoms, indicating that the conformations of the two 
phosphate residues in each ring are very similar. 
In this structure, all the riboses adopt a 2’-exo/3’-endo conformation, as expected for 
RNA. Thus the intramolecular twofold symmetry is broken by the glycosyl torsion angle. The 
guanines are in two different orientations relative to the sugar-phosphate backbone ring, 
meaning the bases are not parallel but skewed at an angle, both being in an anti-
conformation with respect to the riboses.[22] 
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Figure 6: Crystal structure of c-di-GMP showing two intercalated c-di-GMP molecules, 
emphasizing base-solvent and base-backbone hydrogen bonds of c-di-GMP.[22, 23] A: Front 
view shows the alternate stacking of the guanine bases coordinated by the hydrated Mg2+ ion 
(purple). B: Side view shows the cyclic structure with the two phosphodiester linkages. 
(Water molecules are in red. Nitrogen atoms are blue, oxygen atoms are red, phosphorus 
atoms are green and hydrogen bonds are included as dashed lines. All diagrams are 
produced in the programme DINO.) 
 
 
The structure of c-di-GMP might be directly related to the biological processes involving 
it. This is currently under investigation. It is also remarkable that the crystal structure seems 
to be depending on the salts used during the crystallization procedure.[22-23] This might also 
be one of the reasons for difficulties reportedly encountered during the purification of 
synthetic c-di-GMP. 
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1.4 Published c-di-GMP Synthetic Work 
Facing growing needs in cyclic bis(3’-5’) diguanylic acid, the chemical synthesis of this 
compound became an important option. It attracted great attention in the last two decades. 
Hence, it was necessary to develop an efficient chemical method for synthesizing c-di-GMP 
to meet those needs. Thus far, there were three different strategies developed, by three 
groups, with various efficiencies. 
 
 
1.4.1 Phosphotriester Methodology 
For oligonucleotide syntheses via the phosphotriester method, the synthetic 
intermediates are nucleotides were the internucleotidic phosphate linkages are protected by 
a third esterifying function. This must satisfy two main criteria: it must be selectively and 
readily removable from the phosphotriester functions, and secondly, it must remain intact 
under the conditions of acidic and basic hydrolysis which are necessary for the removal of 
the common protecting groups from the sugar hydroxyl functions.  
The phosphotriester approach is considered the most versatile method of 
oligonucleotide synthesis and has a number of significant advantages over other methods 
that have been developed later on. First and most important, both the nucleotide building 
blocks and the phosphotriester intermediates are very stable and easy to handle in solution. 
Another positive aspect includes the possibility to use monomers, dimers as well as large 
nucleotide building blocks. The coupling reactions show a relative lack of sensitivity to small 
quantities of moisture, which are removed by the excess condensing agent. Besides, only a 
slight excess of nucleotide building block is needed to perform the coupling reactions. Finally, 
the most interesting feature of this method is its suitability for the synthesis of small DNA- 
and RNA-oligonucleotides in solution, therefore it is particularly interesting for the synthesis 
of cyclic nucleotides, a prime example being c-di-GMP.[24]  
Van Boom et al.[25-26] were the first group to publish a chemical synthetic pathway for c-
di-GMP in the late eighties. Their strategy was based on a modified hydroxybenzotriazole 
phosphotriester approach were two protected guanosine building blocks were coupled 
through a 2-chlorophenyl protected phosphotriester linkage to form the cyclic dinucleotide. 
(Scheme 1) 
Through a protection-deprotection sequence, building block 1 was synthesized over six 
separate reaction steps in an overall yield of 65%. The 2’- and 5’-hydroxy groups of the 
ribose were protected with the acid-labile tetrahydropyranyl (THP) and dimethoxytrityl (DMT) 
groups. The 2-amine of the base was blocked with the base-labile diphenylacetyl (dpa) 
group.[26] 
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Scheme 1: van Boom synthesis pathway via phosphotriester methodology. 
 
 
Guanosine 1 was phosphorylated via a bis(trifluoromethyl-hydroxybenzotriazole)-2-
chlorophenyl phosphate and combined with a second unit of building block 1, which had 
previously been deprotected at the 5’-OH position, to yield dimer 2. This compound was then 
phosphorylated using the same method as described above; the phosphate was protected 
using allyl alcohol to yield intermediate 3. After removal of the dimethoxytrityl and allyl 
groups, cyclization was achieved. Thus, fully protected compound 4 was obtained in 11 steps 
in an overall yield of 26%, starting from commercially available guanosine. The final 
deprotection of cyclic nucleotide 4 then afforded a small amount of c-di-GMP.[26]  
This synthetic pathway has been the first reported, but it showed some drawbacks. The 
synthesis of the building block was long with its accumulation of steps. The dimerization and 
cyclization to yield to c-di-GMP were also a rather long process with repetition steps. 
Furthermore, only a few of the reaction procedures were described and others were not 
reported in detail. Finally, only a small amount of substance was synthesized and the yield of 
the final deprotection step was not reported.  
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1.4.2 Phosphoramidite Methodology 
The phosphoramidite method requires that the building blocks are nucleotides where 
the phosphate linkage is blocked as a trivalent moiety by two different functional groups. 
First, there is a diisopropylamine group, which is stable until the addition of the tetrazole 
when coupling, and serves to activate the nucleotide coupling process, and second, a 
cyanoethyl protecting group is used, which prevents side reactions, aids the solubility and is 
removed only at the final deprotection stage.[27] 
The phosphoramidite approach is the most efficient as a solid-supported DNA- and 
RNA-oligonucleotide synthesis method.[28] Traditionally, the procedure starts with 
immobilizing the first nucleotide on solid-support by the 3’-hydroxy function. 3’-
phosphoramidite substituted building blocks are prepared separately, and will then be used 
to assemble the oligonucleotides. The 5’-hydroxyl group of the immobilized nucleobase is 
first deprotected, then coupled with a second phosphorylated nucleotide unit, in the presence 
of tetrazole as an activator. Once formed the new phosphite internucleotide bond is finally 
oxidized to the more stable phosphotriester linkage, before the oligonucleotide can enter a 
new deprotection-coupling-oxidation sequence.  
This method can be used in solution, even if the stability of the intermediates and 
building blocks is reduced. In 2004, Hayakawa et al.[29] published an alternative synthetic 
pathway to the van Boom route to prepare c-di-GMP, using modern DNA and RNA synthesis 
methods based on phosphoramidite coupling agents in solution (Scheme 2). The first step of 
the synthesis was the protection of the guanosine with a tertbutyldimethylsilyl group on the 
2’-OH position and a dimethyltrityl group on the 5’-OH of the sugar unit, and a 
dimethylaminoethylene group on the 2-N-amine of the base. This building block 5 was 
synthesized over three steps in an overall yield of 59% from guanosine.[29] 
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Scheme 2: Hayakawa synthesis pathway using phosphoramidite methodology. 
 
 
Precursor 6 was then obtained via condensation of building block 5 with a cyanoethyl 
phosphoramidite in solution. Subsequent treatment of a part of 6 with allyl alcohol led to 
protected intermediate 7. After coupling compound 7 with precursor 6 and removing the 
dimethoxytrityl group, dimer 8 was obtained. The allyl group of the phosphotriester moiety 
was removed and the resulting alcohol was converted to cyclic dinucleotide 9. Finally, 
successive deprotection steps afforded c-di-GMP in an overall yield of 31% in 5 separate 
steps starting from building block 5.[29]  
This synthesis pathway suffers principally from the fact that the phosphoramidite 
methodology is not the method of choice when doing solution phase chemistry with 
nucleotides. Indeed, the yields are lower than in the case of solid supported couplings, and 
the stability of the phosphoramidite substituted nucleotides is also lower. Moreover, the 
synthesis of the building block, as well as the assembling of c-di-GMP, is a rather long 
process to obtain a small quantity of product, and the overall yield was 18% over 8 reaction 
steps, starting from commercially available guanosine. Another drawback is the matter of 
chemoselectivity when trying to protect the 2’-hydroxy group, which will be a recurring theme 
in the different attempt to develop a suitable synthetic route.  
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1.4.3 Hydrogen-Phosphonate Methodology 
H-phosphonate monomers are useful for the preparation of internucleotide linkages 
that are not attainable by standard phosphoramidite chemistry. Here, the monomer used is a 
5'-DMT-3'-hydrogen phosphonate-protected nucleoside that will be activated. The presence 
of the H-phosphonate moiety on these monomers renders phosphate protection unnecessary 
as it is a blocking group.  
The hydrogen-phosphonate synthesis methodology for oligonucleotides, is very similar 
to that of the phosphoramidite approach. Slight differences result from the properties of the 
monomers utilized. For example, a different activating agent is used. The free oxygen on the 
H-phosphonate is activated and the free 5’-OH of the second monomer performs a 
nucleophilic attack on the activated phosphorous. In addition, the H-phosphonate diesters 
generated by these coupling reactions are stable to the normal reaction conditions, so 
oxidation at every step is unnecessary.  
The H-phosphonate approach has primarily been developed as a solid-supported 
synthesis pathway to obtain DNA- or RNA-oligonucleotides, but it can also be applied in 
solution, generally for cyclic nucleotides. In 2004, Jones et al.[30] published a second 
alternative to the synthesis of c-di-GMP using the standard phosphoramidite method coupled 
with an H-phosphonate cyclization process. (Scheme 3) 
The precursor used here to prepare c-di-GMP, was reported by Serebryany et al. in 
2002.[31] The synthetic route was started with the introduction of the appropriate protecting 
groups on a guanosine to yield building block 10. This consists in blocking position 2’-OH of 
the ribose with a tertbutyldimethylsilyl (TBDMS) group and position 5’-OH with a dimethyltrityl 
group. The base was protected as an isobutyryl amide on the 2-N-amine. The building block 
was obtained in five steps in an overall yield of 79%.[31] 
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Scheme 3: Jones synthesis pathway using H-phosphonate method. 
 
 
Following the preparation of precursor 10, conversion to intermediate 11 was achieved 
by using the bis(diisopropylamino)methyl phosphoramidite and compound 12 was obtained 
from 10 by reaction with 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one and subsequent 
removal of the dimethyltrityl group. Dimer 13 was then prepared using the standard 
phosphoramidite methodology. After cyclization, the H-phosphonate is conveniently oxidized 
to a methyl triester to yield fully protected cyclic dinucleotide 14. Finally, deprotection 
reactions led to c-di-GMP in an overall yield of 39% in the five steps.[30] 
The main drawbacks of this method are essentially similar to the ones mentioned for 
the phosphoramidite approach. Indeed, this method is not a pure H-phosphonate coupling 
method only, but is mixed with phosphoramidite coupling steps. This means the difficulties 
encountered for the phosphoramidite methodology are also an issue here. One of the 
building blocks was substituted with a phosphoramidite, which is not ideal for “in solution” 
chemistry, due to the lack of stability of these building blocks. Also the matter of 
chemoselectivity, when trying to block the 2’-OH group is not really solved with this approach 
either, since 3’,5’-cyclic intermediate was prepared first. Nevertheless, c-di-GMP could be 
obtained in a 30% yield over 10 steps, starting from commercially available guanosine. 
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1.5 Research Project 
The aim of this project was to develop a synthetic pathway which could afford an 
efficient, reliable, flexible and up-scalable route to synthesize c-di-GMP. No previously 
described method afforded large quantities of c-di-GMP. A new synthesis had to be designed 
to obtain this compound in sizeable amounts to satisfy the demands for the biological 
investigations. 
One of the more predominant differences between the syntheses of DNA- and RNA-
oligonucleotides is the presence of the 2’-hydroxy function. Many reports on the various 
preparation processes of DNA-nucleotides exist but few can be applied to RNA-nucleotides 
because of this functional group. The difficulty to perform a selective protection of the 2’-OH 
position of the ribose is one of the reasons for the small amount of reported RNA-nucleotide 
syntheses and one of its main drawbacks. Even if selective protecting procedures have been 
reported, most of them have been developed in combination with the other natural 
nucleotides. The existing methodologies have been reportedly more difficult to apply to the 
guanosine series, due to its rather unique behavior under the standard oligonucleotide 
chemistry. 
At the beginning of this work, the only reported synthetic route for c-di-GMP was the 
van Boom et al.[25-26] method starting from guanosine and using the phosphotriester 
methodology (Scheme 1). We have decided to investigate this first route that seemed to be 
the best approach for short cyclic oligonucleotides. Although the phosphoramidite coupling 
procedure seemed more modern, it appeared less suitable for our project.  
Even so, the published synthesis was cause for tedious purification steps and its length 
rendered it only moderately suitable for eventual scale-up purposes. At this point in the 
course of this work, two more synthetic pathways were reported by Hayakawa et al.[29] and 
Jones et al.[30] claiming better yields, easier realization and shorter reaction sequences. It 
was then planed to first modify the guanosine building block to make it less polar, but still use 
the phosphotriester methodology towards an easier assembly of c-di-GMP. (see Scheme 4) 
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Scheme 4: Examples of modifications performed on the building block. 
 
 
The ultimate goal of this research project was to design a new synthetic route that 
could be applied to the process chemistry of c-di-GMP. The newly reported alternatives 
proved difficult to carry out to achieve this goal. They represented long reaction sequences to 
obtain small amounts or even no product. It was then decided to try a completely new 
approach. 
Considering the difficulties inherent to the selective protection of the 2’-hydroxy group 
in the guanosine series, it was decided to bypass this issue by changing the starting material 
completely. Following the report of compound 18[32] (see Scheme 5) as a by-product in the 
synthesis of carbohydrate phosphates, the new reactant that would be tested, would be 
commercially available 1,2-O-isopropylidene-α-D-xylofuranose 19. This new approach, would 
lead to a late introduction of the base moiety on the ribose, which allowed for more variation 
potential and the facile synthesis of base-modified analogues. This modification in the 
strategy would also induce more flexibility in the synthetic pathway and the same approach 
could also be used to prepare internucleotide linkage modified analogues. 
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Scheme 5: Retro-synthetic overview of the carbohydrate phosphate. 
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2. INVESTIGATIONS TOWARDS A NEW APPROACH FOR THE SYNTHESIS OF C-
DI-GMP 
2.1 Synthesis of c-di-GMP Based on the van Boom Route 
2.1.1 Synthesis of the Guanosine Building Block 
At the beginning of this project, the aim was to synthesize c-di-GMP in an efficient 
manner. At the time, this molecule was already attracting considerable attention, due to the 
ongoing investigations of its biological relevance and properties, and the necessity of a 
synthetic method to afford this molecule became obvious. But only one chemical synthetic 
pathway had been reported so far. In 1990, van Boom et al.[26] published the total synthesis 
of c-di-GMP starting from guanosine, using a complex protection-deprotection strategy to 
afford buildings blocks which would then be assembled using the phosphotriester DNA-
coupling method.  
Even if this synthesis was long standing, it was the only available one and thus the 
start of our synthetic efforts. Indeed, we decided to tackle the synthesis of c-di-GMP by first 
reproducing the van Boom et al.[26] methodology, in order to gain more insight into the 
specifics the RNA-oligonucleotide synthesis and the particular behavior of guanosine. 
As mentioned previously, inserting a protecting group selectively on the 2’-OH position 
of the ribose is a challenge due to its similar reactivity with the 3’-OH group. A large number 
of 2’-O-ribonucloeside protecting groups have been reported and can basically be divided 
into three categories: acid-, photo- and fluoride-labile groups.[33] The chosen group, its 
introduction as well as its removal, is required to be compatible with the other protecting 
groups used. Still, the lack of selectivity remains a primary concern. van Boom et al. resolved 
the issue of the 2’-OH protection by inserting the TiPS group which forms a cyclic link 
between the 5’- and 3’-alcohol functions. 
According to the procedure from van Boom et al., to assemble c-di-GMP an adequately 
protected guanosine building block has to be prepared first. The first synthetic step consisted 
in the treatment of guanosine with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (TiPSCl) in 
DMF in the presence of imidazole to give the 3’,5’-O-disilyl derivative 21 in 43% yield. 
(Scheme 6)[25] 
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Scheme 6: Synthesis of guanosine building block 29. 
 
 
To perform the next steps, two protecting group precursors had to be produced. 
Levulinic anhydride (Lev2O) 23 was synthesized quantitatively from levulinic acid in the 
presence of dicyclohexyl carbodiimide (DCC) in diethyl ether. Diphenylacetic anhydride 
(dpa2O) 25 was also prepared quantitatively using the same procedure in a mixture diethyl 
ether:dioxane (1:1). (Scheme 7)[25] 
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Scheme 7: Protecting group precursors Lev2O 23 and dpa2O 25. 
 
 
Subsequent reaction of 21 with Lev2O 23 in DMF in the presence of 4-dimethylamino-
pyridine (DMAP) and triethylamine afforded 26, where the ribose moiety was fully protected, 
in 49% yield. Compound 26 was then reacted with dpa2O 25 in pyridine, to block selectively 
the less reactive, free primary amine function of the guanine and directly treated with 
hydrazine and pentanedione in pyridine, to remove the Lev-group, thus yielding 2’-O-free 
derivative 27 quantitatively. Treatment with 3,4-dihydro-2H-pyran in dichloromethane 
followed directly by triethylamine trihydrofluoride in THF afforded selectively 2’-O-
tetrahydropyranyl protected intermediate 28 in 93% yield. Finally, reaction with 4,4-
dimethoxytrityl chloride in pyridine led to the desired 5’-O-DMT substituted guanosine 
building block 29 in 76% yield. Building block 29 was prepared in 15% overall yield in five 
reaction steps. (see Scheme 6)[25]  
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2.1.2 Synthesis of Cyclic Diguanylic Acid 
To achieve the synthesis of c-di-GMP, a phosphorylating agent is needed. The one 
chosen by van Boom et al. is based on a modified benzotriazole. 2-chloro 
phosphoryldichloridate 31 is reacted with 1-hydroxy-6-trifluoro-methylbenzotriazole 30 in 
anhydrous dioxane in the presence of pyridine under inert atmosphere, to lead to activated 
phosphorylating agent 32 as a 0.2 M stock solution in dioxane. (Scheme 8)[26] 
 
 
 
Scheme 8: Phosphorylating agent 32. 
 
 
The first step to complete the preparation of the cyclic nucleotide was assembling the 
two building block units 28 and 29 through reaction with phosphorylating agent 32 in dioxane 
to form dimer 33 in a 74% yield. In order to perform the ring closure, a second phosphate unit 
was necessary. Compound 33 was reacted again with phosphorylating agent 32 in pyridine 
to substitute the free 3’-OH, and the phosphotriester function was further protected with an 
allylic group via condensation with allylic alcohol in pyridine to give fully protected dimer 34 in 
64% yield.[26] 
This dinucleotide then needed to be deprotected at the 5’-O-DMT position. Dimer 34 
was treated with p-toluenesulfonic acid in a mixture of dichloromethane:methanol (7:3, v/v) to 
afford free 5’-OH dimer 35 in 55% yield. The cyclization was performed in two steps. 
Treatment of compound 35 with Pd(PPh3)4 in the presence of triphenylphosphine and n-
butylamine in THF allowed the cleavage of the allylic group on the phosphate. Afterwards, 
direct addition of TPSNT in pyridine activated the phosphate groups, and enabled cyclization 
via a new phosphotriester linkage to give fully protected cyclic dinucleotide 36 in 38% yield. 
Finally, successive deprotection with syn-pyridine-2-carboxaldoxime and 1,1,3,3-
tetramethylguanidine in pyridine then concentrated ammonia, and treatment with 
hydrochloric acid led to c-di-GMP. The purification of this compound by reverse phase HPLC 
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pure c-di-GMP in a 16% yield. Starting from the building block 29, c-di-GMP was prepared in 
1.5% overall yield over 5 steps (Scheme 9)[26] 
 
 
 
Scheme 9: Synthesis of c-di-GMP using van Boom et al. methodology. 
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2.1.3 Discussion 
The execution of the synthetic pathway as described by van Boom et al. showed some 
drawbacks. The strategy used was based on two important factors. First, the hydroxyl groups 
on the ribose moiety were more reactive than the amine function on the guanine moiety, 
which implied a need to block the alcohols before a selective protecting group for 2-NH2 can 
be introduced. Second and more important, only few satisfactory protecting groups that can 
be inserted on the 2’-OH position have been reported. There is actually no chemoselective 
protecting group for the 2’-OH position, which is why the introduction of a group on 2’-OH 
requires having blocked positions 3’-OH and 5’-OH beforehand. One of the solutions was the 
use of the TiPS group, which allowed blocking the 3’- and 5’-alcohol functions with one cyclic 
derivative. 
The use of the cyclic 3’,5’-O-disilyl protecting group proved to be a challenge. The 
solubility of compound 25 primarily, but also, to some extend, of the other remaining 
intermediates where this group was present, became an issue leading to complex and 
lengthy purification procedures. This choice also revealed that side reactions occurred as 
long as the 2-NH2 functionality was not blocked and thus drops in yields were observed.  
Besides, the need to substitute selectively the 2’-hydroxy position, with a protecting 
group suitable for the remaining synthetic route, induced redundant steps. Indeed, this 
position, due to its greater reactivity compared to the 2-NH2, was first blocked as a levulinic 
ester 26 and later converted again in a pyranyl ether 28.  
Another insight that we have gained was that the amide bond of the guanine was 
insufficiently protected. This functional group contributed to the high polarity of the building 
block intermediates, and thus also, to the difficulties encountered during the purification 
processes. 
In addition, performing the phosphate ring-closure in three separate steps was a cause 
for low overall yields. Due to the high polarity of those compounds, the purification 
procedures were tedious and induced loss of material. Also, using a strategy where the 3’-
OH position of dimer 33 was substituted with a phosphotriester in a primary reaction, led to 
the necessity to block this functionality with allylic alcohol, which had to be removed again at 
a later stage. Combined, those factors resulted in a 14% yield in the three steps to go from 
the dimer 33 to the fully protected cyclic intermediate 36. 
Furthermore, there is some evidence that the deprotection steps needed to be 
performed in a defined order. Indeed, as long as the phosphate linkages were blocked with 
the chlorophenyl groups, the molecule seemed to be sensitive to bases. Even mild 
conditions, such as a basic carbonate workup were enough to cleave the phosphate 
linkages. The free phosphate bonds on the other hand resisted basic treatment. This meant, 
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the chlorophenyl groups had to be the first groups to be cleaved before any basic treatment 
can be performed. 
All the insight gained by reproducing the published van Boom et al.[26] synthesis, 
showed us that this method was a long and tedious process. Indeed, the overall yield we 
obtained to prepare c-di-GMP was only 0.2% over 10 steps, starting from the commercially 
available guanosine. This also suggested that the synthesis was ill suited for scale-up 
purposes. Nevertheless, through this methodology a small quantity (4 mg) of c-di-GMP could 
be obtained and this strategy was the base of our attempts to further develop a synthetic 
pathway that could bypass a few of the drawbacks mentioned above. 
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2.2 Tom Protected Building Blocks 
2.2.1 Synthesis of the Building Block and Introduction of the Tom 
group 
In order to design a new synthesis pathway using protecting groups that would 
withstand the reaction conditions to prepare c-di-GMP, the preparation of a new 2’-O-
protected guanosine building block was undertaken.  
In the large number of investigated protecting groups for the 2’-OH guanosine position, 
the tertbutyldimethylsilyl (TBDMS) group is the one having found the widest applications, 
even though the nucleotide coupling yields are not the most satisfactory. A new class of 
protecting groups, where the steric demands are lower, has been described recently by 
Pitsch et al. The introduction of those 2’-O-protecting groups, derived from a formaldehyde 
acetal linker, such as [(triisopropylsilyl)oxy]methyl chloride (TomCl), was described and the 
building blocks obtained, combined with the phosphoramidite chemistry coupling strategy, 
were shown to have a superior coupling behavior.[33] Hence, we decided to use this new 
protecting group to try and improve the synthesis of c-di-GMP.  
The reagent TomCl 39 was synthesized by condensation of paraformaldehyde and 
(ethylthio)methanol in basic settings and silylation with triisopropylsilyl chloride/imidazole in 
CH2Cl2 to give silylated derivative 38 in 69% yield. This intermediate was transformed with 
SO2Cl2 in dichloromethane into Tom-Cl 39. By distillation in vacuo, compound 39 was 
isolated in 65% yield. (Scheme 10)[33]  
 
 
 
Scheme 10: Synthesis of TomCl precursor 39. 
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dimethoxytrityl group through treatment with DMTCl in pyridine in 82% yield. The final step 
was then the insertion of the Tom group. Compound 42 was first reacted with 
dibutyltindichloride and diisopropylethylamine in dichloroethane to generate a 2’,3’-O-tin 
complex in situ which was immediately treated with TomCl 39 to give a mixture of 2’-O-Tom 
and 3’-O-Tom protected guanosines 43 and 44 in an overall yield of 50%. (Scheme 11) [34]  
 
 
 
Scheme 11: Synthesis of the 2’-O-Tom protected building block 43. 
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2.2.2 Discussion of the Method 
The combination of the chosen protecting groups allowed for overall relatively high 
yields and the required deprotection processes were straightforward. Though, blocking the 
2’-OH position was the least efficient step in the synthesis reported above. 
Reportedly, the Tom group displays some unique properties which render it a valuable 
2’-O-protecting group for the synthesis of oligoribonucleotides. It is stable under the reaction 
conditions required for the assembly and deprotection of RNA sequences. Also, the stability 
of the Tom group towards both strongly acidic conditions and strongly basic conditions is a 
consequence of the sterically very hindered triisopropylsilyl moiety. 
However, in our hands, the introduction of the Tom group was a cause for low yields 
and due to the mixture of two isomers produced, the yield was even lower. The separation of 
the regioisomeric Tom substituted ribonucleosides 43 and 44 proved that the favored regio-
isomer was the 3’-OH Tom substituted compound 44, which was obtained with the highest 
yield.  
The favored isomer was not the desired one, thus the chosen protecting group (Tom), 
proved to be far from ideal to achieve an effective, flexible and most of all up-scalable 
synthetic pathway. Finally, even with this new set of protecting groups, the purification 
operations remained tedious, partly due to the high polarity of the intermediates, but also due 
to the side reactions occurring on the base moiety while reaction steps are undertaken on the 
ribose.  
Those considerations led to the interruption of this methodology and a new strategy 
was devised in order to bypass those difficulties. One of the parameters that were the cause 
for the problems encountered in the methods described before, was the lack of adequate 
protection of the amide function on the guanosine base. This issue was the main focus of our 
next alternative for the synthesis. 
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2.3 Hayakawa Based Building Blocks  
2.3.1 Introduction of the Protecting Groups on the Guanine Moiety 
Among the difficulties in the earlier described methods, the purification processes 
during the building block synthesis are major. Reasons for those complex procedures are 
linked to the insufficiently protected guanine moieties. Blocking the 2-NH2 position only, 
leaves another free 3-NH amine and the free 4-carbonyl function, which can account for 
higher polarities of the intermediates, thus rendering the purification complicated.  
In 1999, in an early report, Hayakawa et al.[35] described the synthesis of RNA building 
blocks (i.e 48, 50) where the 2-NH2 function as well as the amide bond of the guanine moiety 
were protected with two separate allylic groups. By blocking both these functional groups, 
higher solubility can be achieved and side reactions might be avoided. In the course of our 
work, in 2003, the same group then published a following report, describing a new synthetic 
method for c-di-GMP based on these same building blocks.[37] This new pathway seemed to 
resolve a few of the drawbacks from the van Boom et al. method and achieve better yields. 
So we decided to apply some of the improvements showed by Hayakawa et al., and develop 
our own new approach. 
Guanosine was first acetylated in acetonitrile on all the free OH positions of the sugar 
to produce 2’,3’,5’-O-triacetylguanosine 45 in 87% yield. Through a Mitsunobu reaction 
sequence in dioxane, an allylic group was introduced on the 4-O position of the guanine 
moiety in a 77% yield. This intermediate 46 was then treated with allylchloroformate (AOCCl) 
and tertbutylmagnesium chloride in THF to introduce the AOC protecting group to the 2-N-
function in 69% yield. Bis-allyloxycarbonated product 47 was then treated with sodium 
hydroxide in ethanol, to remove the acetyl groups as well as one of the AOC groups 
selectively to give intermediate 48 in 72% yield. (Scheme 12)[35] 
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Scheme 12: Introduction of the blocking groups on the base moiety. 
 
 
2.3.2 Blocking the Ribose Positions 
2.3.2.1 First Alternative to the Synthesis of the Building Block 
After having successfully blocked the guanine moiety, the next step was to prepare the 
building block for the coupling reactions, which supposed introducing satisfactory protecting 
groups on the ribose. 
The first alternative to this end was the following: blocking the 5’-OH with a 
dimethoxytrityl group in pyridine to give compound 49 in an 87% yield.[36] The next step was 
then inserting a silyl derivative selectively on the 2’-OH position. Intermediate 49 was 
activated with silver nitrate and pyridine in THF then tertbutyldimethylsilyl chloride was added 
to yield the two regio-isomers 2’-O-TBDMS-derivative 50 and 3’-O-TBDMS-derivative 51 in a 
combined 48% yield. Although, during the separation procedure the TBDMS-group was 
shown to migrate from the 2’-O to the 3’-O-position, which resulted in a final yield of 8% for 
desired isomer 50. (Scheme 13)[35] 
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Scheme 13: Introduction of the protecting groups on the ribose moiety. 
 
 
The main drawback of this method was the lack of regioselective silylation, which 
resulted in the formation of the mixture of 2’-O, and 3’-O silyl ethers. Although it was 
reported, that the use of silver nitrate or even silver perchlorate in the silylation reaction 
should increase the 2’-O-regioselectivity,[36] in the case of the guanosine derivatives, as 
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conditions the silyl group can migrate. The yield could be increased by equilibration of the 3’-
silyl compound to, again, form a mixture of the 2’- and 3’-isomers and separate them, but this 
step was time and material consuming. 
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2.3.2.2 Second Alternative to the Synthesis of the Building Block 
Due to the setback of the TBDMS group migrating under basic conditions, a new 
alternative was found to complete the synthesis of the guanosine building block. The chosen 
protecting group for the 2’-OH function was the pyranyl group, which implied the prior use of 
the 3’,5’-O-cyclic silyl group. 
Starting again from intermediate 48, the 3’,5’-O-disilyl derivative 52 was formed in 
pyridine in 78% yield. In the next step, intermediate 52 was reacted with 3,4-dihydro-2H-
pyran in dichloromethane to block the 2’-hydroxy group and directly, without further 
purification, treatment with triethylamine trihydrofluoride in THF removed the silyl group to 
yield compound 53 in 78% yield.[25] The final step was then the introduction of the 
dimethoxytrityl group on the 5’-hydroxy function in pyridine to give 54 in 87% yield.[36] 
(Scheme 14) 
 
 
 
Scheme 14: Synthesis of Hayakawa-like building block 54. 
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2.3.3 Synthesis of Linear Dinucleotide GpGp 
After having achieved the synthesis of the two building blocks 53 and 54, the next 
stage was assembling them via an internucleotide phosphate bond. The original Hayakawa 
et al.[37] synthesis reported the use of the phosphoramidite method. Since this kind of 
procedure is generally better suited for solid support preparations than for “in solution” 
reactions, due to the lack of long term stability of the phosphoramidite substituted 
intermediates, we chose instead to continue to utilize the phosphotriester methodology. 
The phosphorylating agent used was the same as the one described by van Boom et 
al.[26] based on 1-hydroxy-6-trifluoro-methylbenzotriazole prepared as a 0.2M stock solution 
of 32 in dioxane (see chapter 2.1.2).  
Precursor 54 was treated with phosphorylating agent 32 in dioxane and immediately 
after, nucleotide monomer 53, in dioxane, was added. Dinucleotide 55 was obtained after 
easy purification processes in 74% yield. This intermediate then undergoes an acidic 
treatment with dichloroacetic acid in dichloromethane to remove the 5’-O-dimethoxytrityl 
group to give 3’,5’-free OH dimer 56 in 59% yield.  
The last step of the synthesis was then closing the 12-membered phosphate-sugar 
ring. Several attempts showed that compound 56 does not undergo cyclization in the 
presence of phosphorylating agent 32 in dioxane, but open chain dinucleotide GpGp 57 was 
obtained in 87% yield. Any further attempts to cyclize the linear dimer through classic 
phosphate activation procedures were unsuccessful. (Scheme 15)[26] 
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Scheme 15: Synthesis of the linear dimer GpGp. 
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2.3.4 Discussion 
The advantage of preparing nucleosides with allylic protecting groups blocking the 
base completely was, first, the easier purification procedures as well as the reduction of 
redundant synthesis steps. Adding these two new protecting groups lowered the polarity of 
the purine base residue, thereby facilitating the purification processes and increasing the 
yields. The introduction of those groups was fairly straightforward and attained in high yields. 
The choice of the protecting groups used on the ribose moiety was more challenging. 
The first alternative, where a silyl group was introduced to block selectively the 2’-hydoxy 
function, proved to be a poor choice, since this protecting group has been shown to migrate 
from 2’-OH to 3’-OH under basic conditions. The yields were low and handling this protecting 
group was time and material consuming, so this option was abandoned. 
Nevertheless, another opportunity has been found by utilizing the 3’,5’-disilyl cyclic 
protecting group. Even if the use of this group previously induced solubility as well as yield 
issues, the aforementioned allylic substituents on the base canceled those concerns nicely. 
This option also helped in rendering the introduction of the pyranyl group on the 2’-OH 
completely selective. Through this pathway, the synthesis of the two building blocks 
necessary, afforded high yields over six and seven steps respectively.  
Assembling the precursors to form the cyclic nucleotide was performed using the 
phosphotriester methodology described by van Boom et al.[26] Unfortunately, the reported 
ring closure could not be reproduced. Indeed, the cyclization could not be achieved, and the 
phosphorylated linear dinucleotide pGpG was the only product obtained, even though a 
number of diverse conditions and procedures have been tried.  
Several explanations can be found for this issue. The first was the sensitivity to bases 
of the phosphate linkage. Indeed, even mildly basic conditions, such as a work up with 
sodium hydrogen carbonate, were enough to open the 12-membered ring and form the linear 
dinucleotide. Furthermore, the introduction of the cyclizing phosphate bond was sensitive to 
moisture. The activated phosphorylating agent has been shown to be hydrolyzed by even 
small amounts of moisture present during the reaction process. And, after this hydrolysis, the 
phosphate formed became inactive and could not be successfully turned into an intermediate 
able to undergo cyclization. 
In summary, the pathway to obtain c-di-GMP, described in this chapter has not led to 
the desired dinucleotide. Even so, it helped in resolving some of the issues, concerning 
solubility, chemoselectivity and purification processes, encountered during the syntheses 
described before. With the experience acquired during the different syntheses performed 
here, it became obvious that the main drawback and therefore also the biggest problem to 
solve, was the protection of the 2’-OH group. We were also able to apply the new insight 
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about the concerns raised by using the phosphotriester methodology, to the synthetic route 
investigated later.  
All the methods described here so far were long and implied difficult purifications, 
therefore they were not suitable for scale-up synthesis processes. This coupled with the fact 
that the 2’-OH protection remained a problem and was expensive in material (at least half 
was lost), prompted us to turn our attention to a method to avoid the 2’-OH protection 
altogether. This new method used again the phosphotriester methodology that we estimate 
to be more suitable for solution phase chemistry as will be described in the next chapter. This 
method turned out to be suitable for scale-up and was also very flexible in terms of base 
modified analogues.  
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3. A NEW SYNTHETIC APPROACH FOR C-DI-GMP: RIBOSE BUILDING BLOCK 
BASED 
After having explored the different existing synthetic routes, it quickly became obvious 
that we would have to design a new method that would be more efficient and account for all 
the problems we encountered previously. The main issues were finding a short and efficient 
synthesis for the building blocks with special attention to the 2’-OH protection of the guanine 
but also increasing the scale of the reaction. The choice of the phosphoramidite versus the 
phosphotriester methodology was also important. In our hands, the phosphotriester 
methodology seemed to be the most efficient for our project.  
To solve the other problems we have decided to adopt a brand new approach in which 
we will synthesize a sugar-phosphate backbone and introduce the base at a late stage (as 
shown in Scheme 16). Through this route we anticipate to solve the matter of the 2’-OH 
protection completely by using the 1’,2’-acetal protecting group. The next section will 
describe in detail this new and very efficient synthesis pathway. 
 
 
 
Scheme 16: Overview of the new synthetic pathway. 
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3.1 Synthesis of the Ribose Unit Starting from Glucose 
The synthetic pathways described in the preceding chapter showed limitations in their 
efficiency and were also tedious to perform. Moreover, the described methods all started 
from guanosine. This meant that, to obtain analogues, the synthesis had to be started over 
from the very first step of the building block preparation.  
Therefore, to solve all the problems encountered before, a different synthesis had to be 
devised. In 1983, Charollais et al.[32] reported the cyclic sugar backbone 18 (see Scheme 16) 
as a by-product in the synthesis of phosphate esters of ribo- and xylo-furanoses. It should be 
easy to convert 18 into c-di-GMP or its analogues by introducing a nucleobase, via modified 
Vorbrüggen conditions[38], at a late stage in the synthesis and starting the pathway with a 
furanose building block.[39]  
Agrofoglio et al.[39] reported the synthesis of a ribo-furanose unit 61 starting from α-D-
glucose. This unit will be the starting point of our new synthesis pathway. α-D-Glucose 58 
was treated with acetone in the presence of zinc chloride and phosphoric acid to be 
converted to α-D-xylose 59 in 54% yield. Oxidation with pyridinium dichromate (PDC) and 
acetic anhydride in dichloromethane led to the selective dehomologation of 1’,2’:5’,6’-di-O-
isopropylidene-3’-oxo-α-D-glucofuranose 60 in 88% yield. This ketone was submitted to a 
one-pot sequential transformation with periodic acid in ethyl acetate and sodium borohydride 
in ethanol to the desired optically pure derivative 61 in 46% yield. The preparation of the first 
ribose building block needed 61, showed an overall yield of 21% over 3 steps starting from α-
D-glucose. (Scheme 17)[39] 
One of the main advantages of this building block was blocking the 1’- and 2’-OH as an 
acetal for the whole synthesis. This allowed us to bypass all the issues inherent to the 
selective protection of the 2’-hydoxy group. Indeed, this was a significant drawback in the 
previously reported syntheses.  
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Scheme 17: Converting glucose to the ribose precursor 61. 
 
 
3.2 Synthesis of the Ribose Building Blocks 
Since synthesizing the ribose building block straight from α-D-glucose did not lead to 
satisfactory yields, another alternative was found. This compound can be prepared more 
efficiently using a higher yielding pathway. Indeed, 1’,2’-O-isopropylidene-α-D-xylofuranose 
62 is a commercially available precursor. In order to be suitable for RNA-nucleotide 
synthesis, this precursor needs to be stereoselectively converted to the desired optically pure 
ribose sugar. 
The 5’-free OH group of 1’,2’-O-isopropylidene-α-D-xylofuranose 62 was first blocked 
with a tertbutyldimethylsilyl (TBDMS) group via treatement with TBDMSCl in 
dichloromethane to afford 5-O-tertbutyldimethylsilyl-1,2-O-isopropylidene-α-D-xylofuranose 
63 in 97% yield.[40] Oxidation with pyridinium dichromate and acetic anhydride in 
dichloromethane led to the selective dehomologation at the 3’-OH position to give the 3’-oxo-
xylofuranose 64 with 91% yield. The ketone was then reduced to the secondary alcohol with 
sodium borohydride in a mixture of ethanol:water (3:1, v/v) to yield the first building block 65 
in 91% yield. Treatment with triethylamine trihydrofluoride in THF led to the removal of the 5’-
TBDMS group and the second building block necessary, 66, was obtained in 93% yield. The 
overall yield for this approach was 75% over 4 steps to obtain both ribose building blocks 
needed, 65 and 66, starting from the commercially available xylose 62. (Scheme 18)[39]  
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Scheme 18: Preparation of the ribose building blocks 65 and 66. 
 
 
3.3 Synthesis of the Cyclic Sugar Backbone 
From our experience, the phosphotriester methodology was more suited in the case of 
an “in solution” synthesis method. Therefore, we chose to use the original van Boom 
phosphorylating reagent, which was based on 1-hydroxybenzotriazole (HOBt). 2-chloro 
phosphoryldichloridate 68 was treated with 1-hydroxybenzotriazole and pyridine in THF 
under inert atmosphere to yield a 1 M stock solution of phosphorylating agent 69 in THF 
under argon. (Scheme 19)[41]  
 
 
 
Scheme 19: Synthesis of the HOBt based phosphorylating agent 69. 
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The synthesis was started with 5’-O-tertbutyldimethylsilyl-1’,2’-O-isopropylidene-α-D-
rifuranose 65. It was treated with phosphorylating agent 69 in THF under inert atmosphere 
and then coupled with precursor 66 in THF to give the dinucleotide 70 in 64% yield.[26] The 
TBDMS protecting group was then removed by treatment with ceric ammonium nitrate (CAN) 
in methanol to afford 3’,5’-free OH dimer 71 in 77% yield.[42] This was a rather unusual 
deprotection method but it was necessary here. In fact, the usual cleavage method for 
TBDMS involved a fluoride treatment. Classical fluoride reagent solutions, like TBAF, 
became basic over time, which was not compatible with the protected phosphate linkage 
since it was base sensitive. Another alternative had to be found and the deprotection of 
choice was this oxidative method involving cerium (IV). 
Cyclization was then performed via a diluted solution of 2-chlorophenyl 
phosphorodichloridate 68 in pyridine to give cyclic intermediate 72 in 64% yield. Conversion 
of the acetal blocking groups to acetate esters was achieved through treatment with acetic 
anhydride in acetic acid to afford c-di-GMP precursor 73 in 70% yield. (Scheme 20)[39]  
 
 
 
Scheme 20: Synthesis of the sugar backbone 12-membered ring 73. 
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The synthesis of phosphate linked dimer 70 afforded a mixture of diastereomers due to 
the phosphorus atom. The R and S isomers can be distinguished in the NMR analysis but 
they could not be separated. The same observations were true for dimer 71. The cyclization 
process added a second phosphate atom, with introduced a second stereo-centre on the 
molecule. The compound 72 was synthesized as a mixture of 4 diastereomers. However, two 
distinct fractions, which have notably different retention factors (Rf), could be obtained during 
the purification process and both have been identified as the desired cyclic product 72. The 
NMR analysis afforded further insight into the nature of the isomers. The fraction with the 
highest Rf value presented two peaks in the 31P NMR analysis, which lead to the belief that 
this fraction contained the RR and SS isomers. On the other hand, the fraction having the 
lowest Rf value, lead to only one peak in the 31P NMR analysis. This seemed to confirm that 
the lowest Rf fraction consisted of the RS and SR fractions. Nevertheless, each of those 
fractions could be converted to the acetylated product 73 and then further used in the 
synthesis of c-di-GMP. To avoid the multiplication of products and facilitate the purification 
processes, both fractions were used separately in the following steps of the reaction 
pathway. The resulting final product, c-di-GMP, has been analyzed by HPLC procedures and 
showed the exact same retention times strating from both fractions.  
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3.4 Synthesis of the Guanine Unit 
The greatest difficulty in the coupling of protected sugar derivatives with guanine-type 
bases, using the modified Vorbrüggen methodology[38], was the mixture of N7/N9 isomeric 
nucleotides that were produced and difficult to separate. Reportedly, coupling “directly 
protected” guanine derivatives has consistently produced 7/9 isomer mixtures, whereas 
constricting the guanine system into “4-enolate” derivatives resulted in enhancement of the 
9/7 isomer ratios.[43] The problem was overcome by blocking sufficiently and appropriately 
the guanine.[44] 
Guanine 74 was treated with isobutyric anhydride in dimethylacetamide (DMA) to block 
the 2-N-amine function as isobutyric amide 75 in 85% yield. This compound was then 
submitted to acetic anhydride in dimethylformamide to yield 9-N-acetylated intermediate 76 
in 85% yield. Finally, through a Mitsunobu type reaction with 2-(p-nitrophenyl)ethanol, the 
protecting group was introduced on the free 4-oxygen and the acetyl group was removed, in 
a one-pot reaction, to lead to the desired appropriately blocked guanine unit 77 in 33%. 
(Scheme 21)[44] 
 
 
 
Scheme 21: Preparation of the guanine building block 77. 
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3.5 Assembling c-di-GMP  
The protected guanine unit 77 was persilylated with BSA in dichloroethane and 
condensed with the acetylated sugar-phosphate 12-membered ring 73 under modified 
Vorbrüggen conditions.[38] The development of these conditions helped to overcome many 
difficulties with the sugar-base couplings and most bases led to high regioselectivities. It was 
reported that the 7-isomers were formed as kinetic products of the glycosylation of 
persilylated guanines, whereas the more thermodynamically stable 9-isomers were obtained 
upon heating.[43] Using this procedure, the fully protected c-di-GMP 78 was obtained in 66% 
yield.  
The o-chlorophenyl protected phosphate bond was sensitive to bases, even mild 
conditions could induce cleavage. Due to the nature of the other protecting groups used and 
the conditions necessary for their cleavage, the chlorophenyl group had to be removed first. 
Treatment with syn-pyridine-2-carbaldoxime in the presence of N,N,N,N-
tetramethylguanidine in pyridine removed the chlorophenyl as well as the Npe groups. 
Finally, treatment with aqueous ammonium hydroxide led to the removal of the acetyl and 
isobutyryl protecting groups. A first purification step was achieved using size exclusion 
chromatography. This allowed the separation of the product from excess reagents and most 
of all the remaining nucleobase, which was responsible for internucleotide phosphate bond 
cleavage. An additional reverse phase HPLC purification was necessary, to separate the 7- 
and 9-isomers and afforded pure c-di-GMP in 84% yield. (Scheme 22)[45] 
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Scheme 22: Synthesis of c-di-GMP. 
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3.6 Conclusions 
The new synthetic pathway designed here, starting from the sugar building blocks, has 
successfully afforded pure c-di-GMP in high yields. Indeed, c-di-GMP was obtained in 10% 
overall yield in 9 steps, starting from commercially available 1’,2’-O-isopropylidene-α-D-
xylofuranose 62. In comparison to the published synthesis methods, several drawbacks have 
been resolved and our new method affords c-di-GMP in higher amounts with high yields. For 
example, the overall yield we obtained to prepare c-di-GMP using the van Boom et al. 
procedure was only 0.2% over 10 steps, starting from commercially available guanosine. 
One of the main concerns with the other methods was the lack of appropriate 
protecting groups for the 2’-OH function. This issue was completely avoided with our new 
strategy, since the 1’- and 2’-OH groups were blocked as an acetal during the synthesis of 
the sugar building blocks. This facilitated enormously the preparation of the two sugar units 
needed, since there were no more troubles with tedious purification processes. The 
synthesis of the building blocks in general, was easy to perform, and we even realized the 
preparation starting from 30 grams xylofuranose with high yields. The guanine precursor was 
also straightforward to synthesize in 3 steps with high yields, and can easily be done on a 
multi-gram (30 grams guanine) scale.  
Assembling the sugar backbone was also easy to perform with high yields (22% over 4 
steps) even when scaling-up. During the backbone assembling process, care had to be 
taken to avoid any basic conditions during the reactions or the work-up procedures. The 
chlorophenyl protected phosphate bond was particularly sensitive to bases, even weaker 
ones. The only problems encountered were during the deprotection of the TBDMS group 
prior to the cyclization. Indeed, the usual method for this step was not compatible with the 
protected phosphate linkage since it was base sensitive. Another efficient alternative was 
found using cerium (IV) ammonium nitrate.  
The introduction of the base on the sugar backbone following modified Vorbrüggen 
conditions[38] was cause for a little more tedious work. Since we made the choice to insert the 
base on the sugar moiety at a late stage, the possibility of forming the 7-N-guanosine as well 
as the desired 9-N-guanosine existed. This trend has been known to be a cause for low 
yields and loss of material when trying to synthesize natural oligonucleotides. Following 
appropriate reports[43], heating the reaction mixture afforded preferentially the thermodynamic 
9-isomer, with only small amounts of the other isomer. Even with the matter that the 9-isomer 
can only be obtained preferentially and not exclusively, a good yield could be achieved and 
c-di-GMP could be obtained in reasonable amounts. 
Care had also to be taken during the final deprotection step. As mentioned before, the 
chlorophenyl protected phosphate was base sensitive, so it had to be the first protecting 
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group to be cleaved. After this, a basic treatment under rather harsh conditions with aqueous 
ammonia afforded c-di-GMP in fairly high yield and in 99% HPLC purity. 
The new synthesis pathway described here was straightforward and suitable for 
scaling-up. The synthesis can be performed in a few weeks and reasonable amounts of c-di-
GMP can be obtained. Indeed, using our method 500 mg product could be easily 
synthesized. 
The only issues we encountered during this process were ones due to the purification 
procedures. The size exclusion chromatography purification was time consuming and poorly 
suitable for larger amounts of c-di-GMP. Efforts were undertaken to find more appropriate 
ways to purify large quantities of c-di-GMP. First tests with crystallization attempts showed 
promising results. 
The main advantage of this new approach for the preparation of c-di-GMP was that it 
allowed for a fairly straightforward preparation of base modified analogues. Indeed, since the 
base was introduced at a late stage, it enabled us to prepare one sugar backbone and 
exchanging the base only required small adaptations of the method in the last steps. It could 
also be imagined to use the same strategy, building a cyclic sugar backbone then introducing 
the base, to prepare internucleotide linkage modified analogues. 
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4. PREPARATION OF C-DI-GMP ANALOGUES 
4.1 Synthesis of Base Modified c-di-GMP Analogues 
4.1.1 Base Precursors 
Since c-di-GMP has attracted great interest due to its various biological activities, it is 
important to investigate, which functions of c-di-GMP are involved in the different biological 
processes. The biological properties also prompted systematical investigations of the activity 
of c-di-GMP related compounds including derivatives with modified nucleobases, 
carbohydrates and internucleotide bonds. 
In 2006, Hayakawa et al.[46] first reported the synthesis of three modified cyclic 
nucleotides following the same synthesis pathway they used for c-di-GMP.[29] The 
compounds they reported were two mixed cyclic dinucleotides, one compound where a 
guanosine was exchanged for an adenosine and the other where one guanosine was 
replaced with an inosine. They also prepared an internucleotide-bond modified cyclic 
diguanosine where a phosphate is replaced by a thiophosphate.  
In order to show the flexibility of our own new synthetic route, the synthesis of base-
modified analogues of c-di-GMP was undertaken. The intend was to show that the synthesis 
was not specific for purine bases but can be applied to pyrimidine bases as well as non 
natural nucleobases, such as xanthine or theophylline for example.  
The first step to this end was preparing the bases for their introduction on the 12-
membered sugar backbone. The analogues we chose to synthesize were those using 
adenine, thymine and theophylline as an alternative nucleobase. Thymine 81 is a pyrimidine 
normally found in DNA and not in RNA. It can be used directly as a nucleotide precursor and 
does not need any further protection steps. Theophylline 82 is an unnatural pyrimidine base 
that is fully protected and therefore can also be used directly as a precursor.  
The only chosen nucleobase that required additional blocking steps was adenine as it 
has a free primary amine function on C-4 of the 6-membered ring. Adenine was treated with 
isobutyric anhydride in dimethylacetamide to afford the protected derivative 80 in 82% yield. 
(Scheme 23)[44]  
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Scheme 23: Base-modified analogues precursors. 
 
 
4.1.2 Synthesis of the c-di-GMP Analogues 
The base introduction procedure was the same as for c-di-GMP. The protected 
adenine 80 was persilylated with BSA in dichloroethane and condensed with the acetylated 
sugar backbone 73 under modified Vorbrüggen conditions.[38] Fully protected c-di-AMP 83 
was obtained in 59% yield. The phosphate protecting groups were removed using syn-
pyridine-2-carbaldoxime in the presence of N,N,N,N-tetremaethylguanidine in pyridine. Final 
treatment with aqueous ammonium hydroxide led to the removal of the acetyl and isobutyryl 
protecting groups. After purification via size exclusion chromatography and HPLC, pure c-di-
AMP 84 was obtained in 81% yield. (Scheme 24)[45] 
The same procedure was used to prepare the analogues containing thymine 81 and 
theophylline 82. Fully protected c-di-TMP 85 was obtained in 51% yield and fully protected c-
di-(theo)MP 86 was obtained in 47% yield. The difference was the simplified deprotection 
strategy needed, due to the lack of protecting groups on the bases. The protecting groups on 
the ribose and on the phosphate bond were removed in one operation, using syn-pyridine-2-
carbaldoxime in the presence of N,N,N,N-tetramethylguanidine in pyridine. After purification 
via size exclusion chromatography and HPLC, pure c-di-TMP 87 and c-di-(theo)MP 88 were 
obtained in 76% and 81% yield respectively. (Scheme 24)[45] 
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Scheme 24: Synthesis of base modified analogues: c-di-AMP, c-di-TMP and c-di-(theo)MP. 
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4.1.3 Conclusions 
The synthesis of base modified analogues of c-di-GMP via this new approach was 
easy since the preparation of the building blocks and the assembling of the sugar backbone 
was the same as for c-di-GMP and the modifications only appeared in the last two steps. 
This means a whole variety of molecules can be prepared starting from the same precursor, 
the sugar backbone.  
This method was easy to apply to purine bases like guanosine or adenosine, even if 
those bases need to be suitably protected before being introduced on the backbone. This 
methodology can also be applied to pyrimidine bases, like thymine, or non natural bases like 
theophylline in high yields.  
Another important feature was the sequence in which the deprotection step was 
performed. The phosphate bond was base sensitive as long as it was blocked with the 
chlorophenyl group. Thus, in order to preserve the cyclic dinucleotide bonds, this group had 
to be cleaved first, since the remaining protecting groups, on the nucleotides, were all base-
labile. If this sequence was respected, the cyclic dinucleotides were obtained with high 
yields. 
The new approach for the synthesis of c-di-GMP we described here, showed a 
flexibility that has not been accounted for in previously published procedures. With a little 
adaptation, we could even imagine preparing non symmetric compounds, where two different 
bases are introduced on the backbone.  
Due to the apparent adaptability of this method, we decided to use the same strategy 
to prepare internucleotide linkage modified compounds. The modified building blocks would 
then be assembled to form a sugar backbone linked through carbamate, amide or non 
hydrolysable bonds. The introduction of the base would again be performed at a late stage to 
afford variation possibilities. 
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4.2 Towards the Synthesis of an Amide Bond Internucleotide Linked 
c-di-GMP Analogue 
4.2.1 Synthesis of the Sugar Building Blocks 
Presumably, c-di-GMP cannot pass through the cell membrane and the interactions 
between c-di-GMP and its target proteins during the recognition mechanisms remain 
unknown. Preparing analogues, whether the base or the internucleotide linkage was 
modified, could help to determine, which functions of c-di-GMP are involved in the various 
biological activities of this dinucleotide. It could also lead to the discovery of new bioactive 
compounds derived from c-di-GMP. 
Oligoribonucleotides having amide internucleotide linkages, instead of the natural 
phosphodiester group, have been synthesized in the last two decades due to their potential 
nuclease-resistant antisense effects. The advantages of the amide bond include a greater 
stability under physiological conditions than the phosphodiester bond. The amide moiety is 
readily accessible by simple synthetic methods and also achiral, thereby avoiding 
diastereomeric mixtures usually obtained during the synthesis of phosphodiesters. Due to the 
charge reduction with respect to phosphates, neutral amide bonds should also favor the 
penetration of the oligonucleotides through the cellular membrane.[47]  
For these reasons, exchanging the phosphodiester bond for an amide linkage seemed 
appropriate to gain more insight into the mode of action of c-di-GMP. After having 
successfully synthesized base-modified analogues, our next goal was to prepare an 
internucleotide amide bond dinucleotide. We decided to apply the same synthesis strategy 
as before, where a sugar backbone was prepared and the base was introduced at a late 
stage. To this end, we had to synthesize two modified building blocks starting from the 
commercially available 1’,2’-O-isopropylidene-α-D-xylofuranose 62 shown in Scheme 18.  
The 5’-free OH group of the xylofuranose precursor was first blocked with a 
tertbutyldimethylsilyl (TBDMS) and the selective dehomologation at the 3’-OH position lead 
to the 3’-oxo-xylofuranose 64, as described in chapter 3.2 (Scheme 18).[39] Through a Wittig 
reaction of the ketone with [(ethoxycarbonyl)methylene] triphenylphosphine in 
dichloromethane the alkene 89 was obtained in 91% yield.[48] Treatment with triethylamine 
trihydrofluoride in THF led to the removal of the 5’-TBDMS group and the free alcohol 90 was 
obtained quantitatively. Catalytic hydrogenation of the alkene function in the presence of 
palladium on activated charcoal in ethanol, afforded free alcohol 91 in 85% yield. The alcohol 
was then converted into its tosylate by treatment with tosyl chloride in pyridine, intermediate 
92 was obtained in 65% yield. Finally, treatment with sodium azide in DMF yielded the 
building block precursor 93 quantitatively. The overall yield for this approach is 45% over the 
66  Analogues 
7 steps to obtain the precursor 93 needed to prepare both building blocks, starting from the 
commercially available 1’,2’-O-isopropylidene-α-D-xylofuranose 62. (Scheme 25)[48] 
 
 
 
Scheme 25: Preparation of the ribose precursor 93. 
 
 
In order to assemble the amide linked sugar dimer, the two different building blocks 
necessary were prepared from precursor 93. Saponification of compound 93 using sodium 
hydroxide in methanol, gave the first building block, the 3’-(carboxymethyl) sodium salt 94, 
quantitatively. Hydrogenation, in the presence of palladium on charcoal in ethanol, of azide 
93 gave the second building block, the free 5’-amine 95, in 85% yield. (Scheme 26)[48] 
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Scheme 26: Preparation of the ribose building blocks 94 and 95. 
 
 
4.2.2 Attempts to Prepare the Amide Linked Cyclic Backbone 
After having prepared the necessary building blocks, the next step was the assembly of 
the sugar backbone. The formation of the amide bond was performed using standard peptide 
coupling processes. The free-acid building block 94 was activated using HCTU in DMF in the 
presence of Hünig’s base, and added to free-amine building block 95 in dichloromethane to 
afford amide linked dimer 96 in 55% yield.[49] Saponification with sodium hydroxide in 
ethanol, followed by catalytic hydrogenation afforded dimer 98 in 85% yield.[48]  
Several attempts to cyclize compound 98 were performed using HCTU as coupling 
reagent in the presence of Hünig’s base as a diluted solution in dichloromethane.[49] 
Unfortunately, only trace amounts of cyclic compound 99 were obtained in yields under 5%. 
These findings showed that the cyclization did occur but more work was required to 
efficiently perform this reaction.  
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Scheme 27: Preparation of the cyclic backbone. 
 
 
a) i. DIPEA, DCM; ii. 94, DIPEA, HCTU, DMF, RT, 1 hr, 55% b) NaOH, MeOH, RT, 1 hr, quant.; c) Pd/C, H2, EtOH,
RT, 16 hrs, 85%; d) HCTU, DIPEA, DMF, DCM , RT, 16 hrs, 5%.
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4.2.3 Discussion 
The preparation of an internucleotide linkage modified analogue for c-di-GMP was 
thwarted by the very low yields obtained during the cyclization process when trying to build 
up the sugar backbone.  
The macrocycle might be more difficult to form presumably due to conformational 
constraints in the cyclic molecule induced by the peptide bond, which would lead to the low 
yields. To further optimize the reaction conditions, such as using longer reaction times, other 
solvent systems or even changing the temperature, might improve the yields. One should 
also consider alternatives, such as different coupling reagents or even different reaction 
sequences.  
Nevertheless, we managed to prepare the necessary building blocks in quite high 
yields as well as preparing the modified dimer efficiently. We used the same type of strategy 
as for the preparation of c-di-GMP where the sugar backbone was prepared first. Even if the 
cyclization only afforded traces of product so far, it might be interesting to continue the work 
in this direction.  
Since the biological mechanisms, as well as the extend of the biological activities, of c-
di-GMP still remain to be discovered, preparing analogues might be useful in uncovering the 
applications of this cyclic dinucleotide.  
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5. BIOLOGICAL PROPERTIES OF C-DI-GMP 
5.1 The Role of c-di-GMP in Caulobacter crescentus 
5.1.1 c-di-GMP: a Secondary Messenger in Caulobacter crescentus 
Caulobacter crescentus is an aquatic bacterium that undergoes an obligate 
developmental transition that enables cells to switch between a sessile, surface-attached 
form (stalked cell) and a motile, flagellated form (swarmer cell). This asymmetrically dividing 
bacterium, produces a nonmotile and a motile cell at the end of each cycle. Upon completion 
of cell division, the motile swarmer cell enters a period of morphogenesis required to 
differentiate into a sessile stalked cell to initiate another cell division cycle. During this 
transition, the swarmer cell undergoes several physiological and morphological changes. As 
a consequence, the cell poles are constantly remodeled. One of those changes is the 
ejection of the polar flagellum (Figure 3).[16] 
 
 
 
Figure 3: Schematic diagram of the Caulobacter crescentus cell cycle with the three different 
cell types: the swarmer cell, the stalked cell and the predivisional cell.[50] 
 
 
PleD is an important protein involved at the flagellar-ejection stage. This unorthodox 
response regulator harbors two N-terminal receiver domains arranged in tandem and a C-
terminal output domain with a highly conserved amino acids sequence. The putative output 
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domain, called “GGDEF” or “DUF1”, is widespread and highly conserved in many bacterial 
species. It has been demonstrated that the PleD regulator dynamically localizes to the 
differentiating stalked pole during the cell cycle when activated, thus postulating a local 
activity of PleD. This called for a mechanism that would convert the input into a readout that 
affects downstream targets, the production of a cyclic nucleotide could be such an output.  
The function and regulation of PleD in the polar development of C. crescentus was 
investigated in collaboration with the group of Prof. Urs Jenal.[51] They demonstrated that 
cells lacking a functional PleD protein are hypermotile, unable to eject the flagellum and fail 
to synthesize a complete structure. In contrast, the presence of the constitutively active 
mutant protein PleD* results in elongated stalks and has a dominant negative effect on 
motility. In vitro experiments showed that the input comes in the form of the phosphorylation 
of the first receiver domain of PleD. Biochemical assays with crude extracts of C. crescentus 
containing the phosphorylated form of PleD, showed that GTP was readily converted into a 
novel nucleotide compound. To attribute this activity to PleD, assays with the purified protein 
were performed and confirmed the rapid disappearing of GTP and the formation of this new 
nucleotide. After analysis and comparison with the chemically synthesized di-nucleotide c-di-
GMP, it was confirmed that the novel nucleotide is indeed the cyclic diguanylic acid.[51]  
To further investigate the proposed enzymatic reaction, product inhibition was 
evaluated. When chemically synthesized c-di-GMP was added to the reaction mix in 
concentrations similar to GTP, strong inhibition was observed. This suggests that c-di-GMP 
and GTP compete for the binding site. Furthermore, monitoring the concentration of c-di-
GMP by HPLC showed that neither a decrease nor a conversion of c-di-GMP into GMP or 
any other degradation product was observed over a prolonged period of time. Those findings 
confirm the absence of phosphodiesterase activity of PleD. To investigate the specificity of 
the activity, tests with deoxyGTP and ATP were performed. It was found that the affinity for 
ATP is low and both GTP and deoxyGTP bind to PleD but only GTP is converted to c-di-
GMP. These experiments proved that PleD harbors an intrinsic nucleotide cyclase activity, 
that specifically catalyses the conversion of GTP into c-di-GMP and that this activity 
constitutes the output signaling action of PleD.[51] 
Finally, experiments with wild-type PleD and mutated forms, where the GGDEF domain 
was modified, showed that the mutant proteins lack diguanylate cyclase (DGC) activity in 
vitro. This confirms the idea that the C-terminal GGDEF domain is responsible for the 
enzymatic activity. The fact that in vitro activity was observed even without phosphorylation 
of PleD also showed that the precise activation process remains to be elucidated but it was 
also clearly indicated that phosphorylation of the first receiver domain increases the activity 
of the dignuanylate cyclase domain.[51]  
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Combined with the knowledge that over 900 GGDEF domains are reported in 
databases, these results imply that diguanylate cyclases (DGCs) might be widespread in the 
bacterial kingdom and that c-di-GMP might be a common secondary messenger in 
prokaryotes.[8] 
 
 
5.1.2 c-di-GMP as a Tool to Investigate the Structure of PleD 
The importance of c-di-GMP can be understood when knowing the omnipresence of 
the GGDEF domain, newly identified as a diguanylate cyclase, in the bacterial genomes, 
where it occurs in various combinations with other sensory and/or regulatory modules. 
Despite the large distribution and relevance of DGC proteins, structural and functional 
information about this class of regulators is largely missing. Response regulators constitute a 
large protein family. Typically they are composed of a conserved receiver domain and a 
DNA-binding effector. All structurally characterized receiver domains share structural 
features that comprise a doubly-wound, five-stranded parallel sheet structure (see Figure 
7).[52] PleD is an unorthodox response regulator in that it consists of three domains, two 
receiver domains and one output domain.  
 
 
 
Figure 7: Typical response regulator receiver domains adopting the (β/α)5 fold. Secondary 
structures are labelled. All helices are marked as α and all sheets as β in this study.[52] 
 
 
In a collaboration work, the group of Prof. Tilman Schirmer investigated the structure of full 
length PleD. Purified nonphosphorylated PleD was crystallized at room temperature in the 
presence of an excess synthetic c-di-GMP. After solving the crystal structure, a linear 
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arrangement of three structural domains (D1, D2 and DGC) that are connected by single 
disordered loops, was identified (Figure 8).[53] 
 
 
 
Figure 8: Crystal structure of PleD: the monomer consists of three domains, D1, D2 and 
DGC, connected by disordered linker peptides.[53]  
 
 
The crystal structure showed that D1 and D2 have the typical response regulator fold with a 
(β/α)5 topology. However in both cases one α helix, the one linking to the next domain, is 
considerably extended beyond the globular domain. Both domains resemble each other, with 
the exception that D1 carries the activation domain while D2 can not be phosphorylated. The 
so-called “acidic-pocket” constitutes the phosphoacceptor and is shown as coordinating an 
Mg2+ ion. The DGC domain has a different structure, consisting of a five-stranded central β –
sheet surrounded by α helixes. The arrangement is closely similar to that of the catalytic core 
of adenylate cyclase and the “palm” domain of DNA-polymerases. Obviously, not only the 
structure but also the function of the DGC domain are closely related to adenylate cyclase 
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and DNA-polymerases, as it also catalyzes the formation of a phosphodiester. The GGDEF 
signature motif is located on the β-hairpin (blue) and is part of the catalytic active site (A-site) 
where a c-di-GMP molecule is formed and can also be bound.[53] 
Surprisingly, the crystal structure also showed that two c-di-GMP product molecules 
are bound at the D2/DGC interface, the inhibition site (I-site). (see Figure 8) The two 
molecules are intercalated in a similar structure as has been observed for crystal forms of c-
di-GMP (see chapter 1.3).[22, 23] Each central guanyl moiety forming an intermolecular 
hydrogen-bond with a phosphate. This ligand is bound to both the D2 and DGC subunits of 
the protein by multiple interactions. Kinetic data revealed strong product inhibition about an 
order of magnitude lower than estimated for the cellular concentration. This supposes 
noncompetitive product inhibition i.e. independent of substrate concentration, and can thus 
be attributed to an allosteric effect of I-site binding.[53] 
PleD catalyzes a condensation reaction between two identical substrates to yield a 
symmetrical product. As determined by analysis, nonactivated PleD seems to exist in 
solution, in the monomeric form. For the enzyme to be efficient, dimerization seems to be 
necessary because a reaction catalyzed by a PleD monomer would be limited by the 
macromolecular diffusion rate. Based on those observations, a mechanistic model was 
proposed (Figure 9). Phosphorylation of the D1 sub-unit, would induce a change of 
configuration at the D1/D2 interface and D1 would change its orientation with regards to D2, 
thereby forming a tight stem. This in turn will enhance the dimer formation mediated by 
interaction at the D1/D2 interfaces. Still, a large distance between the two active sites would 
not permit catalysis. However, when allowing flexibility of the DGC domains, a “closed” dimer 
conformation can be modeled, in which a complete two-fold active site is formed between 
DGC and DGC’. In the context of this activation-by-dimerization model, the observed 
allosteric effect can also be easily explained. By binding the product at the I-site, the D2/DGC 
interface would be stabilized, thereby preventing the active sites to come together. Recently, 
a secondary inhibition site on the DGC domain has also been found. This site would allow for 
a new form of inhibition, by crosslinking DGC and DGC’ through their respective primary and 
secondary inhibition sites. However in both cases, the two substrate loaded active sites are 
hampered from a productive encounter by the immobilization of the DGC domains through 
crosslinking by two product molecules.[53, 54] 
The tight regulation of PleD by product inhibition probably demonstrates the importance 
of imposing an upper limit on the concentration of c-di-GMP. Nevertheless, it remains to be 
shown that, as predicted, inhibition is independent of the phosphorylation state of the 
enzyme. This elucidaded structure of PleD also provides insight into the molecular 
interactions with c-di-GMP that may recur in the recognition by other proteins.[53, 54] 
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Figure 9: Mechanistic model of PleD regulation. The catalytic DGC domain (green) is 
connected via a flexible linker peptide (black) to the D1/D2 stem. The DGC domain is 
postulated to be mobile with respect to the stem, as indicated by the curved arrow (black). 
The bound GTP substrate is indicated in blue.[53,54] 
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5.2 The Role of c-di-GMP in the Biofilm Formation 
5.2.1 Biofilms: Formation, Structure and Characteristics 
The majority of micro-organisms favor a lifestyle where the bacteria are sessile; a 
surface attached state, rather than being free and isolated in their environment. After being 
attached to a surface, bacteria form communities called biofilms. Until recently, biofilms were 
known for their ability to cover and corrode water pipes or ship hulls. In the last few years, 
their importance in the medical field has been increasing since over 65% of bacterial 
infections in mankind involve biofilms. They can form on biotic or abiotic surfaces, such as 
catheters or implants but also on tissues such as teeth, eyes, lungs, ears and uro-genital 
tracts.[55] 
Biofilms are organised multi-layered bacterial communities attached to a surface, and 
coated by an exopolysaccharide (EPS) matrix. Living in a biofilm is advantageous for the 
bacteria. The matrix provides a barrier against physical and chemical assaults and they are 
also resistant to most antibiotics, and to the immune system. The matrix creates an excellent 
environment for metabolic exchange, which allows multiple species to coexist in the biofilm. It 
also enhances the lateral transfer of genetic material, which in turn gives bacteria an 
advantage in dealing with environmental challenges.[56] 
Recent research has focused on understanding the mechanisms and regulations of the 
biofilm development. Biofilm formation is not a random process. Recent studies have 
indicated that biofilms are a stable point in a biological cycle that includes initiation, 
maturation, maintenance and dissolution (see Figure 10).[57] In the early attachment step, 
movement generating appendages, such as flagella, are needed to approach the surface to 
be colonized. During this approach the bacteria will scan the surface and a temporary 
attachment will be formed. This scanning and sensing for environmental clues is called 
quorum sensing, if enough bacteria are present, micro-colonies are formed and their 
differentiation leads to the biofilm maturation. The structure is then strengthened by the 
creation of an exopolysaccharide matrix while still maintaining a strong plasticity. In the case 
of pathogenic bacteria, the virulence factors, such as toxins, are expelled at this stage. In the 
last step, the dissolution, bacteria detach from the structure, due to nutrient limitation or 
unfavorable environmental conditions, to return to a planktonic living mode. Those bacteria, 
free in solution, can then induce the formation of new communities in new locations but little 
is known about the release mechanisms.[55] 
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Figure 10: Biofilm formation cycle.[57] 
 
 
Biofilms are complex three dimensional structures that can be composed of up to 85% 
of exopolysaccharides. Inside the biofilm, the micro-colonies are separated by aqueous 
channels serving to bring in nutrients and oxygen and remove waste in deeper areas. 
Indeed, it was suggested that nutrients are not evenly distributed within biofilms and thus 
help shape their structure. A decreasing gradient of nutrients and oxygen can be observed 
when reaching the deepest locations of the biofilm where bacteria are often in completely 
anaerobic conditions. The channel system also allows for cell-cell communication. Molecules 
called quorum-sensing signals help trigger and coordinate changes in the bacterial behavior. 
They are constantly secreted by bacteria in low levels and the receptors are triggered when 
there are enough bacteria to exceed a critical threshold in signal concentration. The structure 
and characteristics of biofilms are of prime importance, since biofilm inhabitants are up 1,000 
times more resistant to antibiotics than free-floating bacteria. The explanations for this 
phenomenon are diverse. One of them being that: sedentary bacteria having slower 
metabolisms, they might be less susceptible to drugs, and the exchange of DNA is easier in 
the biofilm than for free-floating bacteria, which might also accelerate the transfer of 
antibiotic-resistance genes. For all these reasons, understanding the biofilm formation and 
development is important to design new strategies for the control biofilms, especially those 
involved in chronic diseases or infections.[55, 58] 
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5.2.2 Exogenous c-di-GMP Delays the Biofilm Formation of 
Escherichia coli Strains  
Among the topics that gained a lot of importance in microbiology in the last few years, 
the involvement of c-di-GMP in the biofilm formation was central. It has been shown that an 
increase of intracellular c-di-GMP enhances the biofilm formation of Pseudomonas 
fluorescens[16], Yersinia pestis[17], Vibrio cholerae[59]. An over-expression of the genes 
involved in the exopolysaccharide synthesis was observed. This signaling molecule was also 
reported to be involved in the transition from motility to sessility in Escherichia coli, 
Salmonella typhimurium[7] and Caulobacter crescentus[15]. Again, c-di-GMP is involved in the 
biofilm formation but a different stage. The regulatory activity of this cyclic dinucleotide is 
apparently very complex and different biological events seem to be interconnected through 
this molecule. But this may not be surprising, when considering that the turnover of c-di-GMP 
is controlled by two types of enzymes, diguanylate cyclases and phosphodiesterases that are 
found in large number in bacteria.  
In 2005, a more surprising effect was found with Staphylococcus aureus.[19] Exogenous 
c-di-GMP was shown to inhibit the cell-cell interactions and biofilm formation in vitro. It also 
exhibited antibiotic activity in vivo in a mouse model of mastitis infection.[19] This is a 
completely new effect. However, no obvious link has been found between this signaling 
molecule and the cell development of this bacterium. Although the molecular mechanisms 
involved in this effect are not known, the results seem promising. This prompted new interest 
in c-di-GMP, which could represent a new platform to develop novel antibiotic drugs with new 
modes of action.[20]  
In collaboration with the group of Prof. S. Neunlist in Mulhouse, the study of biofilms 
formed by E. coli is ongoing and should offer more insight in the environmental parameters 
involved in the biofilm formation. c-di-GMP appears to play a central role; therefore it was 
decided to investigate the effects of the presence of this molecule in the environment of the 
bacteria.  
Using synthetic c-di-GMP, a series of preliminary experiments were initiated to study 
the response of different strains of E. coli to an exogenous treatment. Although the response 
was dependant on the strain of bacteria, the trend was that c-di-GMP prevents the biofilm 
formation (Figure 11). Indeed it was observed, after a two hour incubation time, that with c-di-
GMP concentrations of 100 µM or higher a visible inhibition effect on the biofilm formation 
could be obtained. This would suggest that c-di-GMP definitely has a positive effect in the 
prevention of the biofilm formation. However, it was also found that after 7 days biofilm like 
structures were observed. These results could suggest that the efficiency of c-di-GMP is 
limited in time, and is concentration dependant. Moreover, no degradation of c-di-GMP has 
been observed even after a three week period of incubation. This would suggest that this 
compound was not metabolized by the bacteria but remained in their environment.  
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Figure 11: Effects of c-di-GMP on the biofilm formation of E. coli. A: biofilm formation after 2 
hrs in the absence of c-di-GMP (blank experiment). Biofilm formation in the presence of c-di-
GMP, after 2 hrs: B: 60 µM c-di-GMP; C: 100 µM c-di-GMP; D: 400µM c-di-GMP. 
 
 
A model to comply with these results would be that c-di-GMP hindered the biofilm 
formation for a period of time that was longer the higher the concentration of c-di-GMP was, 
but did not completely inhibit the biofilm formation. It would appear that c-di-GMP might 
interfere with cell surface proteins involved in binding to EPS, and necessary to attach the 
bacteria to the EPS matrix. But with the increasing concentration of EPS in the medium, c-di-
GMP might no longer be able to compete for the receptor proteins. It is believed that this was 
an exogenous response as the general census states that this molecule is unable to cross 
the cell membrane.  
Based on these preliminary results, the main outcome of this kind of studies would be a 
better understanding of the parameters that regulate the biofilm formation. Further, once the 
regulation mechanisms are better known, a new class of drugs with new modes of action 
could be designed. A new class of antibiotics would indeed be of interest, as more and more 
pathogenic bacteria have become resistant to existing drugs in recent years. 
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6. SUMMARY AND OUTLOOK 
We have successfully designed a new method, starting from sugar building blocks, for 
the preparation of c-di-GMP that afforded fairly high yields. This new method also proved to 
be applicable to the synthesis of base-modified analogues. 
In comparison to the previously published synthetic methodologies, several drawbacks 
have been removed and our new method afforded c-di-GMP in higher amounts with higher 
yields. Since this new synthesis pathway was relatively straightforward, it proved to be 
suitable for scale-up purposes. Indeed, the synthesis can be performed in a few weeks and 
reasonable amounts of c-di-GMP could be obtained. We managed to perform the synthesis 
in such a manner that we could obtain up to 500 mg product. Considering the issues 
reported in previous methods, our approach seemed the most suitable for the preparation of 
the large quantities required to investigate the biological activities of c-di-GMP. 
One of the main concerns with the other methods, and typically with the synthesis of 
RNA-oligonucleotides, was the lack of appropriate protecting groups for the 2’-OH function. 
This issue was completely avoided with our new strategy, where a sugar backbone was 
prepared first and the base was introduced at a late stage. Since the 1’- and 2’-OH groups 
were blocked as a cyclic acetal for the whole duration of the synthesis of the sugar building 
blocks, the preparation of the two sugar units needed was enormously facilitated. And, the 
synthesis of the building blocks in general, was easy to perform even on a 30 gram scale in 
high yields. 
Assembling the sugar backbone was also easy to perform in fairly high yields even 
when scaling-up. During the process, care had to be taken to avoid any basic conditions 
since the protected phosphate linkage was base sensitive. The guanine precursor was also 
straightforward to synthesize in high yields and could easily be done on a multi-gram scale. 
The introduction of the base on the sugar backbone following modified Vorbrüggen 
conditions[38] also achieved high yields once the proper reaction conditions were successfully 
investigated. 
The main advantage of this new approach for the preparation of c-di-GMP was that it 
allowed for a fairly straightforward preparation of base modified analogues. Indeed, we 
successfully prepared three analogues where the guanosine was replaced by adenosine, 
thymine or theophylline. 
Moreover, using the synthetic c-di-GMP we prepared, our collaborators were able to 
perform investigations of the biological relevance of this dinucleotide. Indeed, a crystal 
structure of the PleD protein of Caulobacter crescentus was obtained, which afforded a 
better understanding of the regulation mechanisms of c-di-GMP in this bacterium. And also 
allowed for the discovery that c-di-GMP was acting as a second messenger in this same 
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bacterium. Preliminary investigations of the effects of exogenous synthetic c-di-GMP on the 
biofilm formation of Escherichia coli were also successful in demonstrating that the cyclic 
nucleotide might have an inhibiting or at least a delaying effect on the formation of biofilms. 
 
 
Even though the efficiency of our new approach has been shown, it remains to be 
effectively applied to the preparation of internucleotide linkage modified analogues. Indeed, 
our attempts to prepare an amide bond linked cyclic dinucleotide have only shown little 
success in preparing the required cyclic backbone. Thus, more work would be necessary to 
further optimize the reaction conditions, such as using longer reaction times, other solvent 
systems or even changing the temperature. It could also be interesting to consider other 
alternatives, such as more potent coupling reagents or even different reaction sequences, 
which might afford better results and lead to the desired internucleotide bond modified c-di-
GMP analogue. 
We could also consider preparing other analogues such as c-di-deoxyGMP or other 
non-hydrolysable internucleotide linkage modified analogues. These analogues, and those 
already synthesized, could then be tested for their biological activity since the regulation 
mechanisms, the functional groups of c-di-GMP involved therein, and the numerous 
biological roles of c-di-GMP still remain to be uncovered.  
Since preliminary results showed an inhibition effect of c-di-GMP on the biofilm 
formation, further investigations of this biological process and then finding ways to immobilize 
the cyclic dinucleotide on solid surfaces might be first steps in creating new materials that 
could be biofilm free. 
Another way to gain more insight into the mode of action of c-di-GMP and its 
interaction towards proteins, might be labeling c-di-GMP (i.e with a fluorophore or a dye) and 
screening it against peptide libraries or receptor libraries.[60, 61] 
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7. GENERAL PROCEDURES 
7.1 Analytical Methods 
NMR-Spectrometry: NMR spectra were recorded on Bruker Avance 400 (400 MHz) 
and Bruker Avance DRX 500 (500 MHz) NMR spectrometers, equipped with BBO broadband 
probeheads. The chemical shift δ is given in ppm, relative to TMS (δ = 0.00 ppm).  
References were 7.26 ppm (1H NMR) and 77.16 ppm (13C NMR) for CHCl3, 2.50 ppm 
(1H NMR) and 39.52 ppm (13C NMR) for DMSO, and 4.79 ppm (1H NMR) for water.[62] 85% 
phosporic acid (0 ppm) was taken as an internal standard in a capillary for 31P NMR 
(sr(CD2Cl2) = 94.2 Hz, sr(CDCl3) = 130.69 Hz, sr(C6D6) = 127.98 Hz) measured on the 500 
MHz NMR spectrometer.  
The assignment of 1H- and 13C-signals was made by 1D-NMR and if necessary 2D-
NMR, namely COSY, HMQC, HMBC, TOCSY and NOESY-spectrometry. 13C and 31P, until 
otherwise noted, were recorded 1H-decoupled. Multiplets were assigned with s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet). The index br stands for broad (usually no 
resolution). The signal for quaternary carbons was abbreviated as: Cq.  
 
 
Mass Spectrometry (MS): Mass spectra were performed by Dr. H. Nadig. Electron 
ionization (EI) was measured on VG70-250, fast atom bombardment (FAB) was measured 
on MAT 312. FAB was performed with 3-nitrobenzyl alcohol as matrix. The signals are given 
in mass units per charge (m/z). The fragment and intensities of the signals are given in 
brackets. 
 
 
MALDI-ToF Mass Spectrometry: Mass Spectra were recorded on Voyager-DE PRO 
BioSpectrometry Workstation from Applied Biosystems. 4-Nitroaniline was used as matrix. 
Sample desorption and ionization was induced by a N2-laser (337 nm, 3ns pulses). The 
signals are referred to the unfragmented charged molecule ions [M-H]- and [M+H]+. The data 
are given in mass units per charge (m/z). 
 
 
High Resolution Mass Spectometry (HRMS): Mass Spectra were performed by the 
“Service de spectrometrie de masse” at the Université Louis Pasteur, Strabourg. The data 
are given in mass units per charge (m/z). 
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Infrared Spectrometry (IR): Infrared spectra were measured on a Perkin-Elmer-1600 
Series Fourier-Transform spectrometer. Solid samples were prepared as KBr wafers, liquid 
samples were prepared between NaCl plates. Absorption bands are given in wave numbers 
ν ~ [cm-1].  
 
 
Elemental Analysis (EA): Elemental analyses were carried out by Mr. W. Kirsch at the 
Department of Chemistry at the University of Basel, on Leco CHN-900 (C-, H-, N-detection) 
and Leco RO-478 (O-detection) analysers. The data are indicated in mass percent. 
 
 
7.2 Purification Methods 
Thin Layer Chromatography (TLC): Reactions were monitored by thin layer 
chromatography. Silica gel 60F254 plates from Merck were used. Coumpounds were 
visualized by UV (254 nm) and/or ceric ammonium molybdate (CAM) dip. Retention Factors 
(Rf) are indicated with corresponding solvent mixture in brackets. 
 
 
Flash Column Chromatography (FC): For Flash Chromatography silica gel Merck 60 
(40-63 µm) was used under low pressure (~1.5 bar, membrane pump). The solvents used 
were of technical grade and freshly re-distilled prior to use. The ratios of solvents in the 
mixtures are referred to volume parts. Generally, the flash column chromatography according 
to Still[63] was performed. 
 
 
High Performance Liquid Chromatography (HPLC): For HPLC analysis Waters 
Alliance 2690 Separations Modul and 2680 Dual Mode UV-Vis detector were used. Merck 
reverse phase RP18e Lichrospher 100, 250-4 (5µm) columns were used for analysis and 
Merck reverse phase RP18e Lichrospher 100, 250-10 (10µm) columns for separation 
purposes. 
 
 
Size Exclusion Chromatography: Size exclusion chromatographies were performed 
either on Sephadex LH 20 resin or on Sephadex G15 resin purchased from Sigma.  
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7.3 Solvents and Chemicals 
Solvents: Toluene, THF and dichloromethane were dried and degassed by reflux over 
an adequate drying agent under nitrogen.[64] Absolute solvents were purchased from Fluka or 
Aldrich in septum sealed bottles, kept under inert atmosphere and over molecular sieves. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc.. Technical 
grade solvents used for extraction and purification were re-distilled prior to use. Nanopure 
water used for purification purposes was filtered over a Barnstead ultrapure water system. 
 
 
Chemicals: Materials and reagents were purchased in the highest commercially 
available grade from Fluka, Aldrich, Acros and Senn and used without further purification. 
 
 
7.4 Buffers and Solutions 
TEAC buffer, 1 M, pH=7: 
54 ml triethylamine, dry ice and 446 ml nanopure water 
 
TEAA buffer, 0.1 M, pH=7: 
100 ml TEAA 1M (Fluka) and 900 ml nanopure water  
 
Na-phosphate buffer 0.1 M, pH=5.5: 
90 g NaH2PO4, 32.7 g Na2HPO4 and 500 ml water 
 
MALDI-ToF matrix preparation:  
~12-15 mg 4-nitroaniline dissolved in 1 ml CH2Cl2:MeOH (9:1, v/v). 
 
CAM-Dip:  
10 g Cerium (IV)sulfate-tetrahydrate, 25 g ammonium-heptamolybdate-tetrahydrate, 100 ml 
96% sulfuric acid and 900 ml distilled water 
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7.5 Assignment of C and H for Purine and Pyrimidine Derivatives 
 
 
 
The protons in the 1H NMR spectra are numbered the same as the related carbon or hetero 
atoms. Atoms within the sugar backbone of the nucleotides are marked with an additional 
prime. If two nucleotides were present, each was referred to separately with an additional “a” 
or “b” in the assignements. 
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8. INVESTIGATIONS TOWARDS A NEW SYNTHETIC PATHWAY FOR C-DI-GMP 
8.1 Van Boom Synthesis Pathway 
8.1.1 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-guanosine (21) 
 
 
 
5 g (17.66 mmol, 1 eq) guanosine 20 and 6.01 g (88.31 mmol, 5 eq) imidazole were poured 
in suspension in 50 ml DMF at RT under argon. 6.64 ml (21.1 mmol, 1.2 eq) 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (TiPS-Cl) were added and the mixture stirred for 3 hrs. 15 ml 
toluene were added and the solvents evaporated under reduced pressure. The residue was 
taken-up in 60 ml CHCl3-MeOH (3:1), washed with a saturated aqueous solution of NaHCO3 
(3 x 50 ml) and the combined organic solvents were dried (MgSO4) and concentrated under 
reduced pressure. The residue was taken up in DMF (20 ml) and the mixture poured into 1 L 
water. The precipitate was filtered off and re-crystallized from boiling ethanol yielding 
compound 21 as a white solid (3.95 g, 7.51 mmol, 43%).  
 
C22H39N5O6Si2: 525.76 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.5;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.73 (s, 1H, 8CH), 5.65 (d, 1H, J= 1.76 Hz, 1’CH), 5.60 
(d, 1H, J= 5.08 Hz, 2’OH), 4.33 (m, 1H, 2’CH), 4.23 (m, 1H, 3’CH), 4.07 (m, 1H, 5’CH2), 3.96 (m, 
1H, 4’CH), 3.90 (m, 1H, 5’CH2), 1.03 (m, 28H, CHisopropyl, CH3 isopropyl);  
MS (Maldi-ToF, m/z): 526.1 ([M]+). 
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8.1.2 Levulinic anhydride (Lev2O) (23) 
 
 
 
5.80 g (49.97 mmol, 1 eq) levulinic acid 22 and 5.15 g (24.99 mmol, 0.5 eq) N,N’-
dicyclohexylcarbodiimide (DCC) were dissolved in 100 ml dry diethyl ether at RT under argon 
and stirred for 5 hrs. The reaction mixture was filtered over celite and the filtrate was 
concentrated under reduced pressure. 5.84 g of a dense oil were obtained (24.97 mmol, 
quant.).  
 
C10H14O5: 214.22 g/mol 
1H NMR (400.0 MHz, CDCl3, δ ppm): 2.75 (m, 2H, CH2, J1= 1.52 Hz, J2= 6.8 Hz), 2.68 (m, 
3H, CH2, J1= 7.08 Hz, J2= 1.52 Hz), 2.16 (s, 3H, CH3);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 206.37 (C=Oketone), 168.89 (C=Oanhydride), 37.69 (CH2), 
30.14 (CH3), 29.42 (CH2);  
MS (Maldi-ToF, m/z): 237.4 ([M+Na]+). 
 
 
8.1.3 Diphenylacetic anhydride (dpa2O) (25) 
 
 
 
25.00 g (0.12 mol, 1 eq) diphenylacetic acid 24 were dissolved in a 1:1 mixture of dioxane-
diethyl ether (250 ml) at RT under argon. 12.15 g (0.06 mol, 0.5 eq) DCC were added and 
the mixture stirred at RT for 2 hrs, then the suspension was cooled to 0°C for 1 hr. The 
mixture was then filtered over celite and the solvents removed under reduced pressure. The 
residue was re-crystallized from pentane to yield 23.90 g of 25 as a white solid (0.06 mol, 
quant.). 
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C28H22O3: 406.49 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.91;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.27 (m, 10H, CHarom), 5.04 (s, 1H, CH);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 167.9 (C=O), 137.2 (Carom), 129.8-128.1 (CHarom), 58.2 
(CH);  
MS (Maldi-ToF, m/z): 429.3 ([M+Na]+). 
 
 
8.1.4 2’-O-levulinoyl-3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-
guanosine (26) 
 
 
 
3.00 g (5.71 mmol) 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-guanosine 21 were dissolved in 
40 ml DMF at RT under argon. 1.9 ml (13.69 mmol, 2.4 eq) triethylamine, 1.46 g (6.84 mmol, 
1.2 eq) levulinic anhydride and a catalytic amount 4-dimethylamino-pyridine (DMAP) were 
added. The mixture was stirred for 15 min then 1 ml water as well as 10 ml toluene were 
added to the solution. The solvents were evaporated under reduced pressure. The residue 
was taken-up in 100 ml chloroform then washed with sat. aq. NaHCO3 sol. (100 ml) and 
water (100 ml). The organic layer was dried (MgSO4) and the volatiles removed under 
reduced pressure. Re-crystallization from ethanol yielded 26 as a white solid (471 mg, 0.75 
mmol, 49%). 
 
C27H45N5O8Si2: 623.86 g/mol 
Rf (CH2Cl2:MeOH, 90:10) = 0.55;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 11.99 (s, 1H, 3NH), 7.81 (s, 1H, 8CH), 6.40 (s, 2H, 2NH), 
5.70 (d, 1H, J1= 4.04 Hz, 1’CH), 4.70 (dd, 1H, J1= 8.45 Hz, J2= 5.47 Hz, 2’CH), 4.13 (m, 1H, 
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3’CH), 3.99 (m, 3H, 5’CH2, 4’CH), 2.70 (m, 4H, CH2 Lev), 2.18 (s, 3H, CH3 Lev), 1.02 (m, 28H, 
CHisopropyl, CH3 isopropyl);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 206.8 (C=OLev), 171.5 (COOLev), 137.8 (6Cq), 137.7 
(5Cq), 128.3 (8CH), 87.5 (4’CH), 82.2 (3CH), 75.8 (2’CH), 69.5 (1’CH), 60.9 (5’CH2), 38.3 
(CH2COLev), 28.1 (CH2COOLev);  
MS (Maldi-ToF, m/z): 646.5 ([M+Na]+). 
 
 
8.1.5 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-2-N-(diphenylacetyl)-
guanosine (27) 
 
 
 
330 mg (0.53 mmol, 1 eq) 2’-O-levulinoyl-3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-
guanosine 26 were dissolved in 10 ml dry pyridine at RT under argon. 640 mg (1.59 mmol, 3 
eq) diphenylacetic anhydride were added and the mixture heated to 60°C for 2 hrs. The 
reaction was quenched with 2 ml water and the solvents were co-evaporated with 20 ml 
toluene. The residue was taken-up in 100 ml chloroform, washed successively with 100 ml 
sat. aq. NaHCO3 sol. and 100 ml water. The organic phase was dried (MgSO4) and 
concentrated under reduced pressure. The residue was taken up in 10 ml dry pyridine. 2.65 
ml (2.64 mmol, 5 eq) of a 1 M solution of hydrazine hydrate in a 3:2 mixture of pyridine:acetic 
acid (v/v), were added and the reaction stirred for 3 min. 1.10 ml (10.60 mmol, 20 eq) 2,4-
pentanedione were added and the mixture stirred at RT for 2 min, then at 0°C for 3 min. 
Chloroform (35 ml) and water (15 ml) were added. The organic layer was washed with 100 
ml sat. aq. NaHCO3 sol., 100 ml water and 100 ml 1 M K2HPO4 sol. The organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography (CH2Cl2:MeOH, gradient from 100:0 to 95:5, v/v, +0.5% triethylamine) to 
yield 0.51 g of 27 as a colorless oil (0.50 mmol, 95%).  
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C36H49N5O7Si2: 719.99 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.47.  
1H NMR (400.0 MHz, CDCl3, δ ppm): 11.99 (s, 1H, 3NH), 7.81 (s, 1H, 8CH), 7.32 (m, 10H, 
CHarom), 6.40 (s, 2H, 2NH), 5.70 (d, 1H, J1= 4.03 Hz, 1’CH), 5.33 (s, 1H, CHdpa), 4.70 (dd, 1H, 
J1= 8.44 Hz, J2= 5.46 Hz, 2’CH), 4.13 (m, 1H, 3’CH), 3.99 (m, 3H, 5’CH2, 4’CH), 1.02 (m, 28H, 
CHisopropyl, CH3 isopropyl);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.4 (C=Odpa), 147.9 (Cqarom), 147.7 (Cqarom), 137.8 
(6Cq), 137.7 (5Cq), 129.4 (CHarom), 129.2 (CHarom), 128.9 (CHarom), 128.3 (8CH), 122.7 
(CHarom), 87.5 (4’CH), 82.2 (3CH), 75.8 (2’CH), 69.5 (1’CH), 60.9 (5’CH2), 59.2 (CHdpa);  
MS (Maldi-ToF, m/z): 742.1 ([M+Na]+). 
 
 
8.1.6 2’-O-tetrahydropyranyl-2-N-diphenylacetyl guanosine (28) 
 
 
 
1.38 g (1.92 mmol, 1 eq) 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-2-N-(diphenylacetyl)-
guanosine 27 were dissolved in 15 ml dichloromethane at RT under argon. 5.22 ml (57.60 
mmol, 30 eq) 3,4-dihydro-2H-pyran and 1.44 g (5.76 mmol, 3 eq) pyridinium toluene-4-
sulfonate (PTs) were added and the mixture stirred for 4 hrs at RT. The reaction mixture was 
diluted with diethyl ether (80 ml) and washed with half-saturated brine (100 ml). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was 
dissolved in THF (20 ml), 3.12 ml (19.19 mmol, 10 eq) triethylamine trihydrofluoride were 
added and the mixture stirred under argon at RT overnight. The reaction was quenched with 
Silica gel and the solvents removed under reduced pressure. Flash chromatography 
(CH2Cl2:MeOH, gradient from 100:0 to 95:5, v/v) yielded 28 as a white solid (1.01 g, 1.78 
mmol, 93%).  
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C29H31N5O7: 561.60 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.18;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.90 (s, 1H, 8CH), 7.32 (m, 10H, CHarom), 5.83 (d, 1H, 
J1= 6.8 Hz, 1’CH), 5.33 (s, 1H, CHdpa), 5.01 (m, 1H, 2’CH), 4.61 (m, 1H, 3’CH), 4.39 (m, 2H, 
CH2 THP), 4.22 (m, 1H, CHTHP), 3.85 (m, 2H, CH2 THP), 3.65 (m, 1H, 5’CH2), 3.57 (m, 1H, 4’CH), 
3.41 (m, 1H, 5’CH2), 1.72 (m, 2H, CH2 THP), 1.46 (m, 4H, CH2 THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.4 (C=Odpa), 174.5 (4C=O), 155.6 (2Cq), 147.9 
(Cqarom), 147.7 (Cqarom), 137.8 (6Cq), 137.7 (5Cq), 129.4 (CHarom), 129.2 (CHarom), 128.9 
(CHarom), 128.3 (8CH), 122.7 (CHarom), 102.4 (CHTHP), 88.5 (4’CH), 86.9 (2’CH), 82.2 (1’CH), 
72.2 (3’CH), 66.1 (5’CH2), 63.1 (CH2 THP), 59.2 (CHdpa), 31.4 (CH2 THP), 31.2 (CH2 THP), 25.2 
(CH2 THP), 21.4 (CH2 THP);  
MS (Maldi-ToF, m/z): 584.5 ([M+Na]+). 
 
 
8.1.7 5’-O-dimethoxytriphenylmethyl-2’-O-pyranyl-2-N-diphenylacetyl 
guanosine (29) 
 
 
 
300 mg (0.53 mmol, 1 eq) 2’-O-tetrahydropyranyl-2-N-diphenylacetyl guanosine 28 were co-
evaporated twice with pyridine and then dissolved in 5 ml dry pyridine under argon. The 
solution was added with 218 mg (0.64 mmol, 1.2 eq) 4,4’-dimethoxytritylchloride (DMTCl) 
and stirred for 16 hrs. The reaction was quenched with 5 ml sat. aq. NaHCO3 sol. then 
extracted with DCM. The organic fractions were dried (MgSO4) and concentrated. Flash 
chromatography (hexane:CH2Cl2, 1:1, CH2Cl2:MeOH gradient from 100:0 to 95:5, v/v, +1% 
Et3N) yielded 352 mg (0.41 mmol, 76%) of the desired product 29.  
 
 
C50H49N5O9: 863.98 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.61;  
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1H NMR (400.0 MHz, CDCl3, δ ppm): 7.92 (s, 1H, 8CH), 7.32 (m, 10H, CHarom), 7.31 (m, 2H, 
CHarom), 7.17 (m, 8H, CHarom), 6.75 (m, 2H, CHarom), 5.81 (d, 1H, J1= 6.8 Hz, 1’CH), 5.34 (s, 
1H, CHdpa), 5.01 (m, 1H, 2’CH), 4.62 (m, 1H, 3’CH), 4.40 (m, 2H, CH2 THP), 4.21 (m, 1H, 
CHTHP), 3.87 (m, 2H, CH2 THP), 3.83 (s, 6H, CH3 DMT), 3.69 (m, 1H, 5’CH2), 3.54 (m, 1H, 4’CH), 
3.41 (m, 1H, 5’CH2), 1.75 (m, 2H, CH2 THP), 1.39 (m, 4H, CH2 THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.5 (C=Odpa), 174.5 (4C=O), 158.9 (Cqarom), 158.8 
(CHarom), 155.6 (2Cq), 147.9 (Cqarom), 147.7 (Cqarom), 143.9 (Cqarom), 137.8 (6Cq), 137.7 (5Cq), 
136.3 (Cqarom), 130.6 (CHarom), 130.5 (CHarom), 129.4 (CHarom), 129.2 (CHarom), 128.9 (CHarom), 
128.5 (CHarom), 128.4 (8CH), 127.9 (CHarom), 122.7 (CHarom), 113.8 (CHarom), 112.9 (CHarom), 
102.3 (CHTHP), 88.5 (4’CH), 86.8 (2’CH), 82.3 (1’CH), 72.3 (3’CH), 66.0 (5’CH2), 63.1 (CH2 THP), 
59.1 (CHdpa), 31.6 (CH2 THP), 31.4 (CH2 THP), 25.1 (CH2 THP), 21.4 (CH2 THP);  
MS (Maldi-ToF, m/z): 888.1 ([M+Na]+). 
 
 
8.1.8 6-trifluoro-methylbenzotriazole phosphorylating agent (32) 
 
 
 
0.50 ml (3.10 mmol, 0.5 eq) 2-chlorophosphoryldichloridate 31 were dissolved into 3 ml dry 
dioxane at RT and added dropwise at RT to a mixture of 1.27 g (6.25 mmol, 1 eq) 1-hydroxy-
6-trifluoro-methylbenzotriazole 30 in 12.5 ml dry dioxane and 0.5 ml (6.37 mmol, 1.02 eq) dry 
pyridine. The obtained suspension was stirred for 1 hr then filtered under an inert 
atmosphere of argon. A yellow 0.2 M stock solution of phosphorylating agent 32 was 
obtained, and used without further purification. 
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8.1.9 (5’-O-dimethoxytriphenylmethyl-2-N-diphenylacetyl-2’-O-
tetrahydropyranyl-guanosine)-(3’-5’)-(2-N-diphenylacetyl-2’-O-
tetrahydropyranyl-guanosine)-2-chlorophenyl phosphate (33) 
 
 
 
344 mg (0.40 mmol, 1 eq) 5’-O-dimethoxytriphenylmethyl-2-N-diphenylacetyl-2’-O-tetra 
hydropyranyl guanosine 29 were co-evaporated with pyridine (2 x 5 ml) and then dissolved in 
dry dioxane (3 ml) under argon. 1.1 ml (0.44 mmol, 0.2 M, 1.1 eq) phosphorylating agent 33 
were added and the mixture stirred at RT for 5 min. 268 mg (0.48 mmol, 1.2 eq) N2-
diphenylacetyl-2’-O-tetrahydropyranyl guanosine 28 in 0.5 ml dioxane were added and the 
reaction mixture stirred at RT for 1 hr. The solution was diluted with CH2Cl2 (20 ml) and 
washed with triethylammoniun acetate (TEAC) buffer (50 ml of a 1 M solution and then 50 ml 
of a 0.1 M solution). The organic fractions were dried (MgSO4) and concentrated under 
reduced pressure. Flash chromatography (CH2Cl2:MeOH, gradient from 100:0 to 95:5, v/v, 
+0.1% Et3N) yielded 477 mg (0.30 mmol, 74%) of the desired product, dimer 33 as a non 
separable mixture of diastereomers.  
 
C85H82ClN10O18P: 1598.08 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.37;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.94-7.92 (m, 2H, 8CH), 7.57-7.15 (m, 23H, CHarom), 
6.85-6.75 (m, 4H, CHarom), 5.84-5.81 (m, 2H, 1’CHa, 1’CHb), 5.34-5.32 (m, 2H, CHdpa), 5.12 
(m, 1H, 3’CHa), 5.05-4.95 (m, 2H, 2’CHa, 2’CHb), 4.63 (m, 1H, 3’CHb), 4.61-4.57 (m, 2H, 
5’CH2b), 4.44-4.38 (m, 2H, CHTHP), 4.27 (m, 1H, 4’CHb), 4.25-4.12 (m, 4H, CH2 THP), 4.13 (m, 
1H, 4’CHa), 3.87-3.35 (m, 10H, CH3 DMT, CH2 THP), 3.67 (m, 1H, 5’CH2b), 3.54 (m, 1H, 5’CH2a), 
3.41 (m, 2H, 5’CH2a, 5’CH2b), 2.75-2.64 (m, 4H, CH2 THP), 1.75-1.48 (m, 4H, CH2 THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.5 (C=Odpa), 174.5 (4C=O), 158.9 (Cqarom), 158.8 
(CHarom), 155.6/155.5 (2Cq), 148.3/143.9 (Cqarom), 137.8/136.9 (6Cq, 5Cq), 136.3/135.9 
(Cqarom), 130.6-128.7 (CHarom), 128.4/128.0 (8CH), 127.9-113.8 (CHarom), 102.3/101.9 (CHTHP), 
88.5/88.3 (4’CHa), 87.9/87.7 (4’CHb), 86.8/86.6 (2’CHa), 86.0/85.9 (2’CHb), 82.4/82.1 (1’CHa), 
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81.9/81.7 (1’CHb), 72.3/72.1 (3’CHa), 70.9/70.5 (3’CHb), 66.0/65.8 (5’CH2b), 63.1 (CH2 THP), 
62.3/62.0 (5’CH2a), 59.1/58.9 (CHdpa), 55.8/55.7 (CH3), 31.6/30.8 (CH2 THP), 25.3/24.8 (CH2 
THP), 21.5/21.2 (CH2 THP);  
MS (Maldi-ToF, m/z): 1621.2 ([M+Na]+). 
 
 
8.1.10 (5’-O-dimethoxytriphenylmethyl-2-N-diphenylacetyl-2’-O-
tetrahydropyranyl-guanosine)-(3’-5’)-(2-N-diphenylacetyl-3’-O-(2-
chlorophenyl phosphate)-2’-O-tetrahydropyranyl-guanosine)-2-
chlorophenyl phosphate (34) 
 
 
 
461 mg (0.28 mmol 1 eq) of dimer 33 were co-evaporated with dioxane (2 x 5 ml) then 
dissolved in dry dioxane at RT under argon, added with 1.44 ml (0.31 mmol, 0.2 M, 1.1 eq) 
phosphorylating agent 32 and stirred for 5 min. 20 µl (0.56 mmol, 2 eq) allylic alcohol were 
added and the reaction mixture stirred for 1 hr at RT. The solution was diluted with DCM (20 
ml) and washed with ammonium hydrogen phosphate buffer (30 ml of a 1 M solution and 30 
ml of a 0.1 M solution). The organic layer was dried and the volatiles removed under reduced 
pressure. Flash chromatography (CH2Cl2:MeOH, gradient from 100:0 to 95:5, v/v, +0.1% 
Et3N) led to 335 mg (0.18 mmol, 64%) of the desired product 34, as a non separable mixture 
of diastereomers.  
 
C96H92Cl2N20O21P2: 1828.63 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.59;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.96-7.93 (m, 2H, 8CH), 7.58-7.18 (m, 27H, CHarom), 
6.88-6.77 (m, H, CHarom), 5.93-5.91 (m, 1H, CHallyl), 5.86-5.83 (m, 2H, 1’CHa, 1’CHb), 5.42-
5.38 (m, 1H, CH2 alkene), 5.33-5.32 (m, 2H, CHdpa), 5.27-5.25 (m, 1H, CH2 alkene), 5.10 (m, 1H, 
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3’CHa), 5.03-4.95 (m, 2H, 2’CHa, 2’CHb), 4.63 (m, 1H, 3’CHa), 4.57-4.54 (m, 2H, 5’CH2b), 4.52-
4.49 (m, 2H, CH2 allyl), 4.44-4.38 (m, 2H, CHTHP), 4.27 (m, 1H, 4’CHb), 4.25-4.14 (m, 4H, CH2 
THP), 4.12 (m, 1H, 4’CHa), 3.85-3.35 (m, 10H, CH3 DMT, CH2 THP), 3.67 (m, 1H, 5’CH2b), 3.54 (m, 
1H, 5’CH2a), 3.40 (m, 2H, 5’CH2a, 5’CH2b), 2.75-2.64 (m, 4H, CH2 THP), 1.74-1.46 (m, 4H, CH2 
THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.6 (C=Odpa), 174.5 (4C=O), 158.9 (Cqarom), 158.8 
(CHarom), 155.6/155.4 (2Cq), 148.2-143.9 (Cqarom), 137.8-136.9 (6Cq, 5Cq), 136.3-135.9 
(Cqarom), 132.5/132.4 (CHallyl), 130.5-128.7 (CHarom), 128.5/128.1 (8CH), 127.9-113.8 (CHarom), 
118.2/118.0 (CH2 alkene), 102.3/101.8 (CHTHP), 88.5/88.2 (4’CHa), 87.9/87.7 (4’CHb), 86.8/86.5 
(2’CHa), 86.1/85.9 (2’CHb), 82.4/82.1 (1’CHa), 81.8/81.7 (1’CHb), 72.3/72.1 (3’CHa), 70.9/70.5 
(3’CHb), 68.1/68.0 (CH2 allyl), 66.0/65.7 (5’CH2b), 63.0 (CH2 THP), 62.2/62.0 (5’CH2a), 59.1/58.9 
(CHdpa), 55.95/5.7 (CH3 DMT), 31.8/30.8 (CH2 THP), 25.2/24.8 (CH2 THP), 21.5/21.2 (CH2 THP);  
MS (Maldi-ToF, m/z): 1850.3 ([M+Na]+). 
 
 
8.1.11 (2-N-diphenylacetyl-2’-O-tetrahydropyranyl-guanosine)-(3’-5’)-(2-
N-diphenylacetyl-3’-O-(2-chlorophenyl phosphate)-2’-O-
tetrahydropyranyl-guanosine)-2-chlorophenyl phosphate (35) 
 
 
 
310 mg (0.17 mmol, 1 eq) of dimer 34 were dissolved in 10 ml of a 7:3 (v/v) mixture of 
CH2Cl2:MeOH at 0°C and added with 307 mg (1.78 mmol, 10.5 eq) p-toluenesulfonic acid 
(pTsA) in 4 ml CH2Cl2:MeOH (7:3, v/v). After 10 min, the reaction mixture was poured into 
ammonium hydrogen phosphate buffer (30 ml, 1 M). The organic layer was dried and the 
volatiles removed under reduced pressure. Flash chromatography (EtOAc, 100%, gradient 
CH2Cl2:MeOH from 100:0 to 95:5, v/v) yielded 142 mg (0.09 mmol, 55%) of the desired 
product 35 as a non separable mixture of diastereomers. 
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C75H74Cl2N10O19P2: 1526.27 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.42;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.96-7.93 (m, 2H, 8CH), 7.58-7.38 (m, 10H, CHarom), 
6.88-6.77 (m, 8H, CHarom), 5.93-5.91 (m, 1H, CHallyl), 5.86-5.83 (m, 2H, 1’CHa, 1’CHb), 5.42-
5.38 (m, 1H, CH2 alkene), 5.33-5.32 (m, 2H, CHdpa), 5.27-5.25 (m, 1H, CH2 alkene), 5.10 (m, 1H, 
3’CHa), 5.03-4.95 (m, 2H, 2’CHa, 2’CHb), 4.63 (m, 1H, 3’CHa), 4.57-4.54 (m, 2H, 5’CH2b), 4.52-
4.49 (m, 2H, CH2 allyl), 4.44-4.38 (m, 2H, CHTHP), 4.27 (m, 1H, 4’CHb), 4.25-4.14 (m, 4H, CH2 
THP), 4.12 (m, 1H, 4’CHa), 3.85-3.35 (m, 4H, CH2 THP), 3.67 (m, 1H, 5’CH2b), 3.54 (m, 1H, 
5’CH2a), 3.40 (m, 2H, 5’CH2a, 5’CH2b), 2.75-2.64 (m, 4H, CH2 THP), 1.74-1.46 (m, 4H, CH2 THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 179.6 (C=Odpa), 174.5 (4C=O), 155.6/155.4 (2Cq), 
148.2-138.5 (Cqarom), 137.8-136.9 (6Cq, 5Cq), 132.5/132.4 (CHallyl), 130.5-128.7 (CHarom), 
128.5/128.1 (8CH), 127.9-122.4 (CHarom), 118.2/118.0 (CH2 alkene), 102.3/101.8 (CHTHP), 
88.5/88.2 (4’CHa), 87.9/87.7 (4’CHb), 86.8/86.5 (2’CHa), 86.1/85.9 (2’CHb), 82.4/82.1 (1’CHa), 
81.8/81.7 (1’CHb), 72.3/72.1 (3’CHa), 70.9/70.5 (3’CHb), 68.1/68.0 (CH2 allyl), 66.0/65.7 
(5’CH2b), 63.0 (CH2 THP), 62.2/62.0 (5’CH2a), 59.1/58.9 (CHdpa), 31.8/30.8 (CH2 THP), 25.2/24.8 
(CH2 THP), 21.5/21.2 (CH2 THP);  
MS (Maldi-ToF, m/z): 1548.3 ([M+Na]+). 
 
 
8.1.12 Cyclic bis(3’,5’)-(2-N-diphenylacetyl-2’-O-tetrahydropyranyl-
guanosine)-2-chlorophenyl phosphate (36) 
 
 
 
142 mg (0.09 mmol, 1 eq) of dimer 35 were dissolved in dry THF (2 ml) and added with 5 mg 
(3.5 mol%) Pd(PPh3)4, 8 mg (25 mol%) PPh3, 0.2 ml (10% of solvent volume) n-butylamine 
and the mixture was stirred for 5 min at RT under argon. After co-evaporation with pyridine (5 
x 2.5 ml), the residue was taken up in dry pyridine (20 ml) and 190 mg (0.49 mmol, 5.5 eq) 1-
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(2,4,6-triisopropylbenzenesulfonyl)-3-nitro-1H-1,2,4-triazole (TPSNT) were added. The 
mixture was stirred for 16 hrs at RT under argon. A few drops of water were then added to 
the mixture and the solvent evaporated. The residue was taken up in DCM and washed with 
TEAC buffer (50 ml, 1 M and 50 ml, 0.1 M). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. Flash chromatography (CH2Cl2:MeOH gradient from 
100:0 to 95:5, v/v) gave 52 mg (35.47 µmol, 38%) of cyclic compound 36 as a white solid. 
 
C70H66Cl2N10O19P2: 1484.18 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.08;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 7.96-7.94 (m, 2H, 8CH), 7.52-7.32 (m, 10H, CHarom), 
6.95-6.88 (m, 8H, CHarom), 5.96-5.89 (m, 2H, 1’CHa, 1’CHb), 5.23-5.21 (m, 2H, CHdpa), 5.03-
4.95 (m, 2H, 2’CHa, 2’CHb), 4.65-4.62 (m, 1H, 3’CHa, 3’CHb), 4.52-4.48 (m, 2H, 5’CH2b), 4.45-
4.39 (m, 2H, CHTHP), 4.25-4.14 (m, 4H, CH2 THP), 4.12-4.05 (m, 2H, 4’CHa, 4’CHb), 3.72-3.70 
(m, 1H, 5’CH2a), 3.67-3.66 (m, 1H, 5’CH2a), 3.64-3.35 (m, 4H, CH2 THP), 2.65-2.54 (m, 4H, CH2 
THP), 1.74-1.46 (m, 4H, CH2 THP);  
13C NMR (100.6 MHz, CDCl3, δ ppm): 175.6 (C=Odpa), 173.5 (4C=O), 154.6/154.4 (2Cq), 
147.6-138.5 (Cqarom), 137.2/137.0 (8CH), 136.8-134.9 (6Cq, 5Cq), 131.0-122.4 (CHarom), 
101.3/100.8 (CHTHP), 86.9/86.6 (1’CH), 85.9/84.9 (2’CH), 82.4/81.7 (4’CH), 72.3/70.6 (3’CH), 
69.2/64.0 (5’CH2), 63.3/63.2 (CH2 THP), 58.7/58.1 (CHdpa), 31.8/30.8 (CH2 THP), 25.2/24.8 (CH2 
THP), 21.5/21.2 (CH2 THP);  
MS (Maldi-ToF, m/z): 1489.4 ([M+Na]+). 
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8.1.13 Cyclic diguanylic acid (c-di-GMP) 
 
 
 
52 mg (35.47 µmol, 1 eq) of compound 36 were dissolved in dry pyridine (4 ml) at RT under 
argon and added with 195 mg (0.35 mmol, 10 eq) syn-pyridine-2-carboxaldoxime and 176 µl 
(1.24 mmol, 35 eq) 1,1,3,3-tetramethylguanidine and then stirred 20 hrs at RT under argon. 
40 ml of an aq. ammonia solution (33%) were added and the mixture heated to 50°C for 48 
hrs. The reaction mixture was concentrated to 1/10 of its volume and washed with diethyl 
ether (2 x 10 ml). The aqueous phase was acidified to pH 2 with 0.1 M HCl and stirred at RT 
for 16 hrs followed by neutralization with an aq. ammonia solution to pH 8. The reaction 
mixture was then concentrated to a small volume and purified by reverse phase HPLC 
(TEAC(0.01 M):MeOH; 92.5:7.5) to yield 4 mg (5.80 µmol, 16%) of c-di-GMP as a white 
foam. 
 
C20H23N10O14P2: 689.08 g/mol 
1H NMR (500 MHz, D2O, δ ppm): 7.90 (s, 2H, 8CH), 5.84 (d, 2H, J= 1.3 Hz, 1’CH), 4.74 (dd, 
2H, J1= 8.5 Hz, J2= 5.0 Hz, 3’CH), 4.59 (dd, 2H, J= 5.0 Hz,2’CH), 4.27 (dd, 2H, J= 8.5 Hz, 
4’CH), 4.21 (m, 2H, 5’CH2), 3.96 (m, 2H, 5’CH2); 
13C NMR (125.8 MHz, D2O, δ ppm): 158.8, 153.8 (4C=O, 6Cq), 150.8 (2Cq), 137.1 (8CH), 
116.3 (5C), 89.2 (1’CH), 79.8 (4’CH), 73.3 (2’CH), 70.5 (3’CH), 62.2 (5’CH2); 
HRMS-ESI: m/z [M-H]- calcd for C20H23N10O14P2: 689.0870; Found: 689.0869.  
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8.2 Synthesis of Tom Protected Guanosine 
8.2.1 Triisopropylsilyl(ethylthio)methyl ether (38) 
 
 
 
10 g (0.33 mol, 1 eq) paraformaldehyde 37 were suspended in 24.6 ml (0.33 mol, 1 eq) 
ethanethiol at RT under argon and the mixture was cooled to 0°C. 1 drop of 10 M NaOH was 
added, the mixture allowed to slowly warm up to RT and then heated to 40°C for 3 hrs. After 
cooling to RT, 350 ml dichloromethane, 41.34 g (0.66 mol, 2 eq) imidazole and 67 ml (0.31 
mol, 0.95 eq) chlorotriisopropylsilane were added and stirred overnight. The reaction mixture 
was diluted with 500 ml hexane and washed with 2x250 ml of a 10% aq. NaH2PO4 sol. The 
organic fractions were dried (MgSO4) and concentrated under reduced pressure. The residue 
was distilled in vacuo (83°C, 0.1 mbar) to give 57.10 g of 38 as a colorless liquid (0.23 mol, 
69%). 
 
C12H28OSSi: 248.50 g/mol 
1H NMR (400.0 MHz, CDCl3, δ ppm): 4.86 (s, 1H, CH2), 2.69 (q, 2H, J= 7.32 Hz, CH2), 1.29 (t, 
3H, J= 7.32 Hz, CH3 ethyl), 1.08 (m, 26H, CHisopropyl, CH3 isopropyl);  
13C NMR (101.0 MHz, CDCl3, δ ppm): 66.4 (S-CH2-O), 25.1 (CH2-S), 18.2 (CH3 ethyl), 15.4 
(CH3 isopropyl), 12.36 (CHisopropyl);  
MS (Maldi-ToF, m/z): 271.1 ([M+Na]+).  
 
 
 
 
 
 
 
 
 
 
 
O x S O
Si
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8.2.2 [(Triisopropylsilyl)oxy]methyl chloride (TomCl) (39) 
 
 
 
A solution of 57 g (0.23 mol 1 eq) triisopropylsilyl(ethylthio)methyl ether 38 in 200 ml 
dichloromethane was added with 18.7 ml (0.23 mol, 1 eq) sulfurylchloride at 0°C under 
argon. The yellow solution was stirred for 1 hr. The solvent was then evaporated under 
reduced pressure. Vacuum distillation (34°C, 0.1 mbar) yielded 31.1 g (0.14 mol, 65%) of 39 
as a colorless liquid. 
 
C10H23ClOSi: 222.83 g/mol 
1H NMR (400.0 MHz, CDCl3, δ ppm): 5.65 (s, 2H, CH2), 1.21 (m, 3H, CHisopropyl), 1.09 (d, 18H, 
J= 7.08 Hz, CH3 isopropyl);  
13C NMR (101.0 MHz, CDCl3, δ ppm): 18.1 (CH3 isopropyl), 14.1 (CHisopropyl), 12.2 (CH2);  
MS (Maldi-ToF, m/z): 255.3 ([M+Na]+).  
 
 
8.2.3 2-N-2’,3’,5’-O-tetrabenzoylguanosine (40) 
 
 
 
5 g (17.66 mmol, 1 eq) guanosine 20 were suspended in 70 ml dry pyridine at RT under 
argon and heated to 40°C and 15.01 g (106.84 mmol, 6.05 eq) benzoylchloride were added. 
An exothermic reaction occured, the temperature went up to 70°C then back to 40°C. After 
2.5 hrs, 100 ml sat. aq. NaHCO3 sol. as well as 35 ml chloroform were added to quench the 
reaction. The aqueous phase was extracted with dichloromethane (3 x 100 ml) and the 
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organic phase was dried (MgSO4) and concentrated under reduced pressure. The residue 
was purified by flash chromatography (CH2Cl2:MeOH, 95:5, v/v) to yield 9.41 g of 40 as a 
white solid (13.42 mmol, 76%). 
 
C38H29N5O9: 699.66 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.55;  
1H NMR (400.0 MHz, CDCl3, δ ppm): 11.99 (s, 1H, 3NH), 9.60 (s,1H, 8CH), 8.02 (m, 10H, 
CHarom), 7.50 (m, 10H, CHarom), 6.92 (dd, 1H, J= 7.56 Hz, J= 4.8 Hz, 3’CH), 6.44 (dd, 1H, J1= 
4.92 Hz, J2= 2.1 Hz, 2’CH), 6.24 (d, 1H, J= 2.4 Hz, 1’CH), 4.87 (m, 2H, 5’CH2), 4.78 (m, 1H, 
4’CH);  
13C NMR (101.0 MHz, CDCl3, δ ppm): 167.7 (C=O), 166.7 (C=O), 166.4 (C=O), 165.6 (C=O), 
133-134 (CHarom), 128-131 (CHarom), 88.7 (1’CH), 79.9 (4’CH), 74.7 (2’CH), 71.2 (3’CH), 62.0 
(5’CH2);  
MS (Maldi-ToF, m/z): 700.1 ([M]+).  
 
 
8.2.4 2-N-benzoylguanosine (41) 
 
 
 
1 g (1.43 mmol, 1 eq) 2-N-2’,3’,5’-O-tetrabenzoylguanosine 40 was suspended in 20 ml 
methanol: pyridine (1:1) at RT. 2N NaOH (10 ml) was added to solubilize the suspension. 
After 35 min, the reaction was quenched with Dowex 50W till neutralization of the solution. 
The mixture was filtered, the resin washed with methanol and the combined solvents 
evaporated under reduced pressure. The residual pyridine was removed through co-
evaporation with toluene. The residue was re-crystallized from boiling ethanol to yield 430 
mg of 41 as a white solid (1.11 mmol, 78%).  
 
C17H17N5O6: 387.35 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.05;  
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1H NMR (400.0 MHz, DMSO, δ ppm): 12.43 (s, 1H, 3NH), 8.26 (s, 1H, 8CH), 8.03 (m, 2H, 
CHarom), 7.54 (m, 3H, CHarom), 5.87 (d, 1H, J= 6.08 Hz, 1’CH), 5.48 (s, 1H, OH), 5.10 (s, 2H, 
OH), 4.47 (t, 1H, J= 5.32 Hz, 2’CH), 4.12 (dd, 1H, J1= 4.52 Hz, J2= 3.28 Hz, 3’CH), 3.90 (dd, 
1H, J1= 7.32 Hz, J2= 3.8 Hz, 4’CH), 3.55 (m, 2H, 5’CH2);  
13C NMR (101.0 MHz, DMSO, δ ppm): 156.1 (6Cq), 149.9 (2Cq), 138.7 (8CH), 129-133 
(CHarom), 121.3 (5Cq), 87.3 (1’CH), 86.3 (4’CH), 74.7 (2’CH), 71.2 (3’CH), 62.1 (5’CH2);  
MS (Maldi-ToF, m/z): 410.2 ([M+Na]+).  
 
 
8.2.5 2-N-benzoyl-5’-O-dimethoxytritylguanosine (42) 
 
 
 
150 mg (0.39 mmol, 1 eq) 2-N-benzoylguanosine 41 were co-evaporated with pyridine (2x4 
ml) then suspended in 2 ml dry pyridine at RT under argon. 145 mg (0.43 mmol, 1.1 eq) 4,4’-
dimethoxytritylchloride (DMTCl) were added and the mixture was stirred overnight. The 
reaction was quenched with 6 ml of a 5% aq. NaHCO3 sol. and extracted with 
dichloromethane (2 x 4 ml). The organic layer was dried and concentrated, then co-
evaporated with toluene (2 x 5 ml). Flash chromatography (DCM:hexane, 1:1, CH2Cl2:MeOH, 
gradient from 100:0 to 95:5, v/v) yielded 220 mg of 42 as a white foam (0.32 mmol, 82%).  
 
C38H35N5O8: 689.71 g/mol 
Rf (CH2Cl2:MeOH, 90:10) = 0.7;  
1H NMR (400.0 MHz, DMSO, δ ppm): 12.43 (s, 1H, 2NH), 11.84 (s, 1H, 3NH), 8.14 (s, 1H, 
8CH), 7.97 (dd, 1H, J1= 5.32 Hz, J2= 1.76 Hz, CHarom), 7.66 (m, 1H, CHarom), 7.54 (m, 2H, 
CHarom), 7.33 (m, 2H, CHarom), 7.21 (m, 8H, CHarom), 6.78 (m, 4H, CHarom), 5.92 (d, 1H, J= 4.8 
Hz, 2’OH), 5.59 (d, 1H, J= 5.8 Hz, 3’OH), 5.18 (d, 1H, J= 5.56 Hz, 1’CH), 4.55 (m, 2H, 2’CH, 
3’CH), 4.19 (q, 1H, J= 5.04 Hz, 4’CH), 4.01 (m, 1H, 5’CH2), 3.70 (m, 1H, 5’CH2), 3.68 (s, 6H, 
CH3);  
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13C NMR (101.0 MHz, DMSO, δ ppm): 156.3 (6Cq), 149.8 (2Cq), 138.5 (8CH), 129-133 
(CHarom), 121.1 (5Cq), 87.3 (1’CH), 86.2 (4’CH), 74.6 (2’CH), 71.1 (3’CH), 62.0 (5’CH2);  
MS (Maldi-ToF, m/z): 712.3 ([M+Na]+).  
 
 
8.2.6 2-N-benzoyl-5’-O-dimethoxytrityl-2’-O-[(triisopropylsilyl)oxy] 
methylguanosine (43) 
 
 
 
51 mg (73.99 µmol, 1 eq) 2-N-benzoyl-5’-O-dimethoxytritylguanosine 42 were dissolved in 
0.5 ml 1,2-dichloroethane (DCE) at RT under argon. 0.44 ml (0.26 mmol, 3.52 eq) 
diisopropylethylamine (DIPEA) then 25.2 mg (0.08 mmol, 1.12 eq) dibutyltindichloride were 
added and the mixture heated at 80°C for 1 hr. 21.7 mg (0.09 mmol, 1.32 eq) 
[(triisopropylsilyl)oxy]methyl chloride (TomCl) were added and the mixture heated at 80°C for 
1.5 hrs. The solution was diluted with 5 ml dichloromethane and extracted with 5 ml sat. aq. 
NaHCO3 sol. The organic layer was dried (MgSO4) and concentrated under reduced 
pressure. Flash chromatography (CH2Cl2, CH2Cl2:MeOH gradient from 100:0 to 90:10, v/v, 
+0.5% triethylamine) yielded 3 mg (3.73 µmol, 5%) of the 2’-O-Tom product 43 and 26 mg 
(32.38 µmol, 44%) of the 3’-O-Tom product 44.  
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C48H57N5O9Si: 876.08 g/mol 
 
2’-O-Tom isomer 43: 
Rf (CH2Cl2:MeOH, 95:5) = 0.63;  
1H NMR (400.0 MHz, DMSO, δ ppm): 12.43 (s, 1H, 2NH), 11.82 (s, 1H, 3NH), 8.10 (s, 1H, 
8CH), 7.95 (m, 2H, CHarom), 7.64 (m, 1H, CHarom), 7.54 (m, 2H, CHarom), 7.31(m, 2H, CHarom), 
7.20 (m, 10H CHarom), 6.78 (m, 4H, CHarom), 5.60 (d, 1H, J= 5.7 Hz, 3’OH), 5.45 (s, 2H, CH2 
Tom), 5.16 (d, 1H, J= 5.59 Hz, 1’CH), 4.64 (m, 1H, 2’CH), 4.57 (m, 1H, 3’CH), 4.19 (q, 1H, J= 
5.1 Hz, 4’CH), 3.99 (m, 1H, 5’CH2), 3.70 (m, 1H, 5’CH2), 3.68 (s, 6H, CH3), 2.14 (s, 3H, CHTom), 
1.10 (s, 18H, CH3 Tom);  
13C NMR (100.6 MHz, DMSO, δ ppm): 167.5 (C=O), 157.1 (4C=O), 147.8 (6Cq), 147.6 (2Cq), 
138.5 (8CH), 133.2-127.5 (CHarom), 117.8 (5Cq), 114.8-114.5 (CHarom), 95.9 (CqTom), 90.1 
(CH2 Tom), 86.9 (1’CH), 86.0 (4’CH), 82.6 (2’CH), 71.1 (3’CH), 62.0 (5’CH2), 30.3 (CHTom), 18.1 
(CH3 Tom);  
MS (Maldi-ToF, m/z): 899.5 ([M+Na]+).  
 
3’-O-Tom isomer 44: 
Rf (CH2Cl2:MeOH, 95:5) = 0.59;  
1H NMR (400.0 MHz, DMSO, δ ppm): 12.43 (s, 1H, 2NH), 11.82 (s, 1H, 3NH), 8.10 (s, 1H, 
8CH), 7.95 (m, 2H, CHarom), 7.64 (m, 1H, CHarom), 7.54 (m, 2H, CHarom), 7.31(m, 2H, CHarom), 
7.20 (m, 10H CHarom), 6.78 (m, 4H, CHarom), 5.60 (d, 1H, J= 5.7 Hz, 2’OH), 5.43 (s, 2H, CH2 
Tom), 5.16 (d, 1H, J= 5.59 Hz, 1’CH), 4.67 (m, 1H, 3’CH), 4.54 (m, 1H, 2’CH), 4.19 (q, 1H, J= 
5.09 Hz, 4’CH), 3.98 (m, 1H, 5’CH2), 3.70 (m, 1H, 5’CH2), 3.68 (s, 6H, CH3), 2.15 (s, 3H, 
CHTom), 1.11 (s, 18H, CH3 Tom);  
13C NMR (100.6 MHz, DMSO, δ ppm): 167.5 (C=O), 157.3 (4C=O), 147.9 (6Cq), 147.7 (2Cq), 
138.5 (8CH), 133.5-127.8 (CHarom), 117.9 (5Cq), 114.8-114.5 (CHarom), 95.7 (CqTom), 89.9 
(CH2 Tom), 86.9 (1’CH), 86.0 (4’CH), 82.6 (3’CH), 71.1 (2’CH), 62.0 (5’CH2), 30.2 (CHTom), 18.1 
(CH3 Tom);  
MS (Maldi-ToF, m/z): 899.6 ([M+Na]+).  
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8.3 Synthesis of the Guanosine Dinucleotide Following the Hayakawa 
Methodology 
8.3.1 2’,3’,5’-O-triacetylguanosine (45) 
 
 
 
10 g (35.32 mmol, 1 eq) guanosine 20 were suspended in 200 ml acetonitrile at RT under 
argon. 0.43 g (3.53 mmol, 0.1 eq) 4-dimethylamino-pyridine (DMAP), 19.5 ml (139.86 mmol, 
3.96 eq) triethylamine and 13 ml (127.15 mmol, 3.6 eq) acetic anhydride were added and the 
mixture stirred for 1 hr. The reaction was quenched with 50 ml methanol, the solvents 
removed under reduced pressure and the oily residue re-crystallized from isopropanol. The 
suspension was filtered and successively washed with ethanol and diethyl ether to yield 
12.51 g (30.58 mmol, 87%) of 45 as a white solid. 
 
C16H19N5O8: 409.35 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.33;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.72 (s, 1H, 3NH), 7.91 (s, 1H, 8CH), 5.96 (d, 1H, J= 
6.04 Hz, 1’CH), 5.76 (t, 1H, J= 6.08 Hz, 2’CH), 5.46 (dd, 1H, J1= 6.08 Hz, J2= 4.04 Hz, 3’CH), 
4.35 (m, 1H, 4’CH), 4.26 (m, 2H, 5’CH2), 2.09 (s, 3H, CH3 acetyl), 2.02 (s, 3H, CH3 acetyl), 2.01 (s, 
3H, CH3 acetyl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 85.2 (1’CH), 80.4 (4’CH), 72.9 (2’CH), 71.1 (3’CH), 63.9 
(5’CH2), 21.4 (CH3 acetyl), 21.2 (CH3 acetyl), 21.0 (CH3 acetyl);  
MS (Maldi-ToF, m/z): 432.2 ([M+Na]+). 
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8.3.2 2’,3’,5’-O-triacetyl-4-O-allyloxyguanosine (46) 
 
 
 
10.89 g (26.62 mmol, 1 eq) 2’,3’,5’-O-triacetylguanosine 45 were suspended in 150 ml dry 
dioxane at RT under argon, added with 11.86 g (45.26 mmol, 1.7 eq) triphenylphosphine and 
16.7 ml (244.96 mmol, 9.2 eq) of freshly distilled allylic alcohol. This mixture was heated to 
80°C for 1hr. After cooling, 21.9 ml (46.41 mmol, 1.8 eq) diethyl azodicarboxylate (DEAD) 
were added dropwise and the resulting solution heated to 60°C for 2 hrs. The solvents were 
evaporated under reduced pressure. The oily residue was taken-up in 80 ml dichloromethane 
and stored at 4°C. The crystalline triphenylphosphine oxide was filtered and the solvents 
evaporated under reduce pressure. Flash chromatography (hexane, hexane:EtOAc gradient 
from 1:0 to 4:6; v/v) yielded 9.21 g of 46 as a white foam (20.49 mmol, 77%).  
 
C19H23N5O8: 449.41 g/mol 
Rf (hexane:EtOAc, 3:1) = 0.3;  
1H NMR (400.0 MHz, DMSO, δ ppm): 8.10 (s, 1H, 8CH), 6.55 (s, 2H, NH2), 6.07 (m, 2H, 
CHalkene,1’CH), 5.85 (t, 1H, J= 6.08 Hz, 2’CH), 5.52 (dd, 1H, J1= 5.8 Hz, J2= 4.04 Hz, 3’CH), 
5.39 (dq, 1H, J1= 17.44 Hz, J2= 1.8 Hz, CH2 alkene), 5.25 (dq, 1H, J1= 10.86 Hz, J2= 1.12 Hz, 
CH2 alkene), 4.93 (dt, 2H, J1= 5.56 Hz, J2= 1.48 Hz, CH2 allyl), 4.40-4.23 (m, 3H, 5’CH2, 4’CH), 
2.11 (s, 3H, CH3 acetyl), 2.03 (s, 3H, CH3 acetyl), 2.01 (s, 3H, CH3 acetyl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 170.9-170.1 (C=Oacetyl), 119.0 (CH2 alkene), 114.7 
(CHalkene), 85.3 (1’CH), 80.4 (4’CH), 72.7 (2’CH), 71.2 (3’CH), 66.9 (5’CH2), 63.9 (CH2 allyl), 21.4-
21.0 (CH3 acetyl);  
MS (Maldi-ToF, m/z): 473.6 ([M+Na]+). 
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8.3.3 2’,3’,5’-O-triacetyl-4-O-allyloxy-2-N-di[(allyloxy)carbonyl] 
guanosine (47) 
 
 
 
9.21 g (20.46 mmol, 1 eq) 2’,3’,5’-O-triacetyl-4-allyloxyguanosine 46 were dissolved in 200 
ml dry THF at RT under argon, then cooled to 5°C and added with 6.5 ml (61.40 mmol, 3 eq) 
allylchloroformate. 35.1 ml (53.21 mmol, 2.6 eq) t-butylmagnesium chloride were added 
dropwise under stirring at 5°C. After completion of the addition, the ice bath was removed 
and the mixture allowed to reach RT and stirred for 1 hr. The reaction was quenched with 15 
ml methanol and diluted with 150 ml ethylacetate. The solution was washed with sat. aq. 
NH4Cl sol. (2 x 150 ml), sat. aq. NaHCO3 sol. (2 x 150 ml) and brine (2 x 150 ml). The 
organic phase was dried (MgSO4) and concentrated in vacuo. Flash chromatography 
(hexane, hexane:EtOAc gradient from 1:0 to 4:6; v/v) yielded 8.76 g of 47 as a white foam 
(14.11 mmol, 69%).  
 
C27H31N5O12: 617.56 g/mol 
Rf (hexane:EtOAc 1:3) = 0.55;  
1H NMR (400.0 MHz, DMSO, δ ppm): 8.70 (s, 1H, 8CH), 6.26 (d, 1H, J= 5.08 Hz, 1’CH), 6.08 
(m, 1H, CHallyl), 5.85 (m, 3H, 2xCHAOC, 2’CH), 5.58 (t, 1H, J= 5.56 Hz, 3’CH), 5.41 (dq, 1H, J1= 
17.16 Hz, J2= 1.52 Hz, CH2 alkene allyl), 5.29 (dq, 1H, J1= 10.36 Hz, J2= 1.52 Hz, CH2 alkene allyl), 
5.21-5.12 (m, 4H, 2xCH2 alkene AOC), 5.03 (d, 2H, J= 5.8 Hz, CH2 allyl), 4.66 (m, 4H, CH2AOC), 
4.38-3.98 (m, 3H, 5’CH2, 4’CH), 2.09 (s, 3H, CH3 acetyl), 2.01 (s, 3H, CH3 acetyl), 1.95 (s, 3H, CH3 
acetyl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 170.1 (C=Oacetyl), 160.3 (4C-O), 154.1 (6Cq), 152.7 
(2Cq), 152.3 (C=OAOC), 142.8 (8CH), 133.6 (CHallyl), 133.5 (CHAOC), 119.8 (5Cq), 118.7 (CH2 
alkene AOC), 118.5 (CH2 alkene allyl), 87.9 (1’CH), 86.4 (4’CH), 74.5 (2’CH), 71.2 (3’CH), 67.5 (CH2 
AOC), 65.9 (CH2 allyl), 62.3 (5’CH2), 21.4-21.0 (CH3 acetyl);  
MS (Maldi-ToF, m/z): 640.4 ([M+Na]+). 
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8.3.4 4-O-allyloxy-2-N-[(allyloxy)carbonyl] guanosine (48) 
 
 
 
8.76 g (14.19 mmol, 1 eq) 2’,3’,5’-O-triacetyl-4-O-allyloxy-2-N-di[(allyloxy)carbonyl] 
guanosine 47 were dissolved in 150 ml ethanol at RT under argon, added with 0.7 ml (7.09 
mmol, 0.5 eq) 10 M NaOH and stirred for 30 mins. The reaction was quenched with Dowex 
50 WX 8-200 (till pH=7), filtered and evaporated in vacuo. Flash chromatography 
(hexane:CH2Cl2 1:1; CH2Cl2:MeOH gradient from 1:0 to 9:1, v/v) yielded 4.13 g of 48 as a 
white foam (10.19 mmol, 72%). 
 
C17H21N5O7: 407.38 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.05;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.38 (s, 1H, NH), 8.42 (s, 1H, 8CH), 6.15 (m, 1H, 
CHallyl), 5.95 (m, 1H, CHAOC), 5.87(d, 1H, J= 6.08 Hz, 1’CH), 5.46 (d, 1H, J= 7.56 Hz, 2’OH), 
5.46-5.39 (dq, 2H, J1= 15.68 Hz, J2= 1.52 Hz, CH2 alkene allyl), 5.29-5.19 (dq, 2H, J1= 3.28 Hz, 
J2= 1.76 Hz, CH2 alkene AOC), 5.16 (d, 1H, J= 4.08 Hz, 3’OH), 5.04 (d, 2H, J= 5.04 Hz, CH2 allyl), 
4.92 (t, 1H, J= 5.52 Hz, 5’OH), 4.59 (m, 3H, CH2 AOC, 2’CH), 4.16 (q, 1H, J= 4.56 Hz, 3’CH), 
3.89 (q, 1H, J= 4.28 Hz, 4’CH), 3.65-3.49 (m, 2H, 5’CH2), 2.09 (s, 3H, CH3 acetyl), 2.01 (s, 3H, 
CH3 acetyl), 1.95 (s, 3H, CH3 acetyl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 160.5 (4C-O), 154.0 (6Cq), 152.9 (2Cq), 152.6 
(C=OAOC), 142.2 (8CH), 133.9 (CHallyl), 133.8 (CHAOC), 119.8 (5Cq), 118.3 (CH2 alkene AOC), 
118.0 (CH2 alkene allyl), 87.9 (1’CH), 86.5 (4’CH), 74.3 (2’CH), 71.3 (3’CH), 67.8 (CH2 AOC), 65.6 
(CH2 allyl), 62.3 (5’CH2);  
MS (Maldi-ToF, m/z): 430.4 ([M+Na]+). 
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8.3.5 First Building Block Possibility 
8.3.5.1 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-5’-O-dimethoxytriphenyl 
methyl-guanosine (49) 
 
 
 
500 mg (1.23 mmol, 1 eq) 4-O-allyloxy-2-N-[(allyloxy)carbonyl] guanosine 48 were co-
evaporated with dry pyridine (2x5 ml). dissolved in 8 ml dry pyridine at RT under argon and 
added with 541 mg (1.59 mmol, 1.3 eq) triethylamine, 0.25 ml (2.46 mmol, 2 eq) DMTCl and 
stirred for 16 hrs. The reaction was quenched with methanol (2 ml) and the solvents 
evaporated under reduced pressure. Flash chromatography (hexane, hexane:EtOAc gradient 
from 1:0 to 1:1, v/v, +0.5% triethylamine) yielded 760 mg of 49 as a white foam (1.06 mmol, 
87%). 
 
C38H39N5O9: 709.74 g/mol 
Rf (hexane:EtOAc, 3:1) = 0.38;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.37 (s, 1H, 2NH), 8.35 (s,1H, 8CH), 7.30 (m, 2H, 
CHarom), 7.20 (m, 2H, CHarom), 7.18 (m, 4H, CHarom), 7.17 (m, 1H, CHarom), 6.78 (m, 4H, 
CHarom), 6.17 (ddt, 1H, J1= 17.2 Hz, J2= 10.4 Hz, J3= 5.8 Hz, CHallyl), 5.97 (ddt, 1H, J1= 17.2 
Hz, J2= 10.6 Hz, J3= 5.2 Hz, CHAOC), 5.94 (d, 1H, J= 4.4 Hz, 1’CH), 5.61 (s, 1H, 2’OH), 5.48 
(dq, 2H, J1= 17.2 Hz, J2= 1.6 Hz, CH2 alkene allyl), 5.39 (dq, 2H, J1= 17.2 Hz, J2= 1.7 Hz, CH2 
alkene AOC), 5.31 (bdq, 1H, J1= 10.4 Hz, J2= 1.3 Hz, CH2 allyl), 5.23 (dq, 1H, J1= 10.6 Hz, J2= 1.5 
Hz, CH2 allyl), 5.13 (s, 1H, 3’OH), 5.06 (dt, 2H, J1= 5.8 Hz, J2= 1.0 Hz, CH2 AOC), 4.72 (q, 1H, J= 
5.0 Hz, 2’CH), 4.61 (dt, 1H, J1= 5.2 Hz, J2= 1.3 Hz, CH2 AOC), 4.37 (q, 1H, J= 5.2 Hz, 3’CH), 
4.00 (m, 1H, 4’CH), 3.71 (s, 3H, CH3), 3.70 (s, 3H, CH3 DMT), 3.20 (dd, 1H, J1= 10.6 Hz, J2= 
6.3 Hz, 5’CH2), 3.18 (dd, 1H, J1= 10.6 Hz, J2= 3.0 Hz, 5’CH2);  
13C NMR (100.6 MHz, DMSO, δ ppm): 159.6 (4C-O), 158.0 (Cqarom), 157.9 (CHarom), 152.8 
(6Cq), 152.0 (2Cq), 151.5 (C=OAOC), 144.9 (Cqarom), 141.5 (8CH), 135.6 (Cqarom), 133.1 
(CHallyl), 132.9 (CHAOC), 129.7 (CHarom), 129.6 (CHarom), 127.7 (CHarom), 127.6 (CHarom), 126.6 
(CHarom), 118.9 (CH2 AOC), 117.4 (CH2 allyl), 117.3 (5Cq), 113.0 (CHarom), 112.9 (CHarom), 88.3 
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(1’CH), 85.4 (Cq), 83.7 (4’CH), 73.1 (2’CH), 70.6 (3’CH), 66.9 (CH2 AOC), 64.7 (CH2 allyl), 64.2 
(5’CH2), 55.0 (CH3 DMT), 54.9 (CH3 DMT);  
MS (Maldi-ToF, m/z): 708.4 ([M]+). 
 
 
8.3.5.2 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-5’-O-dimethoxytriphenyl 
methyl-2’-O-tertbutyldimethylsilyl-guanosine (50) 
 
 
 
760 mg (1.06 mmol, 1 eq) 5’-O-dimethoxytrityl-4-O-allyloxy-2-N-[(allyloxy)carbonyl] 
guanosine 49 were dissolved in 10 ml dry THF at RT under argon and added with 0.32 ml 
(3.95 mmol, 3.7 eq) pyridine. 272 mg (1.60 mmol, 1.5 eq) silver nitrate were added and the 
suspension stirred to obtain a clear solution. 274 mg (1.82 mmol, 1.7 eq) t-butyldimethylsilyl 
chloride were added and stirred for 5 hrs. The reaction was filtered over celite and the filtrate 
poured into 5% aq. NaHCO3 sol. (25 ml) and extracted with DCM (3 x 15 ml). The organic 
layer was dried (MgSO4) and the solvents evaporated under reduced pressure. Flash 
chromatography (hexane, hexane:EtOAc gradient from 1:0 to 2:8, v/v,+0.5% NEt3) yielded 
two isomers as white foams. 70 mg of 2’O-TBDMS substituted compound 50 (0.08 mmol, 8%) 
and 349 mg of 3’O-TBDMS substituted compound 51 (0.42 mmol, 40%) were obtained. 
 
C44H53N5O9Si: 824.01 g/mol 
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2’-O-TBDMS isomer 50: 
Rf (hexane:EtOAc, 1:3) = 0.66;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.38 (s, 1H, 2NH), 8.42 (s,1H, 8CH), 7.32 (m, 2H, 
CHarom), 7.19 (m, 8H, CHarom), 6.79 (m, 4H, CHarom), 6.14 (m, 1H, CHallyl), 5.94 (m, 2H, CHAOC, 
1’CH), 5.48 (ddq, 2H, J1= 39.12 Hz, J2= 17.4 Hz, J3= 1.52 Hz, CH2 alkene allyl), 5.24 (ddq, 2H, J1= 
32.08 Hz, J2= 10.36 Hz, J3= 1.52 Hz, CH2 alkene AOC), 5.03 (d, 1H, J= 5.8 Hz, 3’OH), 4.99 (d, 
2H, J= 6.08 Hz, CH2 allyl), 4.88 (t, 1H, J= 5.04 Hz, 2’CH), 4.57 (d, 2H, J= 4.8 Hz, CH2 AOC), 4.24 
(q, 1H, J= 4.8 Hz, 3’CH), 4.00 (q, 1H, J= 7.08 Hz, 4’CH), 3.38-3.18 (m, 2H, 5’CH2), 0.73 (s, 9H, 
CH3 TBDMS), -0.05 (s, 6H, CH3 TBDMS);  
13C NMR (101.0 MHz, DMSO, δ ppm): 159.5 (4C-O), 157.0 (Cqarom), 156.9 (CHarom), 153.5 
(6Cq), 151.0 (2Cq), 151.5 (C=Oallyl), 142.9 (Cqarom), 141.9 (8CH), 133.9 (Cqarom), 133.1 (CHallyl), 
133.5 (CHAOC), 130.6 (CHarom), 130.5 (CHarom), 128.5 (CHarom), 127.9 (CHarom), 126.6 (CHarom), 
119.9 (CH2 allyl), 117.4 (CH2 AOC), 117.2 (5Cq), 113.8 (CHarom), 112.7 (CHarom), 88.5 (1’CH), 86.3 
(Cq), 83.1 (4’CH), 73.5 (2’CH), 70.9 (3’CH), 67.8 (CH2 AOC), 64.5 (CH2 allyl), 64.0 (5’CH2), 55.8 
(CH3 DMT), 54.9 (CH3 DMT), 26.6 (CH3 TBDMS), 21.6 (CqTBDMS), -4.1 (CH3 TBDMS);  
MS (Maldi-ToF, m/z): 823.9 ([M]+). 
 
3’-O-TBDMS isomer 51: 
Rf (hexane:EtOAc, 1:3) = 0.59;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.37 (s, 1H, 2NH), 8.42 (s,1H, 8CH), 7.32 (m, 2H, 
CHarom), 7.19 (m, 8H, CHarom), 6.79 (m, 4H, CHarom), 6.15 (m, 1H, CHallyl), 5.94 (m, 2H, CHAOC, 
1’CH), 5.48 (ddq, 2H, J1= 39.12 Hz, J2= 17.4 Hz, J3= 1.52 Hz, CH2 alkene allyl), 5.24 (ddq, 2H, J1= 
32.1 Hz, J2= 10.36 Hz, J3= 1.52 Hz, CH2 alkene AOC), 5.03 (d, 1H, J= 5.8 Hz, 3’OH), 4.99 (d, 1H, 
J= 6.08 Hz, CH2 allyl), 4.58 (t, 1H, J= 5.04 Hz, 2’CH), 4.54 (d, 1H, J= 4.8 Hz, CH2 AOC), 4.34 (q, 
1H, J= 4.8 Hz, 3’CH), 4.00 (q, 1H, J= 7.08 Hz, 4’CH), 3.36-3.20 (m, 2H, 5’CH2), 0.73 (s, 9H, 
CH3 TBDMS), -0.06 (s, 6H, CH3 TBDMS);  
13C NMR (101.0 MHz, DMSO, δ ppm): 159.5 (4C-O), 157.1 (Cqarom), 156.9 (CHarom), 153.5 
(6Cq), 151.0 (2Cq), 151.5 (C=Oallyl), 142.9 (Cqarom), 141.9 (8CH), 133.9 (Cqarom), 133.1 (CHallyl), 
133.4 (CHAOC), 130.6 (CHarom), 130.5 (CHarom), 128.5 (CHarom), 127.9 (CHarom), 126.6 (CHarom), 
119.9 (CH2 allyl), 117.4 (CH2 AOC), 117.2 (5Cq), 113.8 (CHarom), 112.7 (CHarom), 88.6 (1’CH), 86.3 
(Cq), 83.5 (4’CH), 73.9 (2’CH), 71.5 (3’CH), 67.8 (CH2 AOC), 64.5 (CH2 allyl), 64.0 (5’CH2), 55.8 
(CH3 DMT), 54.9 (CH3 DMT), 26.6 (CH3 TBDMS), 21.6 (CqTBDMS), -4.0 (CH3 TBDMS);  
MS (Maldi-ToF, m/z): 823.9 ([M]+). 
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8.3.6 Second Building Block Possibility 
8.3.6.1 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-4-O-allyloxy-2-N-
[(allyloxy)carbonyl] guanosine (52) 
 
 
 
250 mg (0.61 mmol, 1 eq) 4-O-allyloxy-2-N-[(allyloxy)carbonyl] guanosine 48 were dissolved 
in 5 ml dry pyridine at RT under argon, added with 231 µl (0.73 mmol, 1.2 eq) 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (TiPSCl) and stirred for 4 hrs. The reaction was quenched 
with 5 ml methanol and the mixture stirred for 10 mins. The solvents were evaporated under 
reduced pressure. Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 7:3, 
v/v) yielded 310 mg of 52 as a white foam (0.48 mmol, 78%).  
 
C29H47N5O9Si: 649.88 g/mol 
Rf (hexane:EtOAc, 1:3) = 0.37;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.35 (s, 1H, 2NH), 8.26 (s,1H, 8CH), 6.13 (m, 1H, 
CHallyl), 5.93 (m, 1H, CHAOC), 5.84 (d, 1H, J= 1.24 Hz, 1’CH), 5.51 (d, 1H, J= 4.56 Hz, 2’OH), 
5.40 (ddq, 2H, J1= 32.32 Hz, J2= 17.16 Hz, J3= 1.52 Hz, CH2 alkene allyl), 5.25 (ddq, 2H, J1= 
25.48 Hz, J2= 11.6 Hz, J3= 1.24 Hz, CH2 alkene AOC), 5.02 (d, 1H, J= 5.8 Hz, CH2 allyl), 4.58 (m, 
2H, 2’CH, 3’CH), 4.55 (d, 2H, J= 5.8 Hz, CH2 AOC), 4.12-3.87 (m, 3H, 4’CH, 5’CH2), 1.02 (m, 
28H, CHisopropyl, CH3 isopropyl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 159.4 (4C-O), 152.7 (6Cq), 151.8 (2Cq), 151.3 
(C=OAOC), 141.2 (8CH), 133.9 (CHallyl), 133.7 (CHAOC), 119.8 (CH2 alkene AOC), 118.2 (CH2 alkene 
allyl), 116.6 (5Cq), 87.5 (1’CH), 84.1 (4’CH), 73.1 (2’CH), 70.2 (3’CH), 67.8 (CH2 AOC), 65.4 (CH2 
allyl), 64.1 (5’CH2), 18.1 (CH3), 13.3 (CH);  
MS (Maldi-ToF, m/z): 648.9 ([M]+). 
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8.3.6.2 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-2’-O-tetrahydropyranyl-
guanosine (53) 
 
 
 
658 mg (1.01 mmol, 1 eq) 3’,5’-O-(tetraisopropyldisiloxane-1,3-diyl)-4-O-allyloxy-2-N-
[(allyloxy)carbonyl] guanosine 52 and 764 mg (3.04 mmol, 3 eq) p-toluenesulfonyl pyridinium 
(pPTs) were dissolved in 20 ml dry dichloromethane under argon, added with 2.75 ml (30.46 
mmol, 30 eq) 3,4-dihydro-2H-pyran and stirred at RT for 16 hrs. The reaction mixture was 
diluted with diethyl ether (50 ml) and washed with a half saturated brine sol. (2 x 50 ml). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The resulting 
oily residue was dissolved in 15 ml dry THF under argon, added with 1.77 ml (10.15 mmol, 
10 eq) triethylamine trihydrofluoride and stirred for 16 hrs. The reaction was quenched with 
silica gel and the solvents were evaporated under reduced pressure. Flash chromatography 
(hexane,hexane:EtOAc gradient from 1:0 to 4:6, then CH2Cl2:MeOH gradient from 100:0 to 
95:5, v/v) yielded 253 mg of 53 a white foam (0.51 mmol, 78%).  
 
C22H29N5O8Si: 491.49 g/mol 
Rf (hexane:EtOAc, 6:4) = 0.08;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.37 (d, 1H, J= 8.6 Hz, 2NH), 8.45 (d,1H, J= 13.12 Hz, 
8CH), 6.16 (m, 1H, CHallyl), 6.01 (m, 2H, CHTHP, CHAOC), 5.41 (ddq, 2H, J1= 32.04 Hz, J2= 17.4 
Hz, J3= 1.76 Hz, CH2 alkene allyl), 5.21 (m, 3H, 1’CH, CH2 alkene AOC), 5.04 (m, 3H, CH2 allyl, 2’CH), 
4.98 (t, 1H, J= 5.56 Hz, 5’OH), 4.70 (m, 2H, 3’CH, 3’OH), 4.60 (m, 2H, CH2 AOC), 4.29 (m, 1H, 
CH2 THP), 3.94 (q, 1H, J= 4.04 Hz, 4’CH), 3.68-3.52 (m, 2H, 5’CH2), 3.09 (m, 1H, CH2 THP), 1.74 
(m, 1H, CH2 THP), 1.54 (m, 2H, CH2 THP), 1.37 (m, 2H, CH2 THP), 1.22 (m, 1H, CH2 THP);  
13C NMR (100.6 MHz, DMSO, δ ppm): 160.4 (4C-O), 154.0 (6Cq), 153.8 (2Cq), 152.9 
(C=OAOC), 152.5 (CHTHP), 143.5 (8CH), 133.9 (CHallyl), 133.7 (CHAOC), 119.8 (CH2 alkene AOC), 
119.8 (CH2 alkene allyl), 117.1 (5Cq), 97.9 (1’CH), 86.6 (4’CH), 78.1 (2’CH), 70.7 (3’CH), 67.8 (CH2 
AOC), 65.5 (CH2 allyl), 62.5 (5’CH2), 30.9 (CH2), 30.4 (CH2), 25.7 (CH2), 25.5 (CH2), 19.4 (CH2);  
MS (Maldi-ToF, m/z): 490.1 ([M]+).  
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8.3.6.3 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-5’-O-dimethoxytriphenyl 
methyl-2’-O-tetrahydropyranyl-guanosine (54) 
 
 
 
368 mg (0.73 mmol, 1 eq) 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-2’-O-tetrahydropyranyl-
guanosine 53 were co-evaporated with dry pyridine (2x5 ml), dissolved into 6 ml dry pyridine, 
added with 150 µl (1.50 mmol, 2 eq) triethylamine, 330 mg (0.97 mmol, 1.3 eq) DMTCl and 
stirred overnight at RT under argon. The reaction was quenched with methanol (5 ml) and 
the solvents evaporated under reduced pressure. Flash chromatography (hexane, 
hexane:EtOAc gradient from 1:0 to 2:3, v/v, +1% triethylamine) yielded 515 mg of 54 as a 
white solid (0.65 mmol, 87%).  
 
C43H47N5O10Si: 793.86 g/mol 
Rf (hexane:EtOAc, 2:3) = 0.33;  
1H NMR (400.0 MHz, DMSO, δ ppm): 10.32 (s, 1H, 2NH), 8.31 (s ,1H, 8CH), 7.31 (m, 2H, 
CHarom), 7.17 (m, 8H, CHarom), 6.77 (m, 4H, CHarom), 6.18 (m, 2H, CHTHP, CHallyl), 5.91 (m, 1H, 
CHAOC), 5.38 (dd, 2H, J1= 37.88 Hz, J2= 17.16 Hz, CH2 alkene allyl), 5.27 (m, 3H, 1’CH, CH2 alkene 
AOC), 5.03 (m, 3H, CH2 allyl, 2’CH), 4.81 (t, 1H, J= 5.04 Hz, 3’OH), 4.73 (m, 1H, 3’CH), 4.59 (m, 
2H, CH2 AOC), 4.48 (m, 1H, CH2 THP), 4.03 (m, 1H, 4’CH), 3.88 (m, 1H, CH2 THP), 3.37-3.15 (m, 
2H, 5’CH2), 1.63 (m, 1H, CH2 THP), 1.54 (m, 2H, CH2 THP), 1.44 (m, 2H, CH2 THP), 1.21 (m, 1H, 
CH2 THP);  
13C NMR (100.6 MHz, DMSO, δ ppm): 161.1 (4C-O), 158.9 (Cqarom), 158.8 (CHarom), 155.0 
(6Cq), 154.1 (2Cq), 151.9 (C=OAOC), 151.8 (CHTHP), 143.9 (Cqarom), 143.3 (8CH), 136.3 
(Cqarom), 133.9 (CHallyl), 133.7 (CHAOC), 130.6 (CHarom), 130.5 (CHarom), 128.5 (CHarom), 127.9 
(CHarom), 126.6 (CHarom), 119.8 (CH2 alkene AOC), 118.2 (CH2 alkene allyl), 117.7 (5Cq), 113.8 
(CHarom), 112.9 (CHarom), 98.5 (1’CH), 87.1 (4’CH), 77.9 (2’CH), 70.1 (3’CH), 67.8 (CH2 AOC), 
65.5 (CH2 allyl), 62.1 (5’CH2), 30.5 (CH2 THP), 30.3 (CH2 THP), 25.8 (CH2 THP), 25.2 (CH2 THP), 18.9 
(CH2 THP);  
MS (Maldi-ToF, m/z): 793.2 ([M]+). 
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8.3.7 (2-N-(allyloxy)carbonyl-4-O-allyloxy-5’-O-dimethoxytriphenyl 
methyl-2’-O-tetrahydropyranyl-guanosine)-(3’-5’)-(2-N-(allyloxy) 
carbonyl-4-O-allyloxy-2’-O-tetrahydropyranyl-guanosine)-2-
chlorophenyl phosphate (55) 
 
 
 
820 mg (1.03 mmol, 1 eq) 4-O-allyloxy-2-N-[(allyloxy)carbonyl]-5’-O-dimethoxy 
triphenylmethyl-2’-O-tetrahydropyranyl-guanosine 54 were dissolved in 9 ml dry dioxane over 
activated powdered 4Å MS and added with 5.6 ml (1.14 mmol, 1.1 eq) of a 0.2 M 
phosphorylating agent 32 sol. at RT under argon. After 10 mins, 913 mg (1.86 mmol, 1.8 eq) 
4-O-allyloxy-2-N-[(allyloxy)carbonyl]-2’-O-tetrahydropyranyl-guanosine 53 in dry dioxane (5 
ml) over activated powdered 4Å MS were added and the mixture stirred at RT under argon 
for 3 hrs. The reaction mixture was diluted with DCM (25 ml), filtered over celite and washed 
with 0.1 M triethylammonium carbonate (TEAC) (2 x 25 ml). The aqueous phase was 
extracted with DCM (3 x 40 ml). The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. Flash chromatography (hexane, hexane:EtOAc 
gradient from 1:0 to 1:1, v/v. +0.5% Et3N) lead to 1.12 g (0.77 mmol, 74%) of 55 a colorless 
foam. 
 
C71H78ClN10O20P: 1457.86 g/mol 
Rf (hexane:EtOAc, 9:1) = 0.66;  
1H NMR (500.0 MHz, DMSO, δ ppm): 10.42-10.37 (m, 2H, 2NH), 8.47-8.38 (m, 2H, 8CH), 
7.55-7.17 (m, 12H, CHarom), 6.77 (m, 4H, CHarom), 6.20-6.09 (m, 2H, CHAOC), 6.12-6.10 (m, 
2H, 1’CHa, 1’CHb), 6.03-5.92 (m, 2H, CHallyl), 5.50-5.43 (m, 2H, CH2 alkene AOC), 5.41-5.34 (m, 
2H, CH2 alkene allyl), 5.31-5.27 (m, 2H, CH2 alkene AOC), 5.31 (m, 1H, 3’OHb), 5.24-5.21 (m, 2H, 
CH2 alkene allyl), 5.22 (m, 1H, 5’OH), 5.19 (m, 1H, 3’CHa) 5.15 (m, 1H, 2’CHa), 5.05-5.01 (m, 4H, 
CH2AOC), 4.83 (m, 1H, 2’CHb), 4.71-4.67 (m, 2H, CHTHP), 4.62-4.60 (m, 4H, CH2 Allyl), 4.59 (m, 
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3H, 3’CHb, 5’CH2b), 4.25 (m, 1H, 4’CHb), 4.18 (m, 1H, 4’CHa), 3.87-3.35 (m, 4H, CH2 THP), 
3.71-3.25 (m, 4H, CH2 THP), 3.60 (m, 1H, 5’CH2a), 3.52 (m, 1H, 5’CH2a), 3.29-3.10 (m, 4H, CH2 
THP), 2.89-2.83 (m, 4H, CH2 THP);  
13C NMR (125.8 MHz, DMSO, δ ppm): 160.1 (C=OAOC), 153.7/152.9 (6Cq), 152.8/152.5 (2Cq), 
152.1/151.9 (4C-O), 146.5 (Cqarom), 142.3/141.4 (8CH), 136.3/133.5 (CHallyl), 133.3 (CHAOC), 
131.0-124.8 (CHarom), 119.5/119.3 (CH2 alkene AOC), 118.0/117.9 (CH2 alkene allyl), 117.7/117.5 
(5Cq), 113.8-112.9 (CHarom), 87.7/87.0 (1’CHa), 85.1/84.8 (1’CHb, 4’CHa), 83.5/83.1 (4’CHb), 
77.8/77.7 (2’CHa), 77.4/77.2 (2’CHb), 76.2/75.9 (3’CHa), 70.3/69.3 (3’CHb), 69.7/69.5 (5’CH2b), 
67.5/67.4 (CH2 AOC), 65.2 (CH2 allyl), 62.5-60.1 (CH2 THP), 61.3 (5’CH2a);  
MS (Maldi-ToF, m/z): 1456.57 ([M]+). 
 
 
8.3.8 (2-N-(allyloxy)carbonyl-4-O-allyloxy-2’-O-tetrahydropyranyl-
guanosine)-(3’-5’)-(2-N-(allyloxy)carbonyl-4-O-allyloxy-2’-O-
tetrahydropyranyl-guanosine)-2-chlorophenyl phosphate (56) 
 
 
 
370 mg (0.25 mmol, 1 eq) dimer 55 were dissolved in 3 ml DCM, added with 60 µl (0.73 
mmol, 1.2 eq) dichloroacetic acid and stirred for 16 hrs at RT under argon. The reaction 
mixture was oured into 20 ml sat. aq. NaHCO3 sol. and extracted with dichloromethane (3 x 
20 ml). The organic layer was dried (MgSO4) and concentrated under reduced pressure. 
Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 1:9, v/v) yielded 173 mg 
of dimer 56 as a white foam (0.15 mmol, 59%). 
 
C50H60ClN10O18P: 1155.49 g/mol 
Rf (hexane:EtOAc, 1:9) = 0.1;  
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1H NMR (500.0 MHz, DMSO, δ ppm): 10.42-10.35 (m, 2H, 2NH), 8.47-8.38 (m, 2H, 8CH), 
7.55-7.22 (m, 4H, CHarom), 6.20-6.09 (m, 2H, CHAOC), 6.12-6.10 (m, 2H, 1’CHa, 1’CHb), 6.00-
5.92 (m, 2H, CHallyl), 5.50-5.43 (m, 2H, CH2 alkene AOC), 5.41-5.34 (m, 2H, CH2 alkene allyl), 5.31-
5.27 (m, 2H, CH2 alkene AOC), 5.30 (m, 1H, 3’OHb), 5.24-5.21 (m, 2H, CH2 alkene allyl), 5.22 (m, 1H, 
5’OH), 5.19 (m, 1H, 3’CHa) 5.16 (m, 1H, 2’CHa), 5.05-5.01 (m, 4H, CH2 AOC), 4.83 (m, 1H, 
2’CHb), 4.71-4.67 (m, 2H, CHTHP), 4.62-4.60 (m, 4H, CH2 Allyl), 4.59 (m, 3H, 3’CHb, 5’CH2b), 
4.25 (m, 1H, 4’CHb), 4.17 (m, 1H, 4’CHa), 3.87-3.35 (m, 4H, CH2 THP), 3.71-3.25 (m, 4H, CH2 
THP), 3.61 (m, 1H, 5’CH2a), 3.52 (m, 1H, 5’CH2a), 3.29-3.10 (m, 4H, CH2 THP), 2.89-2.84 (m, 4H, 
CH2 THP);  
13C NMR (125.8 MHz, DMSO, δ ppm): 160.1 (C=OAOC), 153.7/152.9 (6Cq), 152.8/152.5 (2Cq), 
152.1/151.9 (4C-O), 146.3 (Cqarom), 142.3/141.4 (8CH), 133.5 (CHallyl), 133.3 (CHAOC), 
131.0/124.8 (CHarom), 119.5/119.3 (CH2 alkene AOC), 118.0/117.9 (CH2 alkene allyl), 117.7/117.5 
(5Cq), 87.7/87.0 (1’CHa), 85.1/84.8 (1’CHb), 85.1/84.8 (4’CHa), 83.5/83.1 (4’CHb), 77.8/77.7 
(2’CHa), 77.4/77.2 (2’CHb), 76.1/75.9 (3’CHa), 70.3/69.3 (3’CHb), 69.7/69.5 (5’CH2b), 67.5/67.4 
(CH2 AOC), 65.2 (CH2 allyl), 62.5-60.2 (CH2 THP), 61.3 (5’CH2a);  
MS (Maldi-ToF, m/z): 1155.54 ([M]+). 
 
 
8.3.9 (2-N-(allyloxy)carbonyl-4-O-allyloxy-2’-O-tetrahydropyranyl-
guanosine)-(3’-5’)-(2-N-(allyloxy)carbonyl-4-O-allyloxy-3’-O-(2-
chlorophenylphosphate)-2’-O-tetrahydropyranyl-guanosine)-2-
chlorophenyl phosphate (57) 
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130 mg (0.11 mmol, 1 eq) dimer 56 were dissolved in 55 ml dry dioxane, over activated 
powdered 4Å MS, added with 620 µl (0.12 mmol, 1.1 eq) of a 0.2 M phosphorylating agent 
32 solution and the mixture stirred at RT under argon for 24 hrs. The reaction mixture was 
filtered over celite. The residue was taken up in DCM (20 ml) and washed with 1 M TEAC (20 
ml). The aqueous phase was then extracted with DCM (3 x 20 ml). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. Flash chromatography 
(hexane, hexane:EtOAc gradient from 1:0 to 2:8, then DCM:MeOH gradient from 1:0 to 9:1, 
v/v) lead to 127 mg (0.09 mmol, 83%) of open-chain dinucleotide GpGp 57 as a colorless 
foam. 
 
C56H64Cl2N10O21P2: 1346.02 g/mol 
Rf (CH2Cl2:MeOH, 1:9) = 0.08;  
1H NMR (500.0 MHz, DMSO, δ ppm): 10.42-10.35 (m, 2H, 2NH), 8.47-8.37 (m, 2H, 8CH), 
7.57-7.20 (m, 8H, CHarom), 6.20-6.09 (m, 2H, CHAOC), 6.12-6.10 (m, 2H, 1’CHa, 1’CHb), 6.00-
5.92 (m, 2H, CHallyl), 5.50-5.44 (m, 2H, CH2 alkene AOC), 5.39-5.34 (m, 2H, CH2 alkene allyl), 5.31-
5.27 (m, 2H, CH2 alkene AOC), 5.24-5.21 (m, 2H, CH2 alkene allyl), 5.22 (m, 1H, 5’OH), 5.19 (m, 1H, 
3’CHa) 5.16 (m, 1H, 2’CHa), 5.05-5.01 (m, 4H, CH2 AOC), 4.83 (m, 1H, 2’CHb), 4.76 (m, 1H, 
3’CHb), 4.71-4.67 (m, 2H, CHTHP), 4.62-4.60 (m, 4H, CH2 Allyl), 4.59 (m, 2H, 5’CH2b), 4.25 (m, 
1H, 4’CHb), 4.17 (m, 1H, 4’CHa), 3.87-3.35 (m, 4H, CH2 THP), 3.71-3.27 (m, 4H, CH2 THP), 3.61 
(m, 1H, 5’CH2a), 3.52 (m, 1H, 5’CH2a), 3.29-3.10 (m, 4H, CH2 THP), 2.88-2.83 (m, 4H, CH2 THP);  
13C NMR (125.8 MHz, DMSO, δ ppm): 160.1 (C=OAOC), 153.7/152.9 (6Cq), 152.8/152.5 (2Cq), 
152.1/151.9 (4C-O), 146.3 (Cqarom), 142.3/141.6 (8CH), 133.5 (CHallyl), 133.3 (CHAOC), 131.0-
124.8 (CHarom), 119.6/119.2 (CH2 alkene AOC), 118.0/117.9 (CH2 alkene allyl), 117.7/117.5 (5Cq), 
87.7/87.1 (1’CHa), 85.1/84.8 (1’CHb), 85.1/84.8 (4’CHa), 83.5/83.1 (4’CHb), 77.8/77.7 (2’CHa), 
77.4/77.2 (2’CHb), 76.1/75.9 (3’CHa), 72.3/71.9 (3’CHb), 69.7/69.5 (5’CH2b), 67.5/67.3 (CH2 
AOC), 65.2 (CH2 allyl), 62.5-60.2 (CH2 THP), 61.3 (5’CH2a);  
MS (Maldi-ToF, m/z): 1347.63 ([M]+). 
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9. A NEW SYNTHESIS FOR C-DI-GMP 
9.1 Building Block Synthesis from Glucose 
9.1.1 1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose (59) 
 
 
 
5 g (27.8 mmol, 1 eq) α-D-glucose 58 were suspended in 50 ml dry acetone at RT under 
argon. 4 g (41.7 mmol, 1.5 eq) anhydrous zinc chloride were added, followed by 0.15 ml 85% 
aq. phosphoric acid and the mixture was stirred for 30 hrs at RT. The reaction mixture was 
filtered to remove the unreacted glucose. 10 M NaOH was added (pH=8). The suspension 
was filtered and the filtrate concentrated under reduced pressure. The residue was taken up 
in water (15 ml) and extracted with DCM (3 x 50 ml). The combined organic layers were dried 
(MgSO4) and concentrated. The residue was re-crystallized from hexane to yield 3.90 g 
(15.01 mmol, 54%) of 59 as a white solid. 
 
C12H20O6: 260.28 g/mol 
Rf (hexane:EtOAc, 1:1) = 0.55;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.79 (d,1H, J1= 3.54 Hz, 1’CH), 5.35 (s, 1H, 3’OH), 4.37 
(d, 1H, J1= 3.79 Hz, 2’CH), 4.19 (dd, 1H, J1= 12.88 Hz, J2= 6.32 Hz, 3’CH), 3.95 (m, 2H, 6’CH), 
3.92 (m, 1H, 5’CH), 3.78 (dd, 1H, J1= 8.34 Hz, J2= 6.07 Hz, 4’CH), 1.35 (s, 3H, CH3), 1.29 (s, 
3H, CH3), 1.24 (s, 3H, CH3), 1.20 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 111.5 (Cq ), 108.7 (Cq), 105.4 (1’CH), 85.8 (2’CH), 
81.7 (4’CH), 74.0 (3’CH), 73.1 (5’CH), 66.9 (6’CH2), 27.6 (CH3), 27.4 (CH3), 26.9 (CH3), 26.1 
(CH3);  
MS (Maldi-ToF, m/z): 259.6 ([M-H]+). 
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9.1.2 1’,2’:5’,6’-di-O-isopropylidene-3’-oxo-α-D-glucofuranose (60) 
 
 
 
1 g (3.85 mmol 1 eq) 1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose 59 was dissolved in 
DCM (8 ml) at RT under argon and added portionwise with 868 mg (2.31 mmol, 0.6 eq) 
pyridinium dichromate (PDC) and 1.2 ml (11.55 mmol, 3 eq) acetic anhydride. The mixture 
was refluxed for 1.5 hrs. After cooling to RT, the reaction mixture was evaporated and EtOAc 
(10 ml) was added. The suspension was applied to a short silica pad and eluted with EtOAc. 
The solvent was evaporated under reduced pressure, to yield 0.87 g (3.37 mmol, 88%) of 60 
as a colorless oil.  
 
C12H18O6: 258.27 g/mol 
Rf (hexane:EtOAc, 1:1) = 0.5; 
1H NMR (400.0 MHz, DMSO, δ ppm): 5.80 (d,1H, J1= 3.54 Hz, 1’CH), 4.41 (d, 1H, J1= 3.79 
Hz, 2’CH), 3.95 (m, 2H, 6’CH), 3.92 (m, 1H, 5’CH), 3.79 (dd, 1H, J1= 8.34 Hz, J2= 6.07 Hz, 
4’CH), 1.35 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.24 (s, 3H, CH3), 1.20 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 111.5 (Cq), 108.7 (Cq), 105.4 (1’CH), 85.8 (2’CH), 81.7 
(4’CH), 73.1 (5’CH), 66.9 (6’CH2), 27.6 (CH3), 27.4 (CH3), 26.9 (CH3), 26.1 (CH3);  
MS (Maldi-ToF, m/z): 257.6 ([M-H]+). 
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9.1.3 1’,2’-O-isopropylidene-α-D-ribofuranose (61) 
 
 
 
10 g (38.72 mmol, 1 eq) 1’,2’:5’,6’-di-O-isopropylidene-3-oxo-α-D-glucofuranose 60 were 
dissolved in dry EtOAc (500 ml) at 0°C under argon, added portionwise with 10.6 g (46.46 
mmol, 1.2 eq) periodic acid. After 2 hrs 0°C, the reaction mixture was filtered over celite and 
the filtrate concentrated under reduced pressure. The residue was dissolved in EtOH at 0°C 
and 3.87 g (102.22 mmol, 2.64 eq) sodium borohydride were added in small portions under 
vigorous stirring. After 30 mins the reaction was quenched with a 10% aq. acetic acid sol. 
and volatiles were evaporated. The residue was dissolved in EtOAc (400 ml), the organic 
phase washed with H2O (350 ml), dried (MgSO4) and concentrated under reduced pressure. 
Flash chromatography (hexane:DCM, 1:1, CH2Cl2:MeOH gradient from 1:0 to 8:2, v/v) 
yielded 3.39 g of 61 as a white foam (17.82 mmol, 46%).  
 
C8H14O5: 190.20 g/mol 
Rf (hexane:EtOAc, 1:9) = 0.30;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.62 (d, 1H, J= 3.8 Hz, 1’CH), 4.97 (d, 1H, J= 6.6 Hz, 
3’OH), 4.63 (t, 1H, J= 5.28 Hz, 5’OH), 4.41 (t, 1H, J= 2.84 Hz, 2’CH), 3.61 (m, 3H, 3’CH, 4’CH, 
5’CH2), 3.35 (m, 1H, 5’CH2), 1.41 (s, 3H, CH3), 1.23 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 111.99 (Cq), 104.15 (1’CH), 81.14 (2’CH), 79.92 (4’CH), 
71.33 (3’CH), 61.02 (5’CH2), 27.46-27.26 (CH3);  
MS (FAB, m/z, %): 39 (100), 192 ([M+H]+, 42), 229 ([M+K]+, 58);  
Elemental Analysis 
C8H14O5 (190.20):  Calcd: C 50.52 H 7.42 O 42.06 
 Found: C 50.63 H 7.38 O 41.99 
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9.2 Building Block Synthesis from Xylose 
9.2.1 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-α-D-xylofuranose 
(63) 
 
 
 
30 g (0.16 mol, 1 eq) 1’,2’-O-isopropylidene-α-D-xylofuranose 62 were dissolved in dry 
dichloromethane (1.2 L), added dropwise with 25.4 ml (0.31 mol, 2 eq) pyridine at RT under 
argon. 30.90 g (0.20 mol, 1.3 eq) t-butyldimethylsilyl chloride (TBDMSCl) were added 
portionwise after cooling to -78°C. After the addition was completed, the reaction was stirred 
at -78°C for 3 hrs and for 4 days at RT. Water (700 ml) was added and the aqueous phase 
was extracted with EtOAc (4 x 500 ml). The combined organic layers were dried (MgSO4) 
and concentrated under reduced pressure. Flash chromatography (hexane, hexane:EtOAc 
gradient from 1:0 to 8:2, v/v) yielded 46.67g of 63 as a white foam (0.15 mol, 97%).  
 
C14H28O5Si: 304.46 g/mol 
Rf (hexane:EtOAc, 1:1) = 0.88;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.78 (d, 1H, J= 3.8 Hz, 1’CH), 5.17 (d, 1H, J= 4.8 Hz, 
3’OH), 4.35 (d, 1H, J= 3.56 Hz, 2’CH), 3.96 (m, 1H, 3’CH), 3.93 (dd, 1H, J1= 4.8 Hz, J2= 2.8 
Hz, 4’CH), 3.79 (dd, 1H, J1= 10.2 Hz, J2= 5.28 Hz, 5’CH2), 3.64 (dd, 1H, J1= 10.88 Hz, J2= 
6.32 Hz, 5’CH2), 1.35 (s, 3H, CH3), 1.20 (s, 3H, CH3), 0.84 (s, 9H, CH3 TBDMS), 0.03 (s, 6H, 
CH3 TBDMS);  
13C NMR (100.6 MHz, DMSO, δ ppm): 111.2 (Cq), 105.2 (1’CH), 85.8 (2’CH), 81.9 (4’CH), 74.1 
(3’CH), 61.8 (5’CH2), 27.5-26.6 (CH3), 18.9 (Cq TBDMS), -4.3 (CH3 TBDMS);  
MS (FAB, m/z, %): 73 (100), 305 ([M]+, 19), 343 ([M+K]+, 11);  
Elemental Analysis 
C14H28O5Si (304.46):  Calcd: C 55.23 H 9.27 O 26.27 Si 9.22 
 Found: C 55.14 H 9.36 O 26.28 
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9.2.2 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-3’-oxo-α-D-
xylofuranose (64) 
 
 
 
13.2 g (43.64 mmol 1 eq) 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-α-D-xylofuranose 63 
were dissolved in dry dichloromethane (200 ml), added with 13.3 ml (0.130 mol, 3 eq) acetic 
anhydride and cooled to 0°C under argon. 9.79 g (26.18 mmol, 0.6 eq) PDC were added 
portion wise and after the addition was completed, the reaction mixture was refluxed for 2 
hrs. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The 
residue was taken up in ETOAc (200 ml), filtered over a short pad of silica gel and washed 
with ethylacetate. The filtrate was concentrated under reduced pressure to yield 11.88g of 64 
as a colorless oil (39.27 mmol, 91%).  
 
C14H26O5Si: 302.45 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.82;  
1H NMR (400.0 MHz, DMSO, δ ppm): 6.06 (d, 1H, J= 4.56 Hz, 1’CH), 4.48 (d, 1H, J= 1.28 Hz, 
2’CH), 4.35 (dd, 1H, J1= 4.56 Hz, J2= 1.28 Hz, 4’CH), 3.75 (dq, 2H, J1= 9.12 Hz, J2= 2.56 Hz, 
5’CH2), 1.33 (s, 6H, CH3), 0.80 (s, 9H, CH3 TBDMS), 0.01 (s, 6H, CH3 TBDMS);  
13C NMR (100.6 MHz, DMSO, δ ppm): 212.0 (Cq), 113.8 (Cq), 103.8 (1’CH), 81.5 (2’CH), 77.2 
(4’CH), 64.2 (5’CH2), 28.1-26.5 (CH3 , 18.7 (Cq TBDMS), -4.6 (CH3 TBDMS);  
MS (FAB, m/z, %): 73 (100), 307 ([M+H]+, 7);  
Elemental Analysis 
C14H26O5Si (302.45):  Calcd: C 55.60 H 8.67 O 26.45 Si 9.29 
 Found: C 55.36 H 8.56 O 26.79 
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9.2.3 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-α-D-ribofuranose 
(65) 
 
 
 
33.7 g (0.11 mol) 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-3’-oxo-α-D-xylofuranose 64 
were dissolved in 500 ml ethanol:water (3:1) and cooled to 0°C. 27.4 g (0.72 mol, 6.5 eq) 
sodium borohydride were added portionwise to the solution. After the addition was 
completed, the reaction mixture was stirred at RT for 1 hr. The reaction was quenched with 
water (400 ml) and the mixture extracted with EtOAc (4 x 600 ml). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. Flash chromatography 
(hexane, hexane:EtOAc gradient from 1:0 to 8:2, v/v) yielded 30.86 g of 65 as a colorless oil 
(0.10 mol, 91%).  
 
C14H28O5Si: 304.46 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.75;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.61 (d, 1H, J= 3.8 Hz, 1’CH), 5.01 (d, 1H, J= 6.56 Hz, 
3’OH), 4.42 (t, 1H, J= 4.04 Hz, 2’CH), 3.80 (dd, 1H, J1= 11.84 Hz, J2= 1.24 Hz, 5’CH2), 3.68 (m, 
2H, 3’CH, 4’CH), 3.58 (dd, 1H, J1= 11.64 Hz, J2= 4.32 Hz, 5’CH2), 1.41 (s, 3H, CH3), 1.23 (s, 
3H, CH3), 0.84 (t, 9H, CH3 TBDMS), 0.01 (d, 6H, CH3 TBDMS);  
13C NMR (100.6 MHz, DMSO, δ ppm): 112.0 (Cq), 104.2 (1’CH), 80.8 (2’CH), 79.8 (4’CH), 71.0 
(3’CH), 62.8 (5’CH2), 27.4-26.6 (CH3), 18.9 (Cq TBDMS), -4.3 (CH3 TBDMS);  
MS (FAB, m/z, %): 73 (100), 307 ([M+H]+, 11), 343 ([M+K]+, 17);  
Elemental Analysis 
C14H28O5Si (304.46):  Calcd: C 55.23 H 9.27 O 26.27 Si 9.22 
 Found: C 55.23 H 9.13 O 26.42 
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9.2.4 1’,2’-O-isopropylidene-α-D-ribofuranose (66) 
 
 
 
5.68 g (18.65 mmol, 1 eq) 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-α-D-ribofuranose 
65 were dissolved dry THF (150 ml) at RT under argon. 26.7 ml (0.18 mol, 10 eq) 
trihydrofluoro triethylamine were added dropwise. After the addition was completed, the 
solution was stirred at RT for 16 hrs. The reaction mixture was quenched with silica gel and 
the solvent concentrated under reduced pressure. Flash chromatography (hexane, 
hexane:EtOAc gradient from 1:0 to 1:9, v/v) yielded 2.91 g of 66 as a white foam (15.37 
mmol, 93%).  
 
C8H14O5: 190.20 g/mol 
Rf (hexane:EtOAc, 3:7) = 0.18;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.62 (d, 1H, J= 3.8 Hz, 1’CH), 4.97 (d, 1H J= 6.6 Hz, 
3’OH,), 4.63 (t, 1H, J= 5.28 Hz, 5’OH), 4.41 (t, 1H, J= 2.84 Hz, 2’CH), 3.61 (m, 3H, 3’CH, 4’CH, 
5’CH2), 3.35 (m, 1H, 5’CH2), 1.41 (s, 3H, CH3), 1.23 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 111.9 (Cq), 104.1 (1’CH), 81.1 (2’CH), 79.9 (4’CH), 71.3 
(3’CH), 61.0 (5’CH2), 27.4-27.2 (CH3);  
MS (FAB, m/z, %): 39 (100), 192 ([M+H]+, 42), 229 ([M+K]+, 58) 
Elemental Analysis 
C8H14O5 (190.20):  Calcd: C 50.52 H 7.42 O 42.06 
 Found: C 50.63 H 7.38 O 41.99 
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9.3 Assembling the Sugar Backbone 
9.3.1 HOBt phosphorylating agent (69) 
 
 
 
16.2 g (0.12 mol, 1 eq) hydroxybenzotriazole (HOBt) 67 were suspended in 50 ml dry THF at 
RT under argon and added with 10 ml (60.10 mol, 0.5 eq) 2-chlorophenylphosphoro 
dichloridate, 10 ml (0.12 mol, 1.05 eq) pyridine and 12 ml dry THF. The reaction mixture was 
stirred at RT overnight then filtered under inert atmosphere to yield 50 ml of a 1 M stock 
solution of phosphorylating agent 69. 
 
 
9.3.2 (5’-O-t-butyldimethylsilyl-1’,2’-bis-O-isopropylidene-D-ribo 
furanosyl)-(3’-5’)-(1’,2’-bis-O-isopropylidene-D-ribofuranosyl)-2-
chlorophenyl phosphate (70) 
 
 
 
2.28 g (7.49 mmol, 1 eq) 5’-O-t-butyldimethylsilyl-1’,2’-O-isopropylidene-α-D-ribofuranose 65 
were dissolved in 65 ml dry THF over activated powdered 4Å MS and added with 8 ml (8.98 
mmol, 1.2 eq) of a 1 M HOBt phosphorylating agent 69 sol. at RT under argon. After 10 mins, 
1.86 g (9.78 mmol, 1.3 eq) 1’,2’-O-isopropylidene-α-D-ribofuranose 66 in dry THF (20 ml) 
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over activated powdered 4Å MS were added and the mixture stirred for 1 hr. The reaction 
mixture was filtered over celite and washed with 0.1 M TEAC (2 x 110 ml). The aqueous 
phase was extracted with DCM (3 x 140 ml). The combined organic layers were dried and 
concentrated under reduced pressure. Flash chromatography (hexane, hexane:EtOAc 
gradient from 1:0 to 1:1, v/v) lead to 3.19 g (4.78 mmol, 64%) of a colorless foam, the desired 
product 70 as a mixture of diastereomers. 
 
C24H44ClO12PSi: 667.17 g/mol 
Rf (hexane:EtOAc, 4:6) = 0.75;  
 
Diastereomer 1 of 70: 
1H NMR (500.0 MHz, DMSO, δ ppm): 7.58 (d, 1H, J= 7.93 Hz, CHarom), 7.44 (d, 1H, J= 11.73 
Hz, CHarom), 7.38 (m, 1H, CHarom), 7.26 (m, 1H, CHarom), 5.75 (d, 1H, J= 0.28 Hz, 1’CHa), 5.67 
(d, 1H, J= 3.57 Hz, 1’CHb), 5.32 (d, 1H, J= 6.76 Hz, 3’OHb), 4.72 (t, 1H, J= 4.34 Hz, 2’CHa), 
4.63 (m, 1H, 3’CHa), 4.47 (m, 1H, 2’CHb), 4.43 (m, 1H, 5’CH2b), 4.16 (sx, 1H, J= 5.76 Hz, 
5’CH2b), 4.01 (m, 1H, 4’CHa), 3.95 (m, 1H, 4’CHb), 3.83 (m, 1H, 5’CH2a), 3.75 (m, 1H, 3’CHb), 
3.71 (m, 1H, 5’CH2a), 1.43 (s, 6H, CH3a, CH3 b), 1.26 (s, 6H, CH3 a, CH3 b), 0.82 (s, 9H, CH3 
TBDMS), 0.015 (s, 3H, CH3 TBDMS), 0.008 (s, 3H, CH3 TBDMS);  
13C NMR (125.8 MHz, DMSO, δ ppm): 145.9 (Cqarom), 130.5 (CHarom), 128.4 (CHarom), 126.60 
(CHarom), 124.3 (CHarom), 121.3 (Cqarom), 112.2 (Cq), 111.6 (Cq), 103.5 (1’CHa), 103.4 (1’CHb), 
78.9 (2’CHb), 78.2 (4’CHa), 77.5 (4’CHb), 77.2 (2’CHa), 74.2 (3’CHa), 70.4 (3’CHb), 67.6 
(5’CH2b), 60.6 (5’CH2a), 26.6 (CH3a), 26.6 (CH3b), 26.4 (CH3a), 26.3 (CH3b), 25.7 (CH3 TBDMS), 
17.9 (Cq), -5.3 (CH3 TBDMS), -5.4 (CH3 TBDMS);  
 
Diastereomer 2 of 70: 
1H NMR (500.0 MHz, DMSO, δ ppm): 7.58 (d, 1H, J= 7.93 Hz, CHarom), 7.44 (d, 1H, J= 11.73 
Hz, CHarom), 7.38 (m, 1H, CHarom), 7.26 (m, 1H, CHarom), 5.75 (d, 1H, J= 0.28 Hz, 1’CHa), 5.62 
(d, 1H, J= 3.56 Hz, 1’CHb), 5.32 (d, 1H, J= 6.79 Hz, 3’OHb), 4.76 (t, 1H, J= 4.25 Hz, 2’CHa), 
4.59 (m, 1H, 3’CHa), 4.46 (m, 1H, 2’CHb), 4.43 (m, 1H, 5’CH2b), 4.16 (sx, 1H, J= 5.76 Hz, 
5’CH2b), 4.01 (m, 1H, 4’CHa), 3.95 (m, 1H, 4’CHb), 3.79 (m, 1H, 5’CH2a), 3.74 (m, 1H, 3’CHb), 
3.60 (m, 1H, 5’CH2a), 1.46 (s, 6H, CH3a, CH3b), 1.29 (s, 6H, CH3a, CH3b), 0.81 (s, 9H, CH3 
TBDMS), -0.011 (s, 3H, CH3 TBDMS), -0.015 (s, 3H, CH3 TBDMS);  
13C NMR (125.8 MHz, DMSO, δ ppm): 145.9 (Cqarom), 130.6 (CHarom), 128.5 (CHarom), 126.67 
(CHarom), 124.4 (CHarom), 121.3 (Cqarom), 112.4 (Cq), 111.6 (Cq), 103.6 (1’CHa), 103.6 (1’CHb), 
78.9 (2’CHb), 78.3 (4’CHa), 77.6 (4’CHb), 77.2 (2’CHa), 74.3 (3’CHa), 70.5 (3’CHb), 68.0 
(5’CH2b), 60.7 (5’CH2a), 26.6 (CH3a, CH3b), 26.4 (CH3a), 26.4 (CH3b), 25.7 (CH3 TBDMS), 17.9 
(Cq), -5.4 (CH3 TBDMS), -5.4 (CH3 TBDMS);  
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MS (FAB, m/z, %): 154 (100), 705 ([M+K]+, 12);  
Elemental Analysis 
C24H44ClO12PSi (667.17):  Calcd: C 50.41 H 6.65 O 28.78 Si 4.21 
 Found: C 50.45 H 6.62 O 28.77 
 
 
9.3.3 (1’,2’-bis-O-isopropylidene-D-ribofuranosyl)-(3’-5’)-(1’,2’-bis-O-
isopropylidene-D-ribofuranosyl)-2chloro-phenyl phosphate (71) 
 
 
 
0.74 g (1.11 mmol, 1 eq) protected dimer 70 were dissolved in 30 ml dry methanol, added 
with 0.67 g (1.22 mmol, 1.1 eq) cerium ammonium nitrate (CAN) and stirred for 16 hrs at RT 
under N2. The reaction mixture was diluted with EtOAc (90 ml) and washed with TEAC (0.1 
M, 2 x 100 ml). The aqueous phase was extracted with DCM (3 x 100 ml). The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. Flash 
chromatography (hexane, hexane:EtOAc, gradient from 1:0 to 1:9, v/v) lead to 0.47 g (0.85 
mmol, 77%) of a white foam of dimer 71 as a non-separable mixture of diastereomers. 
 
C22H30Cl2O12P: 552.90 g/mol 
Rf (CH2Cl2:MeOH, 95:5) = 0.23;  
 
Diastereoisomer 1 of 71:  
1H NMR (500.0 MHz, DMSO, δ ppm): 7.59 (m, 4H, Harom), 5.77 (d, 1H, J= 3.65 Hz, 1’CHa), 
5.68 (d, 1H, J= 3.54 Hz, 1’CHb), 5.32 (dd, 1H, J1= 4.21 Hz, J2= 2.58 Hz, 3’OHb), 4.89 (m, 1H, 
5’OHa), 4.71 (m, 1H, 2’CHa), 4.61 (m, 1H, 3’CHa), 4.48 (bt, 1H, 2’CHb), 4.44 (m, 1H, 5’CH2b), 
4.18 (m, 1H, 5’CH2b), 3.99 (m, 1H, 4’CHa), 3.96 (m, 1H, 4’CHb), 3.79 (m, 1H, 3’CHb), 3.69 (m, 
1H, 5’CH2a), 3.47 (m, 1H, 5’CH2a), 1.44 (s, 6H, CH3a, CH3b), 1.27 (s, 6H, CH3a, CH3b); 
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13C NMR (125.8 MHz, DMSO, δ ppm): 146.0 (Cqarom), 130.6 (CHarom), 128.6 (CHarom), 126.6 
(CHarom), 121.4 (Cqarom), 112.2 (Cq), 111.6 (Cq), 103.6 (1’CHa), 103.4 (1’CHb), 78.9 (2’CHb), 
78.6 (4’CHa), 77.6 (4’CHb), 77.3 (2’CHa), 74.5 (3’CHa), 70.3 (3’CHb), 67.9 (5’CH2b), 59.1 
(5’CH2a), 26.6 (CH3a, CH3b), 26.4 (CH3a, CH3b);  
 
Diastereoisomer 2 of 71:  
1H NMR (500.0 MHz, DMSO, δ ppm): 7.59 (m, 4H, Harom), 5.77 (d, 1H, J= 3.65 Hz, 1’CHa), 
5.68 (d, 1H, J= 3.54 Hz, 1’CHb), 5.32 (dd, 1H, J1= 4.21 Hz, J2= 2.58 Hz, 3’OHb), 4.89 (m, 1H, 
5’OHa), 4.71 (m, 1H, 2’CHa), 4.61 (m, 1H, 3’CHa), 4.48 (bt, 1H, 2’CHb), 4.44 (m, 1H, 5’CH2b), 
4.18 (m, 1H, 5’CH2b), 3.99 (m, 1H, 4’CHa), 3.96 (m, 1H, 4’CHb), 3.79 (m, 1H, 3’CHb), 3.69 (m, 
1H, 5’CH2a), 3.47 (m, 1H, 5’CH2a), 1.44 (s, 6H, CH3a, CH3b), 1.27 (s, 6H, CH3a, CH3b);  
13C NMR (125.8 MHz, DMSO, δ ppm): 146.0 (Cqarom), 130.6 (CHarom), 128.6 (CHarom), 126.6 
(CHarom), 121.4 (Cqarom), 112.2 (Cq), 111.6 (Cq), 103.6 (1’CHa), 103.4 (1’CHb), 78.9 (2’CHb), 
78.6 (4’CHa), 77.6 (4’CHb), 77.3 (2’CHa), 74.5 (3’CHa), 70.3 (3’CHb), 67.9 (5’CH2b), 59.1 
(5’CH2a), 26.6 (CH3a, CH3b), 26.4 (CH3a, CH3b);  
 
MS (FAB, m/z, %): 97 (100), 591 ([M+K]+, 26);  
Elemental Analysis 
C22H30Cl2O12P (552.90):  Calcd: C 47.79 H 5.47 O 34.72  
 Found: C 47.62 H 5.67 O 34.70 
 
 
9.3.4 Cyclic bis(3’-5’)-(1’,2’-bis-O-isopropylidene-D-ribo-furanosyl)-2-
chloro phenyl phosphate (72) 
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1.80 g (3.26 mmol, 1 eq) dimer 71 were co-evaporated with pyridine (2 x 10 ml), dissolved in 
pyridine (900 ml), added with 0.79 ml (4.89 mmol, 1.5 eq) 2-chlorophenyl phosphoro 
dichloridate and the reaction mixture was stirred at RT under N2 for 1 hr. The solvent was 
evaporated, the residue taken up in CH2Cl2 (200 ml) and washed with 0.25 M TEAC buffer. 
The organic phase was dried over MgSO4 and the solvent was removed under reduced 
pressure. Flash silica gel chromatography (hexane, gradient from hexane 1:0 to 
hexane:EtOAc, 1:1, v/v) yielded two fractions containing the four possible stereoisomers of 
72. 683 mg (0.94 mmol, 29 %) of high Rf stereoisomer and 826 mg (1.13 mmol, 35 %) of low 
Rf stereoisomer were isolated as colorless oils.  
 
C28H32Cl2O14P2: 725.41 g/mol 
 
Rf (hexane:EtOAc, 3:7) = 0.71.  
High Rf stereoisomer of 72: 
1H NMR (500 MHz, DMSO, δ ppm): 7.73 (m, 8H, CHarom), 5.88 (d, 1H, J= 3.51 Hz, 1’CHa), 
5.75 (d, 1H, J= 3.61 Hz, 1’CHb), 4.93-4.87 (m, 2H, 3’CHa, 2’CHb), 4.85-4.81 (m, 1H, 3’CHb), 
4.74 (t, 1H, J= 4.17 Hz, 2’CHb), 4.52-4.45 (m, 2H, 5’CHa, 5’CHb), 4.34-4.24 (m, 4H, 5C’Ha, 
5’CHb, 4’CHa, 4’CHb), 1.52 (s, 3H, CH3), 1.43 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.27 (s, 3H, 
CH3);  
13C NMR (125.8 MHz DMSO, δ ppm): 145.7(Cqarom), 145.6 (Cqarom), 130.8(CHarom), 
130.6(CHarom), 128.8(CHarom), 128.5(CHarom), 127.0(CHarom), 126.8(CHarom), 121.4, 121.0 
(CHarom), 112.8(Cq), 112.6 (Cq), 103.6 (1’CHa), 103.5 (1’CHb), 77.4 (2’CHa), 77.3 (2’CHb), 74.4 
(4’CHa), 74.3 (4’CHb), 74.1(3’CHa), 74.1 (3’CHb), 65.2/65.1 (5’CH2a, 5’CH2b), 26.6 (CH3), 
26.4(CH3), 26.3 (CH3);  
31P NMR (202 MHz, DMSO, δ ppm): -8.35, -8.52;  
MS (ESI) m/z = 725.5 [M+H]+;  
Elemental Analysis 
C28H32Cl2O14P2 (725.41):  Calcd: C 46.36 H 4.45 O 30.88  
 Found: C 46.27 H 4.49 O 30.95 
 
Rf (hexane:EtOAc, 3:7) = 0.49.  
Low Rf stereoisomer of 72:  
1H NMR (500 MHz, DMSO, δ ppm): 7.60-7.28 (m, 8H, CHarom), 5.85 (d, 2H, J= 3.36 Hz, 
1’CHa, 1’CHb), 4.82-4.78 (m, 4H, 2’CHa, 2’CHb, 3’CHa, 3’CHb), 4.46-4.45 (m, 4H, 5’CHa, 
5’CHb), 4.25-4.22 (m, 2H, 4’CHa, 4’CHb), 1.42 (s, 6H, CH3), 1.28 (s, 6H, CH3);  
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13C NMR (125.8 MHz, DMSO, δ ppm): 145.6 (Cqarom), 130.6(CHarom), 128.9(CHarom), 
128.4(CHarom), 121.3 (CHarom), 112.5(Cq), 112.8 (Cq), 103.7 (1’CH), 77.3 (2’CH), 74.6 (4’CH), 
73.5 (3’CH), 65.7 (5’CH2), 26.5 (CH3), 26.3 (CH3);  
31P NMR (202.5 MHz, DMSO, δ ppm): -8.08;  
MS: m/z = 725.5 [M+H]+;  
Elemental Analysis 
C28H32Cl2O14P2 (725.41):  Calcd: C 46.36 H 4.45 O 30.88  
 Found: C 46.27 H 4.49 O 30.95 
 
 
9.3.5 Cyclic bis(3’-5’)-(1’,2’-O-diacetyl-D-ribo-furanosyl)-2-
chlorophenyl phosphate (73) 
 
 
 
670 mg (0.92 mmol, 1 eq) cyclic bis(3’-5’) (1’,2’-bis-O-isopropylidene-D-ribofuranosyl)-2-
chlorophenyl phosphate 72 were dissolved in glacial acetic acid (10 ml). Acetic anhydride 
(0.1 ml) and sulfuric acid (0.4 ml) were added and the reaction mixture stirred for 18 hrs at 
RT under atmosphere of N2. The reaction mixture was poured in ice water bath and the 
aqueous phase extracted with DCM (4 x 50 ml). The organic phase was washed with sat. aq. 
NaHCO3 sol. (100 ml). The organic phase was dried (MgSO4) and the solvent was removed 
under reduced pressure. The residue was dissolved in dichloromethane, filtered through a 
short pad of silica gel, yileding 525 mg (0.64 mmol, 70%) of the acetylated product 73 were 
obtained. 
 
C30H32Cl2O18P2: 813.42 g/mol 
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Rf (hexane:EtOAc, 3:7) = 0.79;  
High Rf stereoisomer of 73: 
1H NMR (500 MHz, DMSO, δ ppm): 7.73 (m, 8H, CHarom), 5.88 (d, 1H, J= 3.51 Hz, 1’CHa), 
5.75 (d, 1H, J= 3.61 Hz, 1’CHb), 4.93-4.87 (m, 2H, 3’CHa, 2’CHb), 4.85-4.81 (m, 1H, 3’CHb), 
4.74 (t, 1H, J= 4.17 Hz, 2’CHb), 4.52-4.45 (m, 2H, 5’CHa, 5’CHb), 4.34-4.24 (m, 4H, 5C’Ha, 
5’CHb, 4’CHa, 4’CHb), 2.10 (s, 3H, CH3a), 2.06 (s, 3H, CH3b);  
13C NMR (125.8 MHz DMSO, δ ppm): 145.7(Cqarom), 145.6 (Cqarom), 130.8(CHarom), 
130.6(CHarom), 128.8(CHarom), 128.5(CHarom), 127.0(CHarom), 126.8(CHarom), 121.4, 121.0 
(CHarom), 112.8(Cq), 112.6 (Cq), 103.6 (1’CHa), 103.5 (1’CHb), 77.4 (2’CHa), 77.3 (2’CHb), 74.4 
(4’CHa), 74.3 (4’CHb), 74.1(3’CHa), 74.1 (3’CHb), 65.2/65.1 (5’CH2a, 5’CH2b), 21.8 (CH3), 21.4 
(CH3);  
31P NMR (202 MHz, DMSO, δ ppm): -8.34, -8.51;  
MS (ESI) m/z = 812.4 [M-H]+;  
 
Rf (hexane:EtOAc, 3:7) = 0.70.  
Low Rf stereoisomer of 73:  
1H NMR (500 MHz, DMSO, δ ppm): 7.60-7.28 (m, 8H, CHarom), 5.85 (d, 2H, J= 3.36 Hz, 
1’CHa, 1’CHb), 4.82-4.78 (m, 4H, 2’CHa, 2’CHb, 3’CHa, 3’CHb), 4.46-4.45 (m, 4H, 5’CHa, 
5’CHb), 4.25-4.22 (m, 2H, 4’CHa, 4’CHb), 2.10 (s, 3H, CH3a), 2.06 (s, 3H, CH3b);  
13C NMR (125.8 MHz, DMSO, δ ppm): 145.6 (Cqarom), 130.6(CHarom), 128.9(CHarom), 
128.4(CHarom), 121.3 (CHarom), 112.5(Cq), 112.8 (Cq), 103.7 (1’CH), 77.3 (2’CH), 74.6 (4’CH), 
73.5 (3’CH), 65.7 (5’CH2), 21.8 (CH3), 21.4 (CH3);  
31P NMR (202.5 MHz, DMSO, δ ppm): -8.09;  
MS (ESI): m/z = 812.4 [M-H]+;  
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9.4 Synthesis of the Protected Base 
9.4.1 2-N-isobutyrylguanine (75) 
 
 
 
 
10 g (66.20 mmol, 1 eq) guanine 74 were suspended in N,N-dimethylacetamide (DMA) (140 
ml) at RT under argon and added with 29.6 ml (0.18 mol, 2.7 eq) isobutyric anhydride. The 
mixture was refluxed at 150°C for 2 hrs. The clear solution was cooled to RT and the solvent 
evaporated to 1/10 of its volume. The precipitated crude product was filtered and re-
crystallized from 1.5 L boiling ethanol:water (1:1) to give 13.31 g (56.51 mmol, 85%) of 75 as 
a white solid.  
 
C5H5N5O: 151.05 g/mol 
1H NMR (400.0 MHz, DMSO, δ ppm): 8.01 (s, 1H, 8CH), 2.72 (t, 1H, J= 6.8 Hz, CH), 1.09 (d, 
6H, J= 6.8 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 180.8 (C=O), 148.1 (Cq), 35.6 (CH), 19.7 (CH3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH
NNH
N
O
NH2
NH
NNH
N
O
N
H
O(iBuCO)2O, DMA
74 75
Experimental Part   137 
9.4.2 9-N-acetyl-2-N-isobutyrylguanine (76) 
 
 
 
13.31 g (56.51 mmol, 1 eq) 2-N-isobutyrylguanine 75 were suspended in dry DMF (75 ml) at 
RT under argon and added with 15.3 ml (0.15 mol, 2.65 eq) acetic anhydride. The mixture 
was refluxed at 100°C for 1 hr. The solution was cooled to RT and the solvent evaporated 
under reduced pressure. The residue was re-crystallized from ethanol (30 ml) to give 13.41 g 
(50.9 mol, 85%) of 76 as a white solid.  
 
C11H13N5O3: 263.25 g/mol 
1H NMR (400.0 MHz, DMSO, δ ppm): 8.44 (s, 1H, 8CH), 2.80 (s, 3H, CH3 acetyl), 2.79 (m, 1H, 
CHisobutyryl), 1.12 (d, 6H, J= 6.8 Hz, CH3 isobutyryl);  
13C NMR (100.6 MHz, DMSO, δ ppm): 181.3 (C=O), 168.9 (6Cq), 155.5 (5Cq), 149.5 (2Cq), 
148.1 (8Cq), 138.4 (Cq), 122.4 (Cq), 35.6 (CHisobutyryl), 25.6 (CH3 acetyl), 19.7 (CH3 isobutyryl);  
 
 
9.4.3 2-N-isobutyryl-4-O-[2-(p-nitrophenyl)ethyl]guanine (77) 
 
 
 
16.56 g (62.3 mmol) 9-O-acetyl-2-N-isobutyrylguanine 76 were suspended in dioxane (625 
ml), added with 24.5 g triphenylphosphine (93.4 mmol, 1.5 eq) and 15.1 g 2-(p-nitrophenyl)-
ethanol (93.42 mmol, 1.5 eq). 24.2 ml DEAD (0.14 mol, 2.2 eq) were added dropwise and the 
reaction mixture stirred at RT for 16 hrs. The volatiles were removed under reduced pressure 
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and the residue re-crystallized in a 1:1 mixture of EtOH/H2O (9 L). The residual 
triphenylphosphinoxide was washed away with DCM (100 ml) and the crude product re-
crystallized again in a 1:1 mixture of EtOH/H2O (9 L) to yield 7.8 g of 77 as a white solid 
(21.06 mmol, 33%). 
 
C17H18N6O4: 370.86 g/mol 
1H NMR (400 MHz, DMSO, δ ppm): 13.18 (s, 1H, 9NH), 10.27 (s, 1H, 2NH), 8.19 (s, 1H, 8CH), 
8.18 (d, 2H, J= 8.9 Hz, CHarom), 7.66 (d, 2H, J= 8.7 Hz, CHarom), 4.77 (t, 2H, J= 6.8 Hz, CH2 
Npe), 3.32 (t, 2H, J= 6.8 Hz, OCH2 Npe), 2.85 (sept, 1H, J= 6.8 Hz, CH), 1.09 (s, 3H, CH3), 1.08 
(s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 175.8 (C=O), 152.7 (6Cq), 147.5 (5Cq), 147.1 (2Cq), 
131.2 (CHarom), 124.3 (CHarom), 67.1 (OCH2 Npe), 35.2 (CH2 Npe), 35.1 (CH), 20.2 (CH3). 
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9.5 Base introduction and Deprotection of c-di-GMP 
9.5.1 Cyclic bis(3’-5’)-(2’-O-acetyl-2-N-isobutyryl-4-O-p-nitrophenyl 
ethyl-guanosine)-2-chlorophenyl phosphate (78) 
 
 
 
820 mg (2.21 mmol, 3 eq) 2-N-isobutyryl-4-O-[2-(p-nitrophenyl)ethyl]guanine 77 were 
suspended in dichloroethane (DCE) (20 ml). 1.08 ml (4.42 mmol, 6 eq) N,O-
bis(trimethylsilyl)acetamide (BSA) were added and the reaction mixture was heated to 80oC 
for 16 hrs in a sealed flask. The excess of BSA and DCE were removed by evaporation 
under reduced pressure. The residue was dissolved in toluene (20 ml). 0.70 ml trimethylsilyl 
triflate (TMSOTf) (3.69 mmol, 5 eq) and 600 mg cyclic sugar 73 (0.73 mmol, 1 eq), dissolved 
in toluene (10 ml), were added and stirred for 30 min at 80oC in a sealed flask. The reaction 
mixture was diluted with EtOAc (60 ml) and the solution washed with 0.25 M TEAC buffer 
(100 ml). The aqueous layer was extracted with EtOAc (2 x 100 ml). The combined organic 
phases were dried (MgSO4), filtered and the solvent was evaporated under reduced 
pressure. Flash chromatography (CH2Cl2, CH2Cl2:MeOH gradient from 100:0 to 95:5, v/v) 
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followed by a final purification step, using size exclusion chromatography with Sephadex 
LH20 and a 1:1 mixture of nanopure water: CH2Cl2 as eluent, yielded 779 mg of 78 as a 
white oily residue (0.54 mmol, 66 %).  
 
C60H60Cl2N12O22P2: 1434.07 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.53;  
1H NMR (500 MHz, CDCl3, δ ppm): 8.78 (s, H, 2NHa), 8.70 (s, H, 2NHb), 8.14 (m, 4H, 
CHarom), 7.85 (s, 2H, 8CHa), 7.76 (s, 2H, 8CHb), 7.52-7.00 (m, 16H, CHarom), 6.33 (m, 1H, 
3’CHa), 6.19 (dd, 1H, J1= 5.6 Hz, J2= 4.6 Hz, 2’CHa), 6.15 (dd, 1H, J1= 5.2 Hz, J2= 4.0 Hz, 
2’CHb), 6.02 (d, 1H, J= 4.4 Hz, 1’CHb), 5.99 (m, 1H, 3’CHb), 5.86 (d, 1H, J= 3.6 Hz, 1’CHa), 
4.98 (ddd, 1H, J1= 10.7 Hz, J2= 7.8 Hz, J3= 6.5 Hz, 5’CHb), 4.91-4.80 (m, 4H, O-CH2 Npe), 
4.70 (m, 1H, 4’CHb), 4.65-4.49 (m, 3H, 5’CHa, 4’CHa, 5’CHa), 4.45 (ddd, 1H, J1= 10.7 Hz, J2= 
5.0 Hz, J3= 3.6 Hz, 5’CHb), 3.34-3.30 (m, 4H, CH2 Npe), 2.92 (bd, 2H, CH), 1.99 (s, 3H, CH3 
acetyl), 1.94 (s, 3H, CH3 acetyl), 1.21-1.15 (m, 12H, CH3 isobutytryl);  
13C NMR (125.8 MHz, CDCl3, δ ppm): 175.9 (C=Oisobutyryl), 169.4 (C=Oacetyl), 169.2 (C=Oacetyl), 
160.8 (6Cq), 152.4/152.3(2Cq), 152.1/151.9 (4C-O), 146.9-145.7 (Cqarom), 141.1 (8CH), 130.9-
120.9 (CHarom), 118.9/118.6 (5Cq), 88.0/87.0 (1’CH), 81.2/79.0 (4’CH), 75.6/74.6 (3’CH), 
72.4/72.2 (2’CH), 66.1/65.9 (5’CH2), 35.8/35.0 (CHisobutyryl), 20.4/20.3 (CH3 isobutyryl), 19.4/19.3 
(CH3 acetyl); 
31P NMR (202.5 MHz, CDCl3, δ ppm): -5.8, -9.5; 
MS (Maldi-ToF, m/z): 1434.2 [M]+; 
Elemental Analysis  
C60H60Cl2N12O22P2 (1434.07):  Calcd: C 50.25 H 4.22 O 24.55.  
 Found: C 50.14 H 4.29 O 24.64.  
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9.5.2 c-di-GMP 
 
 
 
430 mg (0.29 mmol, 1 eq) fully protected c-di-GMP 78 in pyridine (5 ml) were treated with 
0.21 ml (1.40 mmol, 4.5 eq) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) at 0oC. The reaction 
mixture was stirred at RT for 8 hrs and neutralized to pH=7 with glacial acetic acid. The 
solvents were evaporated under reduced pressure. The residue was dissolved in pyridine (5 
ml), 1.5 g (11.99 mmol, 40 eq) syn-pyridine-2-carbaldoxime and 1.35 ml (10.49 mmol, 35 eq) 
N,N,N,N-tetramethylguanidine were added. The reaction mixture was stirred for 16 hrs at RT. 
14 M ammonium hydroxide (100 ml) was added and the mixture stirred for 2 days at 50oC in 
a sealed flask. The solution was concentrated to 1/10 of its volume and washed with DCM (2 
x 20 ml). Size exclusion chromatography with Sephadex G15 and nanopure water as eluent, 
followed by reverse phase HPLC chromatography (TEAC(0.01 M):MeOH; 92.5:7.5, isocratic) 
yielded 173 mg of pure c-di-GMP (84%, 99.99% pure).  
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1H NMR (500 MHz, D2O, δ ppm): 7.90 (s, 2H, 8CH), 5.84 (d, 2H, J= 1.3 Hz, 1’CH), 4.74 (dd, 
2H, J1= 8.5 Hz, J2= 5.0 Hz, 3’CH), 4.59 (dd, 2H, J= 5.0 Hz,2’CH), 4.27 (dd, 2H, J= 8.5 Hz, 
4’CH), 4.21 (m, 2H, 5’CH2), 3.96 (m, 2H, 5’CH2); 
13C NMR (125.8 MHz, D2O, δ ppm): 158.8, 153.8 (4C=O, 6Cq), 150.8 (2Cq), 137.1 (8CH), 
116.3 (5C), 89.2 (1’CH), 79.8 (4’CH), 73.3 (2’CH), 70.5 (3’CH), 62.2 (5’CH2); 
HRMS-ESI: m/z [M-H]- calcd for C20H23N10O14P2: 689.0870; Found: 689.0869.  
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10. ANALOGUES 
10.1 Synthesis of Base-Modified Analogues 
10.1.1 2-N-isobutyryladenine (80) 
 
 
 
10 g (74.04 mmol, 1 eq) adenine 79 were suspended in DMA (140 ml) at RT under argon 
and added with 33.2 ml (0.20 mol, 2.7 eq) isobutyric anhydride. The mixture was refluxed at 
150°C for 2 hrs. The reaction mixture was cooled to RT and the solvent concentrated to 1/10 
of its volume. The precipitated crude product was filtered and re-crystallized from EtOH/H2O 
(1:1) (1.5 L), to give 12.45 g (60.71 mmol, 82%) of 80 as a white solid.  
 
C9H11N5O: 205.22 g/mol 
1H NMR (400.0 MHz, DMSO, δ ppm): 8.68 (s, 1H, 8CH), 2.92 (t, 1H, J= 6.8 Hz, CH), 1.15 (d, 
6H, J= 6.8 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 175.5 (C=O), 150.5 (Cq), 39.2 (CH), 19.3 (CH3). 
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10.1.2 Cyclic bis(3’-5’)-(2’-O-acetyl-4-N-isobutyryl adenosine)-2-chloro 
phenyl phosphate (83) 
 
 
 
28.3 mg (0.13 mmol, 2.0 eq) 2-N-isobutyryl-adenine 80 were suspended in DCE (3 ml), 63 µl 
(0.26 mmol, 4.2 eq) BSA were added and the reaction mixture was heated at 80oC for 16 hrs 
in a sealed flask. The excess of BSA and DCE were removed by evaporation under reduced 
pressure. The residue was dissolved in toluene (3 ml), 83 µl TMSOTf (0.46 mmol, 7.5 eq), 50 
mg (0.06 mmol, 1 eq) cyclic sugar 73, dissolved in toluene (1.5 ml), were added and the 
reaction mixture stirred for 30 min at 80oC in a sealed flask. The reaction mixture was diluted 
with EtOAc (10 ml) and washed with 0.25 M TEAC buffer (10 ml). The aqueous layer was 
extracted with EtOAc (2 x 10 ml). The combined organic phases were dried (MgSO4), filtered 
and the solvent was evaporated under reduced pressure. Flash chromatography (CH2Cl2, 
CH2Cl2:MeOH gradient from 100:0 to 95:5, v/v) yielded 39.6 mg of 83 as a white residue 
(35.93 µmol, 59%).  
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C44H46Cl2N10O16P2: 1103.75 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.48;  
1H NMR (500 MHz, DMSO, δ ppm): 10.74, (s, 1H, 2NHa), 10.70 (s, 1H, 2NHb), 8.74 (s, 1H, 
8CHa), 8.68 (s, 1H, 2CHa), 8.66 (s, 1H, 8CHb), 8.60 (s, 1H, 2CHb), 7.64-7.15 (m, 8H, CHarom), 
6.44 (d, 1H J= 6.44 Hz, 1’CHa,), 6.38 (m, 1H, 1’CHb), 6.36 (m, 1H, 2’CHa), 6.17 (d, 1H, J= 
5.18 Hz, 2’CHb), 5.86 (m, 1H, 3’CHb), 5.74 (m, 1H, 3’CHa), 4.87 (m, 1H, 4’CHb), 4.80 (m, 1H, 
4’CHa), 4.60 (m, 2H, 5’CH2a, 5’CH2b), 4.50 (m, 2H, 5’CH2a, 5’CH2b), 2.94 (q, 2H, J= 6.88 Hz, 
CHisobutyryl), 1.95 (s, 3H, CH3 acetyla),1.94 (s, 3H, CH3 acetylb), 1.13 (2s, 12H, CH3 isobutyryl);  
13C NMR (125.8 MHz, DMSO, δ ppm): 175.3 (C=Oisobutyryl), 169.2/169.1 (C=Oacetyl), 
151.9/151.8 (6Cq), 151.6/151.3 (2CHb), 150.2 (5Cq), 145.6 (4Cq), 145.5 (Cqarom), 143.3/143.2 
(8CH), 130.8-126.8 (CHarom), 124.3 (Cqarom), 121.7-120.8 (CHarom), 85.7 (1’CHa), 85.1 (1’CHb), 
80.5 (4’CH), 78.2 (3’CH), 71.4 (2’CHa), 70.8 (2’CHb), 65.5 (5’CH2a), 65.4 (5’CH2b), 39.0 
(CHisobutyryl), 20.2 (CH3 acetyl), 19.3 (CH3 isobutyryl);  
MS (Maldi-ToF, m/z): 1125.13 ([M+Na]+). 
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10.1.3 Cyclic diadenylic acid (c-di-AMP) (84) 
 
 
 
29 mg (22.68 µmol, 1 eq) fully protected c-di-AMP 83 were dissolved in pyridine (2 ml), 118 
mg (0.91 mmol, 40 eq) syn-pyridine-2-carbaldoxime and 10 µl (0.79 mmol, 35 eq) N,N,N,N-
tetramethyl guanidine were added, and the reaction mixture stirred for 16 hrs at RT. 14 M 
ammonium hydroxide (30 ml) was added and the mixture stirred for 2 days at 50oC in a 
sealed flask. The solution was concentrated to 1/10 of its volume and washed with CH2Cl2 (2 
x 10 ml). Size exclusion chromatography with Sephadex G10 and a 1:1 mixture of MeOH-
nanopure water as eluent, followed by reverse phase HPLC chromatography (TEAC(0.01 
M):MeOH; 92.5:7.5, isocratic) yielded 14 mg of pure c-di-AMP 84 (21.3 µmol, 81%).  
 
C20H23N10O12P2: 657.09 g/mol 
1H NMR (500 MHz, DMSO, δ ppm): 8.45 (s, 2H, 8CH), 8.14 (s, 2H, 2CH), 7.32 (s, 4H, NH2), 
5.88 (d, 2H, J= 4.4 Hz, 1’CH), 4.93 (m, 2H, 2’CH), 4.68 (t, 2H, J= 5.3 Hz, 3’CH), 4.22 (dd, 2H, 
J1= 9.7 Hz, J2= 5.3 Hz, 4’CH), 4.00-3.98 (m, 4H, 5’CH2);  
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13C NMR (125.8 MHz, DMSO, δ ppm): 156.1 (4C=O), 152.7 (6Cq), 149.6 (5Cq), 139.7 (8CH), 
119.2 (2CH), 87.0 (1’CH), 81.1 (2’CH), 73.5 (3’CH), 71.3 (4’C), 63.9 (5’CH2);  
HRMS-ESI: m/z [M-H]- calcd for C20H23N10O12P2: 657.0972; Found 657.0967. 
 
 
10.1.4 Cyclic bis(3’-5’)-(2’-O-acetyl-thymidine)-2-chlorophenyl 
phosphate (85) 
 
 
 
22.8 mg (0.18 mmol, 2.1 eq) thymine 81 were suspended in DCE (3 ml), 88 µl (0.36 mmol, 
4.2 eq) BSA were added and the reaction mixture heated at 80oC for 16 hrs in a sealed flask. 
The excess of BSA and DCE were removed by evaporation under reduced pressure. The 
resulting residue was dissolved in toluene (3 ml), 117 µl (0.65 mmol, 7.5 eq) TMSOTf, 70 mg 
cyclic sugar 73 (0.086 mmol, 1 eq), dissolved in toluene (1.5 ml), were added and the 
reaction mixture stirred for 30 min at 80oC in a sealed flask. The reaction mixture was diluted 
with EtOAc (10 ml) and washed with 0.25 M TEAC buffer (10 ml). The aqueous layer was 
extracted with EtOAc (2 x 10 ml). The combined organic phases were dried over MgSO4, 
filtered and the solvent was evaporated under reduced pressure. Flash chromatography 
(CH2Cl2, CH2Cl2:MeOH gradient from 100:0 to 95:5, v/v) lead to 41.4 mg of 85 as a white oily 
residue (22.67 µmol, 51%).  
 
C36H36Cl2N4O18P2: 945.54 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.41;  
1H NMR (500.0 MHz, DMSO, δ ppm): 7.73 (m, 2H, 6CH), 7.63 (m, 2H, CHarom), 7.46 (m, 2H, 
CHarom), 7.43 (m, 2H, CHarom), 7.31 (m, 2H, CHarom), 5.92 (d, 2H, J= 5.92 Hz, 1’CH), 5.63 (t, 
2H, J= 5.87 Hz, 2’CH), 5.36 (m, 2H, 3’CHa), 4.70 (m, 2H, 5’CH2), 4.38 (m, 4H, 4’CH, 5’CH2), 
1.89 (s, 6H, CH3), 1.76 (s, 6H, CH3 acetyl);  
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13C NMR (125.8 MHz, DMSO, δ ppm): 169.1 (C=Oacetyl), 163.6 (4C=O), 150.4 (2C=O), 145.6 
(Cqarom), 136.9 (6CH), 130.8 (CHarom), 128.8 (CHarom), 127.2 (CHarom), 124.4 (Cqarom), 121.6 
(CHarom), 110.1 (5Cq), 86.7 (1’CH), 79.1 (4’CH), 73.5 (3’CH), 70.6 (2’CH), 65.5 (5’CH2), 20.2 
(CH3 acetyl), 12.0 (CH3);  
MS (Maldi-ToF, m/z): 967.76 ([M+Na]+). 
 
 
10.1.5 Cyclic dithymidic acid (c-di-TMP) (87) 
 
 
 
29 mg (30.72 µmol, 1 eq) cyclic bis (3’-5’) (2’-O-acetyl-thymidine)-2-chlorophenyl phosphate 
81 were dissolved in pyridine (2 ml), 150 mg (1.22 mmol, 40 eq) syn-2-pyridinecarbaldoxime, 
134 µl (1.07 mmol, 35 eq) N,N,N,N-tetramethyl guanidine were added and the reaction 
mixture stirred for 16 hrs at RT. The solvents were evaporated and the residue taken up in 
H2O (10 ml) then washed with DCM (2 x 10 ml). The aqueous phase was then evaporated 
under reduced pressure. Size exclusion chromatography with Sephadex G10 and a mixture 
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of nanopure H2O:MeOH (1:1) as eluent, followed by reverse phase HPLC chromatography 
(TEAC(0.01 M):MeOH; 92.5:7.5, isocratic) yielded 15.7 mg of pure c-di-TMP 87 (24.57 µmol, 
80%, 99.99% pure).  
 
C20H25N4O16P2: 639.07 g/mol 
1H NMR (500.0 MHz, DMSO, δ ppm): 11.32 (s, 2H, NH), 9.33 (s, 1H, OH), 8.38 (s, 1H, OH), 
7.73 (s, 2H, CHalkene), 5.75 (d, 2H, J= 5.08 Hz, 1’CH), 4.47 (m, 2H, 3’CH), 4.19 (t, 2H, J= 4.88 
Hz, 2’CH), 4.07 (m, 2H, 4’CH), 3.95 (m, 2H, 5’CH2), 3.87 (m, 2H, 5’CH2), 1.77 (s, 6H, CH3);  
13C NMR (125.8 MHz, DMSO, δ ppm): 163.6 (4C=O), 150.4 (2C=O), 135.6 (CHalkene), 109.7 
(5Cq), 87.6 (1’CH), 80.0 (4’CH), 72.0 (3’CH), 71.7 (2’CH), 62.9 (5’CH2), 11.9 (CH3);  
HRMS-ESI: m/z [M-H]- calcd for C20H25N4O16P2: 639.0741; Found 639.0735. 
 
 
10.1.6 Cyclic bis(3’-5’)-(2’-O-acetyl-theophylline)-2-chloro-phenyl 
phosphate (86) 
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32.5 mg (0.18 mmol, 2.1 eq) theophylline 82 were suspended in DCE (3 ml), 88 µl (0.36 
mmol, 4.2 eq) BSA were added and the reaction mixture heated at 80oC for 16 hrs in a 
sealed flask. The excess of BSA and DCE were removed by evaporation under reduced 
pressure. The residue was dissolved in toluene (3 ml), 117 µl TMSOTf (0.65 mmol, 7.5 eq), 
70 mg cyclic sugar 73 (86.10 µmol, 1 eq), dissolved in toluene (1.5 ml), were added and 
stirred for 30 min at 80oC in a sealed flask. The reaction mixture was diluted with EtOAc (10 
ml) and washed with 0.25 M TEAC buffer (2 x 10 ml). The aqueous layer was extracted with 
EtOAc (2 x 10 ml). The combined organic phases were dried (MgSO4), filtered and the 
solvent was evaporated under reduced pressure. Flash chromatography (CH2Cl2, 
CH2Cl2:MeOH gradient from 100:0 to 95:5, v/v) lead to 42 mg of 86 a white solid (40.46 
mmol, 47 %).  
 
C40H40Cl2N8O18P2: 1053.64 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.32;  
1H NMR (500 MHz, DMSO, δ ppm): 8.49 (s, 1H, 8CHa), 8.44 (s, 1H, 8CHb), 7.63 (md, 1H, J= 
7.55 Hz, CHarom), 7.56 (d, 1H, J= 7.89 Hz, CHarom), 7.47-7.24 (m, 6H, CHarom), 6.39 (d, 2H, J= 
6.70 Hz, 1’CHa, 1’CHb), 6.08 (m, 1H, 2’CHb), 6.04 (t, 1H, J= 6.29 Hz, 2’CHa), 5.62 (m, 1H, 
3’CHb), 5.58 (m, 1H, 3’CHa), 4.79 (m, 1H, 5’CH2a), 4.76 (m, 1H, 5’CH2b), 4.51 (m, 1H, 4’CHb), 
4.50 (m, 1H, 4’CHa), 4.33 (m, 2H, 5’CH2a, 5’CH2b), 3.43 (s, 3H, 4CH3a), 3.41 (s, 3H, 4CH3b), 
3.24 (s, 3H, 2CH3a), 3.23 (s, 3H, 2CH3b), 1.95 (s, 3H, CH3 acetyl),1.93 (s, 3H, CH3 acetyl);  
13C NMR (125.8 MHz, DMSO, δ ppm): 169.1 (C=Oacetyl), 168.8 (C=Oacetyl), 154.1/153.9 
(3C=O), 150.7/150.6 (1C=O), 149.7/149.6 (5Cq), 145.7/145.6 (Cqarom), 143.6 (8CHb), 142.9 
(8CHa), 130.8-126.7 (CHarom), 124.6 (Cqarom), 124.2 (Cqarom), 121.7 (CHarom), 120.7 (CHarom), 
105.6/105.5 (6Cq), 86.8 (1’CHb), 86.5 (1’CHa), 80.5 (4’CHa), 80.0 (4’CHb), 75.4 (3’CHb), 74.4 
(3’CHa), 71.7 (2’CHa), 71.6 (2’CHb), 65.5 (5’CH2a), 64.8 (5’CH2b), 29.7 (4CH3), 27.9 (2CH3), 
20.2 (CH3 acetyl), 20.1 (CH3 acetyl);  
MS (Maldi-ToF, m/z): 1075.17 ([M+Na]+). 
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10.1.7 Cyclic bis(3’-5’)-theophylline monophosphate (88) 
 
 
 
22 mg (20.91 µmol, 1 eq) cyclic bis (3’-5’) (2’-O-acetyl-theophyllosine)-2-chlorophenyl 
phosphate 86 were dissolved in pyridine (2 ml), 150 mg (1.22 mmol, 40 eq) syn-2-pyridine 
carbaldoxime, 134 µl (1.07 mmol, 35 eq,) N,N,N,N-tetramethyl guanidine were added and 
stirred for 16 hrs at RT. The solvents were evaporated under reduced pressure, the residue 
taken up in H2O (10 ml) and washed with DCM (2 x 10 ml). The aqueous phase was 
evaporated under reduced pressure. Size exclusion chromatography with Sephadex G10 
and a mixture of nanopure H2O:MeOH (1:1) as eluent, followed by reverse phase HPLC 
chromatography (TEAC(0.01 M):MeOH; 92.5:7.5, isocratic) yielded 11.8 mg of pure c-di-
(theophyllosine)MP 88 (15.79 µmol, 76%, 99.99% pure).   
 
C24H29N8O16P2: 747.11 g/mol 
1H NMR (500 MHz, DMSO, δ ppm): 8.51 (s, 1H, 8CH), 7.17 (s, 1H, 2’OH),6.12 (d, 1H, J= 5.80 
Hz, 1’CH), 4.57 (m, 2H, 2’CH, 3’CH), 4.18 (m, 1H, 4’CH), 3.91 (m, 2H, 5’CH2), 3.43 (s, 3H, 
4CH3), 3.23 (s, 3H, 2CH3);  
OAcO
O
O
O OAc
O
O
P
P
O
O
O
O
Cl
Cl
N
N
N
N
N
N
N
N
OHO
O
O
O OH
O
O
P
P
HO
OH
O
O
N
N
N
N
N
N
N
N
1. syn-pyridine-2-carbaldoxime,
N,N,N,N-tetramethylguanidine, pyridine
2. NH4OH
O
O
O
O
O
O
O
O
86
88
152   Experimental Part 
13C NMR (125.8 MHz, DMSO, δ ppm): 154.1 (1C=O), 150.9 (3C=O), 148.9 (5Cq), 141.0 (8CH), 
105.9 (6Cq), 89.1 (1’CH), 81.2 (4’CH), 73.0 (3’CH), 72.4 (2’CH), 63.3 (5’CH2), 29.5 (4CH3), 27.7 
(2CH3);  
HRMS-ESI: m/z [M-H]- calcd for C24H29N8O16P2: 747.1177; Found 747.1171. 
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10.2 Synthesis of an Internucleotide Bond Modified Analogue: an 
Amide Linked Dinucleotide 
10.2.1 Synthesis of the Building Blocks 
10.2.1.1 5’-O-t-butyldimethylsilyl-3’-deoxy-3’-[(ethoxycarbonyl) 
methylene]-1’,2’-O-isopropylidene-α-D-erythro-pentofuranose 
(89) 
 
 
 
2 g (6.61 mmol, 1 eq) 5’-O-t-butyldimethylsilyl-3’-oxo-1’,2’-O-isopropylidene-α-D-erythro-
pentofuranose 64 were dissolved in dry DCM (50 ml), added with 2.79 g (7.60 mmol, 1.15 
eq) [(ethoxycarbonyl)methylene] triphenylphosphorane and stirred for 16 hrs at RT under N2. 
After evaporation of the volatiles, flash chromatography (hexane, hexane:EtOAc gradient 
from 1:0 to 8:2; v/v) yielded 2.25 g (6.04 mmol, 91%) of 89 as a colorless oil as an E/Z 
mixture.  
 
C18H32O6Si: 372.53 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.82;  
Major isomer:  
1H NMR (400.0 MHz, DMSO, δ ppm): 6.05 (t, 1H, J= 1.76 Hz, CHalkene), 5.84 (d, 1H, J= 4.28 
Hz, 1’CH), 5.49 (m, 1H, 2’CH), 4.84 (m, 1H, 4’CH), 4.15 (m, 2H, CH2 EtO), 3.72 (m, 2H, 5’CH2), 
1.35 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.21 (t, 3H, J= 7.04 Hz, CH3), 0.84 (s, 9H, CH3 TBDMS), 
0.01 (t, 6H, J= 4.04 Hz, CH3 TBDMS);  
13C NMR (100.6 MHz, DMSO, δ ppm): 165.6 (C=O), 157.5 (3’CH), 116.9 (1’CH), 112.5 
(CHalkene), 105.8 (Cq), 82.5 (2’CH), 79.2 (4’CH), 66.1 (5’CH2), 61.0 (CH2 Et), 28.4-27.9 (CH3), 
18.6 (CqTBDMS), 14.8 (CH3 TBDMS), -4.7- -4.9 (CH3 TBDMS);  
MS (Maldi-ToF, m/z): 395.4 [M+Na]+. 
Elemental Analysis 
C18H32O6Si (372.53):  Calcd: C 58.03 H 8.66 O 25.77 Si 7.54 
 Found: C 57.61 H 8.50 O 25.51 
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10.2.1.2 3’-deoxy-3’-[(ethoxycarbonyl)methylene]-1’,2’-O-isopropylidene 
-α-D-erythro-pentofuranose (90) 
 
 
 
500 mg (1.34 mmol, 1 eq) 5’-O-t-butyldimethylsilyl-3’-deoxy-3’-[(ethoxycarbonyl) methylene]-
1’,2’-O-isopropylidene-α-D-erythro-pentofuranose 89 were dissolved dry THF (15 ml) at RT 
under argon. 2.2 ml (13.4 mmol, 10 eq) trihydrofluoro triethylamine were added dropwise 
and, after the addition was completed, the solution stirred at RT for 16 hrs. The reaction 
mixture was quenched with silica gel and the solvent evaporated under reduced pressure. 
Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 4:6, v/v) yielded 348 mg 
of 90 as a colorless oil (1.34 mmol, quant.).  
 
C12H18O6: 258.27 g/mol 
Rf (hexane:EtOAc, 3:7) = 0.39;  
Major isomer: 
1H NMR (400.0 MHz, DMSO, δ ppm): 6.02 (t, 1H, J= 1.76 Hz, CHalkene), 5.88 (d, 1H, J= 4.32 
Hz, 1’CH), 5.53 (m, 1H, 2’CH), 4.92 (t, 1H, J= 5.84 Hz, 5’OH), 4.75 (m, 1H, 4’CH), 4.14 (m, 2H, 
CH2 EtO), 3.56 (m, 2H, 5’CH2), 1.35 (s, 3H, CH3), 1.30 (s, 3H, CH3), 1.21 (t, 3H, J= 7.32 Hz, 
CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 165.2 (C=O), 157.6 (3’CH), 116.6 (1’CH), 112.3 
(CHalkene), 105.4 (Cq), 81.7 (2’CH), 78.9 (4’CH), 63.6 (5’CH2), 60.9 (CH2), 28.1-27.9 (CH3), 14.9 
(CH3);  
MS (Maldi-ToF, m/z): 281.5 [M+Na]+. 
Elemental Analysis 
C12H18O6 (258.27):  Calcd: C 55.81 H 7.02 O 37.17  
 Found: C 55.03 H 6.88 O 38.09 
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10.2.1.3 3’-deoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-isopropylidene-α-
D-ribofuranose (91) 
 
 
 
348 mg (1.35 mmol, 1 eq) 3’-deoxy-3’-[(ethoxycarbonyl) methylene]-1’,2’-O-isopropylidene-α-
D-erythro-pentofuranose 90 were dissolved in ethanol (15 ml) at RT under argon, added with 
35 mg (10% weight) palladium on activated charcoal and flushed with argon. The reaction 
mixture was shaken under H2 pressure (3 bar) for 16 hrs. The suspension was filtered over 
celite, washed with ethanol and the volatiles evaporated under reduced pressure, to yield 
299 mg of 91 as a colorless oil (1.15 mmol, 85%).  
 
C12H20O6: 260.29 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.03;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.76 (d, 1H, J= 3.8 Hz, 1’CH), 4.72 (m, 2H, 2’CH, 5’OH), 
4.07 (m, 2H, CH2), 3.67 (m, 1H, 4’CH), 3.56 (m, 1H, 5’CH2), 3.44 (m, 1H, 5’CH2), 2.46 (d, 2H, 
J= 7.32 Hz, 3’CH2), 2.20 (m, 1H, 3’CH), 1.38 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.17 (t, 3H, J= 
5.04 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 171.5 (C=O), 110.4 (Cq), 104.3 (1’CH), 80.9 (2’CH), 
80.6 (4’CH), 60.5 (5’CH2), 59.9 (CH2), 40.2 (3’CH), 29.3-26.3 (CH3), 14.0 (CH3);  
MS (Maldi-ToF, m/z): 283.4 [M+Na]+. 
Elemental Analysis 
C12H20O6 (260.29):  Calcd: C 55.37 H 7.74 O 36.88  
 Found: C 54.14 H 7.53 O 38.33 
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10.2.1.4 3’-deoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-isopropylidene-5’-
O-p-toluenesulfonyl-α-D-ribofuranose (92) 
 
 
 
4.02 g (15.44 mmol, 1 eq) 3’-deoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-isopropylidene-α-D-
erythro-pentofuranose 91 were dissolved in abs. pyridine (140 ml), added with 3.53 g (18.53 
mmol, 1.2 eq) TsCl and stirred for 16 hrs at RT under N2. The reaction mixture was diluted 
with water (100 ml) and extracted with EtOAc (3 x 200 ml). The combined organic phases 
were washed with 1 M HCl (300 ml) then dried (MgSO4) and concentrated under reduced 
pressure. Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 3:7, v/v) 
yielded 4.36 g of 92 as a colorless oil (10.12 mmol, 65 %).  
 
C19H26O9S: 430.48 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.54;  
1H NMR (400.0 MHz, DMSO, δ ppm): 7.78 (dd, 2H, J1= 1.52 Hz, J2= 6.6 Hz, CHarom), 7.47 (d, 
2H, J= 8.08 Hz, CHarom), 5.71 (d, 1H, J= 3.52 Hz, 1’CH), 4.66 (t, 1H, J= 4.32 Hz, 2’CH), 4.25 
(m, 1H, 5’CH2), 4.05 (m, 3H, CH2, 5’CH2), 3.80 (m, 1H, 4’CH), 2.41 (m, 5H, 3’CH2, CH3), 2.15 
(m, 1H, 3’CH), 1.34 (s, 3H, CH3), 1.21 (s, 3H, CH3), 1.17 (t, 3H, J= 7.08 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 172.0 (C=O), 145.90 (Cq), 133.0 (Cq), 131.0 (CHarom), 
128.5 (CHarom), 111.7 (Cq), 105.2 (1’CH), 81.1 (2’CH), 78.4 (4’CH), 70.22 (5’CH2), 60.9 (3’CH2 
EtO), 41.0 (3’CH), 29.8 (CH2), 27.3-26.9 (CH3), 14.9 (CH3);  
MS (Maldi-ToF, m/z): 453.8 [M+Na]+. 
Elemental Analysis 
C19H26O9S (430.48):  Calcd: C 53.01 H 6.09 O 33.45  
 Found: C 54.85 H 6.30 O 38.85 
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10.2.1.5 5’-azido-3’,5’-dideoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-
isopropylidene-α-D-ribofuranose (93) 
 
 
 
4.36 g (10.12 mmol, 1 eq) 3’-deoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-isopropylidene-5’-O-
p-toluenesulfonyl-α-D-erythro-pentofuranose 92 were taken up in abs. DMF (250 ml), added 
with 3.29 g (50.60 mmol, 5 eq) NaN3 and stirred for 16 hrs at 100°C under N2. After cooling 
to RT, the reaction mixture was added with water (200 ml) and extracted with ethylacetate (4 
x 250 ml). The combined organic phases were dried and the volatiles evaporated under 
reduced pressure. Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 1:1, 
v/v) yielded 3.0 g o 93 as a colorless oil (10.10 mmol, quant.).  
 
C12H19N3O5: 285.30 g/mol 
Rf (hexane:EtOAc, 7:3) = 0.87;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.79 (d, 1H, J= 3.52 Hz, 1’CH), 4.71 (t, 1H, J= 4.28 Hz, 
2’CH), 4.06 (m, 2H, CH2), 3.86 (m, 1H, 4’CH), 3.60 (m, 1H, 5’CH2), 3.30 (m, 1H, 5’CH2), 2.47 (d, 
2H, J= 7.08 Hz, 3’CH2), 2.22 (m, 1H, 3’CH), 1.38 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.18 (t, 3H, 
J= 7.04 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 172.1 (C=O), 111.7 (Cq), 105.3 (1’CH), 81.4 (2’CH), 
80.1 (4’CH), 60.9 (3’CH2), 51.8 (5CH2), 41.8 (3’CH), 29.8 (CH2), 27.2-26.9 (CH3), 14.8 (CH3);  
IR (νmax/cm-1, neat): 2102;  
MS (Maldi-ToF, m/z): 308.8 [M+Na]+. 
Elemental Analysis 
C12H19N3O5 (285.30):  Calcd: C 50.52 H 6.71 N 14.73 O 28.04  
 Found: C 50.50 H 6.68 N 14.60 O 28.22 
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10.2.1.6 5’-azido-3’,5’-dideoxy-3’-[(carbonyl)methyl]-1’,2’-O-
isopropylidene-α-D-ribofuranose sodium salt (94) 
 
 
 
500 mg (1.75 mmol, 1 eq) 5’-azido-3’,5’-dideoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-
isopropylidene-α-D-ribofuranose 93 were dissolved in 5 ml methanol, added with 10 M NaOH 
(0.3 ml) and stirred for 2 hrs at RT under argon. The reaction mixture was evaporated in 
vacuo to yield 491 mg of 94 as a sodium salt (1.74 mmol, quant.).  
 
C10H15N3NaO5: 279.23 g/mol 
Rf (hexane:EtOAc, 2:8) = 0.05;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.72 (d, 1H, J= 3.52 Hz, 1’CH), 4.69 (t, 1H, J= 4.04 Hz, 
2’CH), 3.78 (m, 1H, 4’CH), 3.57 (m, 1H, 5’CH2), 3.25 (m, 1H, 5’CH2), 2.15 (m, 1H, 3’CH), 2.06 
(m, 1H, 3’CH2), 1.85 (m, 1H, 3’CH2), 1.38 (s, 3H, CH3), 1.21 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 174.2 (C=O), 110.3 (Cq), 104.1 (1’CH), 81.9 (2’CH), 
80.2 (4’CH), 51.8 (5CH2), 43.3 (3’CH), 33.4 (3’CH2), 26.7-26.3 (CH3);  
IR (νmax/cm-1, neat): 2101;  
MS (ESI, m/z): 257.3 [M-Na]-, 535.5 [2M+Na]-. 
 
 
10.2.1.7 5’-amino-3’,5’-dideoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-
isopropylidene-α-D-ribofuranose (95) 
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2 g (7.01 mmol, 1 eq) 5’-azido-3’,5’-dideoxy-3’-[(ethoxycarbonyl)methyl]-1’,2’-O-
isopropylidene-α-D-ribofuranose 93 were dissolved in ethanol (15 ml), added with 200 mg 
(10% weight) palladium on activated charcoal and flushed with argon. The reaction mixture 
was shaken under H2 pressure (3 bar) for 16 hrs at RT. The suspension was filtered over 
celite, washed with methanol and the volatiles evaporated under reduced pressure, to yield 
1.6 g of compound 95 as a colorless oil (6.17 mmol, 84%). 
 
C12H21NO5: 259.30 g/mol 
Rf (hexane:EtOAc, 2:8) = 0.18;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.76 (d, 1H, J= 3.8 Hz, 1’CH), 4.69 (t, 1H, J= 4.32 Hz, 
2’CH), 4.06 (m, 2H, CH2), 3.62 (m, 1H, 4’CH), 2.75 (m, 1H, 5’CH2), 2.54 (m, 1H, 5’CH2), 2.45 (d, 
2H, J= 7.32 Hz, 3’CH2), 2.17 (m, 1H, 3’CH), 1.38 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.18 (t, 3H, 
J= 7.04 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 171.6 (C=O), 110.3 (Cq), 104.2 (1’CH), 81.7 (2’CH), 
80.9 (4’CH), 59.9 (3’CH2), 42.6 (5CH2), 40.6 (3’CH), 29.4 (CH2), 26.4-26.3 (CH3), 14.0 (CH3);  
MS (Maldi-ToF, m/z): 282.1 [M+Na]+. 
 
 
10.2.2 Assembling the Backbone 
10.2.2.1 Amide Linked Blocked Dimer (96) 
 
 
 
2.82 g (6.83 mmol, 2 eq) HCTU were dissolved in 3 ml DMF, added with 1.17 ml (6.83 mmol, 
2 eq) DIPEA, 3 ml DCM and 956 mg (3.41 mmol, 1 eq) of the 5’-azido-3’,5’-dideoxy-3’-
[(carbonyl)methyl]-1’,2’-O-isopropylidene-α-D-ribofuranose sodium salt 94 at RT under N2. 
The mixture was added with a solution of 885 mg (3.41 mmol, 1 eq) 5’-amino-3’,5’-dideoxy-
3’-[(ethoxycarbonyl)methyl]-1’,2’-O-isopropylidene-α-D-ribofuranose 95 and 1.17 ml (6.83 
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mmol, 2 eq) N,N-diisopropylethylamine (DIPEA) in 5 ml DCM and stirred for 1.5 hrs at RT 
under N2. The reaction mixture was washed with phosphate buffer (pH=5.5) (3 x 100 ml) and 
brine (100 ml). The organic layer was dried (MgSO4) and evaporated under reduced 
pressure. Flash chromatography (hexane, hexane:EtOAc gradient from 1:0 to 2:8, v/v) 
yielded 958 mg of 96 as a white solid (1.86 mmol, 55%).  
 
C22H34N4O9: 498,23 g/mol 
Rf (hexane:EtOAc, 2:8) = 0.71;  
1H NMR (400.0 MHz, DMSO, δ ppm): 8.08 (s, 1H, NH), 5.76 (s, 1H, 1’CHa, 1’CHb), 4.69 (m, 
1H, 2’CHa), 4.61 (m, 1H, 2’CHb), 4.07 (m, 2H, CH2), 3.86 (m, 1H, 4’CHb), 3.72 (m, 1H, 4’CHa), 
3.57 (m, 1H, 5’CH2b), 3.28 (m, 3H, 5’CH2b, 5’CH2a), 2.55 (m, 1H, 3’CH2a), 2.43 (m, 1H, 3’CH2a), 
2.33 (m, 1H, 3’CH2b), 2.22 (m, 2H, 3’CH2b, 3’CHb), 2.02 (m, 1H, 3’CHa), 1.40 (s, 3H, CH3), 
1.38 (s, 3H, CH3), 1.25 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.19 (t, 3H, J= 5.56 Hz, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 171.4 (C=Ob), 170.7 (C=Oa), 110.8/110.6 (Cq), 
104.2/104.1 (1’CH), 81.1 (2’CHb), 80.5 (2’CHa), 79.7 (4’CHb), 78.9 (4’CHa), 60.0 (CH2), 51.3 
(5’CH2b), 41.5 (3’CHb), 41.2 (3’CHa), 38.2 (5’CH2a), 30.5 (3’CH2b), 29.2 (3’CH2a), 26.7-26.2 
(CH3), 14.0 (CH3);  
MS (ESI, m/z): 521.6 [M+Na]+. 
 
 
10.2.2.2 Amide Linked Free Acid Dimer (97) 
 
 
 
400 mg (0.78 mmol, 1 eq) dimer 96 were dissolved in 7 ml methanol, added with 10 M NaOH 
(0.1 ml) and stirred for 4 hrs at RT under argon. The reaction mixture was evaporated in 
vacuo to yield 375 mg of 97 as a white foam (0.77 mmol, quant.).  
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C20H30N4O9: 470.20 g/mol 
Rf (hexane:EtOAc, 2:8) = 0.1;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.75 (d, 1H, J= 3.56 Hz, 1’CHa), 5.66 (s, 1H, J= 3.76 
Hz, 1’CHb), 4.66 (m, 2H, 2’CHa, 2’CHb), 3.87 (m, 1H, 4’CHb), 3.62 (m, 1H, 4’CHa), 3.56 (m, 1H, 
5’CH2b), 3.35 (m, 1H, 5’CH2b), 3.25 (m, 1H, 5’CH2a), 3.00 (m, 1H, 5’CH2a), 2.25 (m, 2H, 
3’CH2a), 2.13 (m, 2H, 3’CH2b), 1.99 (m, 2H, 3’CHa, 3’CHb), 1.40 (s, 3H, CH3), 1.35 (s, 3H, 
CH3), 1.24 (s, 3H, CH3), 1.20 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 174.2 (C=Ob), 170.8 (C=Oa), 110.7/110.5 (Cq), 
104.2/104.1 (1’CH), 81.0 (2’CHb), 80.6 (2’CHa), 79.5 (4’CHb), 79.0 (4’CHa), 51.4 (5’CH2b), 41.4 
(3’CHb), 41.2 (3’CHa), 38.1 (5’CH2a), 30.7 (3’CH2b), 29.2 (3’CH2a), 26.6-26.2 (CH3);  
MS (ESI, m/z): 493.1 [M+Na]+. 
 
 
10.2.2.3 Amide Linked Free Acid and Free Amine Dimer (98) 
 
 
 
375 mg (0.80 mmol, 1 eq) dimer 97 were dissolved in ethanol (15 ml), added with 38 mg 
(10% weight) palladium on activated charcoal and flushed with argon. The reaction mixture 
was shaken under H2 pressure (3 bar) for 16 hrs at RT. The suspension was filtered over 
celite, washed with ethanol and the volatiles evaporated under reduced pressure, to yield 
300 mg of compound 98 as a white solid (0.67 mmol, 85%). 
 
C20H32N2O9: 444.48 g/mol 
Rf (hexane:EtOAc, 2:8) = 0.1;  
1H NMR (400.0 MHz, DMSO, δ ppm): 5.66 (s, 2H, 1’CHa, 1’CHb), 4.65 (s, 2H, 2’CHa), 4.61 (s, 
1H, 2’CHb), 3.66 (m, 3H, 4’CHb, 4’CHa, 5’CH2b), 3.41 (m, 1H, 5’CH2b), 3.29 (m, 1H, 5’CH2a), 
H2, Pd/C
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2.96 (m, 1H, 5’CH2a), 2.20 (m, 2H, 3’CH2a), 2.12 (m, 2H, 3’CH2b), 2.00 (m, 2H, 3’CHa, 3’CHb), 
1.38 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.20 (s, 3H, CH3);  
13C NMR (100.6 MHz, DMSO, δ ppm): 174.2 (C=Ob), 170.8 (C=Oa), 110.8/110.6 (Cq), 
104.2/104.0 (1’CH), 81.3 (2’CHb), 80.8 (2’CHa), 79.5 (4’CHb), 79.1 (4’CHa), 51.8 (5’CH2b), 41.2 
(3’CHb), 41.1 (3’CHa), 38.8 (5’CH2a), 30.5 (3’CH2b), 29.3 (3’CH2a), 26.6-26.2 (CH3);  
MS (ESI, m/z): 467.3 [M+Na]+. 
 
 
10.2.2.4 Cyclic Amid Linked Sugar Backbone (99) 
 
 
 
1.13 g (2.73 mmol, 9 eq) HCTU were dissolved in 2 ml DMF and added with 0.15 ml (0.91 
mmol, 3 eq) DIPEA and 60 ml DCM at RT under N2. 135 mg (0.30 mmol, 1 eq) dimer 98 
were dissolved in 2.5 ml DCM under N2 then added over 1 hr to the first mixture. The 
reaction was then stirred at RT under N2 for an additional 16 hrs. The reaction was washed 
with phosphate buffer (pH=5.5) (3 x 70 ml) and brine (70 ml). The organic layer was dried 
(MgSO4) and evaporated under reduced pressure. Flash chromatography (hexane, 
hexane:EtOAc gradient from 1:0 to 2:8 then CH2Cl2:MeOH gradient from 1:0 to 9:1, v/v) 
yielded 6.5 mg of 99 as a white solid (0.01 mmol, 5%).  
 
C20H30N2O8: 426.46 g/mol 
Rf (CH2Cl2:MeOH, 9:1) = 0.54;  
1H NMR (400.0 MHz, DMSO, δ ppm): 7.59 (t, 2H, J= 3.56 Hz, NH), 5.69 (d, 1H, J= 4.28 Hz, 
1’CHa, 1’CHb), 4.59 (t, 2H, J= 4.32 Hz, 2’CHa, 2’CHb), 3.77 (m, 2H, 4’CHb, 4’CHa), 3.38 (m, 2H, 
5’CH2b), 3.14 (m, 2H, 5’CH2a), 2.34 (m, 2H, 3’CH2a), 2.24 (m, 2H, 3’CH2b), 2.00 (m, 2H, 3’CHa, 
3’CHb), 1.38 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.20 (s, 3H, CH3);  
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13C NMR (100.6 MHz, DMSO, δ ppm): 174.2 (C=Ob), 173.8 (C=Oa), 110.8/110.6 (Cq), 
104.2/104.0 (1’CH), 81.3 (2’CHb), 80.8 (2’CHa), 79.4 (4’CHb), 79.1 (4’CHa), 51.8 (5’CH2b), 51.7 
(5’CH2a), 41.3 (3’CHb), 41.1 (3’CHa), 30.5 (3’CH2b), 29.8 (3’CH2a), 26.6-26.2 (CH3);  
MS (ESI, m/z): 449.2 [M+Na]+. 
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